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SYNTHETIC LETHALITY OF CDK INHIBTION AND DOXORUBICIN IN TRIPLE-
NEGATIVE BREAST CANCER REQUIRES P53 INACTIVATION 
 
Natalie A. Jabbour-Leung, B.A.  
Advisory Professor: Khandan Keyomarsi, Ph.D.  
Triple-negative breast cancer (TNBC) is an aggressive malignancy in which the 
tumors lack expression of estrogen receptor, progesterone receptor and HER2. As such, 
TNBC patients cannot benefit from clinically available targeted therapies and must rely on 
chemotherapy and surgery for treatment.  While initially responding well to chemotherapy, 
TNBC patients are at increased risk of developing distant metastasis and have decreased 
overall survival compared to non-TNBC patients.  A majority of TNBC tumors carry p53 
mutations, enabling them to bypass the G1 checkpoint and complete the cell cycle even in 
the presence of DNA damage.  Therefore, we hypothesized that TNBC cells are sensitive 
to cell cycle targeted combination therapy, which leaves non-transformed cells 
unharmed.  Our findings demonstrate that sequential administration of the pan-CDK 
inhibitor roscovitine prior to doxorubicin treatment is synthetic lethal explicitly in TNBC cells.  
Furthermore, this novel combination therapy is well tolerated and efficacious, significantly 
reducing tumor volume and increasing overall survival compared to single drug treatment 
arms in a pre-clinical model system.  Mechanistic studies found that combination treatment 
arrested TNBC cells in the G2/M cell cycle phase, where cells rely on homologous 
recombination for repair of DNA double strand breaks.  Notably, combination treatment 
increased DNA double strand breaks, while simultaneously reducing recruitment of 
homologous recombination proteins.  Examination of isogenic immortalized human 
mammary epithelial cells and isogenic tumor cell lines found that abolishment of the p53 
pathway is required for combination-induced cytotoxicity; making mutated p53 a putative 
predictor of response to therapy.  Consequently, p53 wildtype non-transformed cells are 
able to avoid cell death by arresting in G1.  By exploiting the specific biological and 
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molecular characteristics of TNBC tumors, this innovative therapy has the potential to 
greatly impact the treatment and care of TNBC patients.     
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CHAPTER 1: INTRODUCTION 
1.1 EPIDIEMOLGOY AND RISK FACTORS OF BREAST CANCER 
Although the rate of cancer mortality has decreased 20% over the past two decades, 
it is expected that over half a million people will die from cancer in the United States in the 
year 2015 [1]. Second only to lung cancer, breast cancer kills over 40,000 women each year 
[1, 2].  While 1 in 8 women will develop breast cancer in their lifetime [2], there are many 
reproductive, dietary and hereditary factors that can contribute to the risk of developing 
breast cancer.   
Non-hereditary factors 
Several reproductive factors affect the development of breast cancer.  Early onset of 
menarche increases the risk of breast cancer [3, 4].  Moreover, beginning menstruation at or 
after the age of 15 reduces the risk by 23% compared to women who began menstruating at 
age 12.  Since early menarche coincides with regular menstrual cycles, girls who begin 
menstruating early are exposed to hormones that may have a causative effect on breast 
cancer at an earlier age.  Additionally, women with early menarche have increased estrogen 
levels.  Similarly, longer exposure to the premenopausal hormone estrogen, due to later 
onset of menopause, leads to increased risk of breast cancer [3]. Furthermore, presence of 
circulating oestrogens and androgens are correlated with increased breast cancer risk in 
premenopausal women [5].  Bilateral oophorectomies are associated with lower risk of 
breast cancer compared to natural menopause at the same age.  This may be due to the 
more dramatic decrease in estrogen hormone levels associated with an oophorectomy [3].     
 The age of a woman’s first full-term pregnancy can influence her risk for breast 
cancer [3].  Pregnancy initially causes a transient increased risk of developing breast cancer 
for up to 15 years [6-8].  However, in the long-term, childbearing has a protective effect 
specifically against hormone receptor-positive breast cancer, but has no effect on hormone 
receptor-negative breast cancer [9].  While it is currently unknown why pregnancy causes a 
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temporary increase in risk, there are four main hypotheses as to why parity has long-term 
protective effect: (1) differentiation of breast epithelial cells, causing them to become less 
prone to transformation (2) changes in responsiveness of breast epithelial cells to estrogen 
(3) changes in hormone profile, especially the pregnancy hormones estrogen, progesterone, 
the lactogenic hormone PRL and placental lactogen (4) possible effects of pregnancy 
hormones on stem cells [6].  Pregnancies that occur before the age 20 cause a 50% 
reduction in the risk of developing breast cancer, with the first full-term pregnancy continuing 
to have a protective effect until the age of 35 [6, 10].  However, women who begin having 
children later in life (over 35) are subject to increased risk of developing breast cancer [11].  
This may be because the increased risk that is associated with pregnancy persists for 30-50 
years post-partum [12].  The age of subsequent pregnancies has little to no effect on risk 
development [13].  Therefore, while age of first pregnancy affects risk of developing breast 
cancer, further studies are needed to fully understand the link between parity and breast 
cancer.    
The same protective effect of parity is observed in rodents.  Exposure to pregnancy 
hormones estrogen and progesterone reduced incidence of carcinogen-induced mammary 
tumors, and had a protective effect in the p53-null mammary transplant model and the 
MMTV-Her2 transgenic mouse model [14].  Additionally, studies showed that the basal and 
progenitor cells of parous mice upregulated differentiation genes while reducing the 
Wnt/Notch signaling ratio compared to virgin mice.  This alteration in signaling led to 
decreased proliferation potential [15].  
In addition to age of pregnancy, other factors associated with childbearing can affect 
the risk of developing breast cancer.  Increased parity of seven or more children decreases 
the risk of developing breast cancer [16].  Also, a multi-center case control study performed 
by the Cancer and Steroid Hormone group, compared 4599 women between the ages of 20-
55 with confirmed breast cancer to 4536 control women and found that women who 
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breastfed for over 25 months had a 33% less risk of developing breast cancer compared to 
women who never breastfed [16].  While it was previously hypothesized that offspring birth 
size could affect breast cancer mortality, a population-based cohort study found no 
correlation between child birth size and premenopausal breast cancer mortality or tumor 
features [17].    
 Weight and obesity can impact the risk of developing breast cancer.  Body mass 
index (BMI) is often used to define obesity (BMI >30) [18].  Although high BMI is usually 
associated with increased disease risk, there is an inverse relationship between weight and 
risk of developing breast cancer in premenopausal women [18].  However, a four year 
prospective study that included a cohort of 121,964 female registered nurses ages 30-55 
demonstrated that while lean women are subjected to increased risk of breast cancer, their 
tumors tend to be non-metastatic, low-grade tumors [19].  In contrast, overweight or obese 
postmenopausal women have increased risk of developing breast cancer, with a relative risk 
of 1.26 [18].  Relative risk is defined as the proportion of an adverse outcome in the 
intervention group divided by the proportion of adverse outcome in the control group; a 
relative risk over 1 means that the treatment group is at a higher risk of the poor outcome 
[20].  Several hypotheses have been proposed as to why obesity increases the risk of breast 
cancer in postmenopausal women.  Adipose tissue is the primary site of estrogen synthesis, 
where aromatase catalyzes androgens to estrogen.  Aromatase levels have a direct 
relationship with BMI, with a higher BMI increasing exposure to estrogen and estrogen 
receptor (ER) activation [21, 22].  Moreover, metabolic disease, in which higher amounts of 
insulin are released into the blood stream due to unabsorbed glucose, can cause activation 
of IGF-1, a mitogenic factor [21].  Obese women also have increased risk of dying from 
breast cancer.   A prospective study that included participants from the Cancer Prevention 
Study II followed 495,477 women over a 16-year period demonstrated that grade II 
overweight women (BMI 35-39.9) had a relative risk of 1.41 and obese women (BMI >40) 
  
4 
had a relative risk of 2.12 of dying from breast cancer compared to lean (BMI 18.5-24.9) 
women with a relative risk of 1 [21, 23].  Moreover, obese breast cancer patients exhibited 
higher risk of developing lymph node metastasis, a poor prognostic maker, compared to 
non-obese breast cancer patients [18].  These findings suggest that the level of obesity 
directly correlates to risk of dying from breast cancer and aggressive disease. Unfortunately, 
weight loss upon diagnosis does not appear to benefit the survival of obese women with 
breast cancer [24].    
Hereditary factors 
 Although most breast cancers are sporadic, 5-7% of breast cancers are due to germ 
line mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2. 
Inheriting just one mutated copy of either gene results in hereditary breast and ovarian 
cancer (HBOC) syndrome [25]. Women who carry mutations in either gene have a lifetime 
risk of 60 to 85 percent of developing breast cancer [26].  More specifically, BRCA1 
mutation carriers were found to have 65% and 39% risk of developing breast and ovarian 
cancer by age 70, respectively.   BRCA2 mutation carriers had a 45% and 11% risk of 
developing breast and ovarian cancer, respectively.  It was found that while the risk for 
BRCA1 mutation carriers decreased with age, the same trend was not observed in BRCA2 
mutation carriers [27].  Also, women with HBOC are more likely to be diagnosed with 
aggressive high grade, triple-negative tumors at an early age [25, 28].  The Ashkenazi 
Jewish population have a high incidence of about 2% of three specific mutations: BRCA1 
185delAG, BRCA1 5382insC, and BRCA2 6174delT [29].   
Both proteins participate in the DNA double strand break (DSB) repair pathway 
homologous recombination (HR) and maintain genomic stability, but have separate 
functions [30].  During HR, BRCA1 acts upstream of BRCA2 by recruiting other HR proteins 
to the site of DNA DSB damage and facilitating strand resection.  In response to DNA 
damage, the BRCA1-BARD1 complex can also induce transcription of p21, activating the 
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G1/S checkpoint, and also has a lesser defined role during the G2/M checkpoint [25]. 
BRCA2 binds to the HR protein Rad51, mediating its recruitment to the site of the DNA DSB 
[31]. Without either BRCA1 or BRCA2, cells are forced to undergo a more error-prone form 
of DNA DSB called non-homologous end joining (NHEJ), potentially increasing genomic 
instability [25].  
 Mutation carriers for the PALB2 gene, which also participates in DNA repair, also 
have an increased risk of developing breast cancer.  PALB2 interacts with both BRCA1 and 
BRCA2.  At 50 years of age, PALB2 mutation carriers have a 14% likelihood of developing 
breast cancer, which increases to 35% by age 70 [32].  The association of mutations in 
PALB2 and other DNA repair proteins and their role in cancer will be discussed in 
proceeding sections.        
1.2 CELL CYCLE 
A detailed understanding of normal cell function is required before examining the 
causes and deregulated pathways associated with cancer.  In order to grow and divide, cells 
must successfully progress through the cell cycle.  During the cell cycle, cells must transition 
through a highly regulated series of orchestrated events that is managed by cyclins, their 
cyclin dependent kinase (CDK) counterparts and CDK inhibitors (CKIs), leading to the 
generation of daughter cells (Figure 1, Table 1) [33].  There are two stages of the cell cycle:  
(1) interphase, which occurs between cell divisions and where DNA is synthesized, and (2) 
mitosis (M), where the cell divides [34].  If the cell is not undergoing DNA synthesis and 
division, it can become quiescent and enter a G0 stage [35].  Interphase is composed of gap 
1 (G1), DNA synthesis (S) and gap 2 (G2) (Figure 1).  Within interphase there are three 
checkpoints, including G1/S, intra-S and G2/M, which ensure that the DNA is accurately 
replicated and separated [36].  There are 20 CDKs and four classes of cyclins, including D, 
E, A and B that form complexes with the CDKs [33].  Cyclin expression oscillates through 
the cell cycle depending on which CDK activity is needed (Table 1).  The CKI INK4 family 
includes p16 INK4A, p15 INK4B, p18 INK4C and p19 INK4D, which can selectively inhibit 
CDK4 and CDK6 activity [37]
p57Kip2 and can selectively inhibit CDK2 and CDK1 activity
  
 
Figure 1: Regulation of the cell cycle. 
G1, S, G2 and M to generate two identical daughter cells.  Specific CDK/cyclin activity is 
required per cell cycle phase.
replicate and divide accurately. 
cellular stress.  During transition through G1, CDK phosphorylation of Rb will release 
transcription factor E2F to activate
inhibitory phosphate groups.  
CDK1 upon DNA damage detection.
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.  The CKI Cip/Kip family includes p21Cip1/Waf1/Sdi1
 [33]. 
 The cell can enter quiescence (G0), or complete 
  CKIs provide quality control checkpoints to ensure that cells 
 The transcription factor p53 activates p21 transcription upon 
 S phase genes. Phosphatases CDC25A/B/C remove 
Kinases Wee1 and Myt add inhibitory phosphate groups to 
   
, p27Kip1 and 
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Table 1. CDK-cyclin complex that regulate the cell cycle 
CDK-cyclin 
complex 
Peak  
Activity Substrates Function 
CDK4/CDK6-cyclin D G1 Rb protein family Inhibit Rb and release E2F transcription factors 
CDK2-cyclin E G1/S 
Rb protein family 
Maintains Rb 
phosphorylation, required for 
G1-S transition 
p27 Signal for degradation 
Histone 1 Chromosome condensation 
NPAT Initiate histone gene transcription 
CDK2-cyclin A S 
Rb protein family Maintains Rb inhibition 
 Unbound Cdc6 Inhibit re-replication 
DNA polymerase α/δ Initiate replication 
DNA polymerase d Elongation 
PCNA Links CDK2 to DNA 
replication substrates 
MCM4, 6, 7 Inhibit helicase activity 
Histone 1 Chromosome condensation 
CDC45 Initiate DNA replication, DNA 
unwinding 
CDK1-cyclin A G2/M Rb protein family Required for G2 to M transition 
CDK1-cyclin B M 
CDC25C 
Positive feedback loop 
required for continued CDK1 
activation 
Histone1/Histone 3 Chromosome condensation 
Nuclear lamins Nuclear envelope breakdown 
Kinesin-related 
motors (ex. Eg5) 
Centrosome separation 
Microtubule-binding 
proteins (eg. 
stathmin) 
Spindle assembly 
Condensins Chromosome condensation 
Golgi matrix 
components 
Golgi fragmentation  
APC E3 ligase Activate anaphase 
CDK7-cyclin H All CDK-cyclin 
complexes 
CAK, activate CDKs 
Adapted from: [33, 38-40] 
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Mitogenic signaling can stimulate quiescent cells to exit GO and enter G1.  Mitogenic 
signaling, including growth factors that can activate the Ras/Raf/Mek pathway, is only 
required to progress through the first two-thirds of G1 [41, 42].   A major regulator of G1, the 
retinoblastoma (Rb) protein family consists of Rb, p107 and p130.  Together they are known 
as pocket proteins, due to their conserved binding pocket domain that binds E2F and other 
oncoproteins [41].  Rb is a tumor suppressor and serves as the molecular determinant of 
whether the cell will pass through the G1/S transition, known as the restriction point [41].  
Once the cell has passed through the restriction point, mitogenic signaling is no longer 
required as the cell is then committed to completing G1 and transitioning through S phase 
[43].  Passage through the restriction point occurs 2-3 hours prior to S phase [44].  Rb is 
maintained in a hypophosphorylated state to inhibit inaccurate progression through G1 [45].  
The hypophosphorylated form of Rb binds to the transactivation domains of E2F 
transcription factor family members, inhibiting their activity.  Rb can also inhibit transcription 
of S phase genes by binding to histone deacetylase (HDAC) [45]. Furthermore, the Rb/E2F 
complex can act as a transcription repressor complex by binding to the promoters of E2F 
regulated genes [46].  Upon mitogenic signaling, Ras will activate cyclin D transcription and 
CDK4 and CDK6 are released from CKI INK4 proteins, allowing them to bind to D-type 
cyclins (D1, D2 and D3). The CDK4/CDK6- cyclin D complex is shuttled to the nucleus 
where they are phosphorylated by a CDK activating kinase (CAK).  CAK is composed of the 
CDK7/cyclin H complex (Table 1).  Upon CAK activation, the cyclin D-CDK4/CDK6 complex 
can phosphorylate Rb, forcing it to release the E2F family of transcription factors [37, 41, 
47].  E2F target genes include cyclin E- and cyclin-A type cyclins [33].  Cyclin D-
CDK4/CDK6 complexes can also bind to Cip/Kip inhibitors, separating them from CDK2 [37].  
As the cell progresses through G1, E-type and A-type cyclins are synthesized, with their 
expression climaxing at the G1/S transition.  Cyclin E and cyclin A will associate with CDK2, 
  
9 
further phosphorylating Rb and initiating S phase.  Rb has 16 CDK phosphorylation sites 
[38], where complexes CDK2-cyclin A, CDK1-cyclin A and CDK1-cyclin B1 maintain Rb 
phosphorylation at specific sites as the cell transitions through the cell cycle [37].   
 Due to the complexity of DNA synthesis and the vast amount of genetic information 
that must be replicated, there are an array of errors that can occur during S-phase.  
Moreover, the cell can be assaulted by genotoxic stress such as ionizing or UV radiation 
outside of S-phase.  Fortunately, the cell has developed three checkpoints, including the 
G1/S, intra-S and G2/M, to ensure its DNA has been accurately duplicated prior to dividing 
[36].  While these checkpoints act only at certain times, the proteins used to detect and 
repair the DNA damage overlap.  The detection and repair of DNA damage will be 
discussed in proceeding sections.  
The replication or the G1/S checkpoint prevents progression through S-phase when 
there is a stalled replication fork due to lack of deoxyribonucleotides, inhibition of the DNA 
polymerases or the replication fork encountering a damaged piece of DNA [48].  The 
phosphotyrosine phosphatases CDC25A, CDC25B and CDC25C promote the G1/S 
transition when they are in their active, unphosphorylated state (Figure 1) [36].  
Unphosphorylated CDC25A is an activator of CDK2 and removes inhibitory phospho-groups 
from CDK2 [49].  Upon detection of DNA damage, either ataxia telangiectasia (ATM) for 
DNA DSBs or Rad3 related (ATR) for DNA single strand breaks (SSBs) activate Chk2 or 
Chk1 via phosphorylation, respectively.  ATM and ATR are phosphoinositide 3-kinase 
related kinases (PIKKs).  Once activated, Chk1 or Chk2 will inhibit CDK2 activation by 
phosphorylating CDC25A, causing it to be exported from the nucleus and undergo ubiquitin-
mediated proteolytic degradation, inducing a G1 arrest [36]. Activated Chk1 and Chk2 will 
also phosphorylate downstream proteins that can lead to cell apoptosis (p53), transcription 
of DNA repair genes (BRCA1, E2F1) and chromatin remodeling (Tlk 1/2) [50]. 
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The tumor suppressor protein p53 can also initiate a G1 arrest. Upon detection of 
DNA damage, ATM/Chk2 or ATR/Chk1 act together to phosphorylate and stabilize p53 
through BRCA1 [36].  BRCA1 forms a complex with BRCA1-associated RING domain 
protein 1 (BARD1), which must be phosphorylated by either ATM or ATR to aid in the 
phosphorylation and activation of p53 [51].  p53 has several phosphorylation sites, including 
serines 15 and 20.  Phosphorylation of p53 disassociates it from its negative regulators 
MDM2 and MDM4, stabilizing its expression [52].  Stabilized p53 activates transcription of 
p21, which will inhibit CDK2 activity [36].  Activation of the G1 checkpoint should allow the 
cell to repair any DNA damage prior to progressing into S-phase.   
 Once the cell transitions through the restriction point, the entire cell genome must be 
truthfully replicated during S-phase.  Preceding S phase, DNA replication begins with the 
assembly of the pre-replicative complex (pre-RC) on the replication origins of genomic DNA.  
The first six proteins that bind form a complex called the origin recognition complex (ORC).  
While multiple replication sites are bound at the same time throughout the genome, not all 
will initiate DNA replication, with some serving as back up origins. After ORC has been 
assembled, Cdc6 and Cdt1 are recruited to the origination site, followed by the binding of 
Mcm2-Mcm7, which serve as a helicase complex that unwinds the DNA [53].    
 As cells transition into S-phase, CDK2-cyclin A and Dbf4 dependent kinase activity 
are required for the transition of the pre-RCs to replication forks [33, 53, 54].  At this point, 
helicase activity unwinds the DNA, the DNA single strands are stabilized and DNA 
polymerases are loaded onto the DNA.  CDK2 phosphorylates Cdc45, allowing it to bind to 
the Mcm2-7 complex, which is required for DNA unwinding and for binding of the DNA 
polymerase [53, 54]. The resulting single strands of DNA are stabilized by replication protein 
A (RPA) binding [55].  Three types of polymerases (pol), including DNA pol α, DNA pol δ 
and DNA pol ε, participate in the elongation of the newly synthesized DNA.  The proliferating 
cell nuclear antigen (PCNA) protein serves as a clamp for DNA pol δ and ε, linking the 
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polymerase to the DNA template [56].  Since DNA can only by synthesized 5’ to 3’, there is 
a leading strand and a lagging strand.  The leading strand is synthesized continuously, while 
the lagging strand is synthesized in discontinued Okazaki fragments, with the gaps later 
filled and ligated together.  DNA pol α synthesizes RNA primers for the leading and lagging 
strands, acting as template for the other polymerases. DNA pol α is the only polymerase that 
that can begin DNA synthesis without primers. DNA pol δ is required for synthesis of both 
strands [57]. 
 Genotoxic stress can also occur during DNA replication, activating the intra-s-phase 
checkpoint [48]. This checkpoint acts to temporarily inhibit the firing of DNA origins of 
replication [49].  Two main pathways work to initiate the intra-S-phase checkpoint upon DNA 
damage.  Similar to the G1 checkpoint, one pathway relies on inhibition and degradation of 
CDC25A.  When activation of ATM/ATR pathway causes CDC25A degradation, CDK2 
activity is inhibited, preventing the loading of CDC45 onto the chromatin.  Since CDC45 is 
required for the recruitment of DNA polymerase α, inhibition of CDC25A and CDK2 prevents 
the firing of new origins [49].  The second pathway acts through ATM-Chk2 to phosphorylate 
proteins NBS1 and SMC1 to both detect DNA damage and initiate arrest [36, 49].     
Before cells can pass through mitosis and divide into two daughter cells, they must 
pass the G2/M checkpoint.  This checkpoint is activated in the event that remnants of DNA 
damage that were not repaired in G1 or S are detected or DNA damage occurs during G2 
[49].  CDK1, the major regulator of mitosis, is inhibited if the cell detects DNA damage 
through either the ATM/Chk2 or ATR/Chk1 pathways.  Wee1 and Myt1 add inhibitory 
phospho-groups on CDK1 at tyrosine 15 and tyrosine 14, respectively, with CDC25 family 
removing these phospho-groups to activate CDK1 [58, 59].  If DNA damage is detected, 
phosphatase CDC25 is inhibited via the ATM/ATR pathways, inhibiting CDK1 activity [59]. 
The kinase p38 can also inhibit CDK1 activity by sequestering and inhibiting CDC25A.  
Expression of p53 is required for the maintenance of the G2 checkpoint [49].  
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The p53 transcriptional targets, p21, GADD45 and 14-3-3σ, act to inhibit CDK1 
activity.  CDK1 is inhibited by p21 directly, while 14-3-3σ sequesters CDC25 to the 
cytoplasm, preventing it from activating CDK1.  GADD45 separates cyclin B1 from CDK1, 
also inhibiting CDK1 activity.  On its own, p53 can suppress cyclinB1 and CDC2 (CDK1) 
transcription [58].   
During G2, in which the cells continue to grow and make proteins in preparation for 
mitosis, the CDK1-cyclin B1 complex is exported from the nucleus to the cytoplasm.  
However as cells begin to transition into mitosis, CDK1 or polo like kinase 1 (Plk1) 
phosphorylate cyclin B1, preventing the complex from being exported.  This allows the 
CDK1-cyclin B1 complex to aggregate in the nucleus and induce mitosis [60].  In addition to 
CDC25B and CDC25C phosphatase activity, CAK activates and phosphorylates CDK1 at 
threonine 161 [58].  The five phases of mitosis are prophase, prometaphase, metaphase, 
anaphase and telophase followed by cytokinesis [39].  The CDK1-cyclin A complex is active 
during prophase and will facilitate chromatin DNA coiling tightly into two sister chromatids, 
which requires several post-translational modifications to histones [39, 61].  Also, the 
centrosomes, which will later pull the sister chromatids apart, migrate to opposite poles.  
CDK1-cyclin B1 activity is required for the recruitment of motor proteins that will participate 
in the separation of the two centrosomes.  The centrosomes will then begin to organize and 
nucleate microtubule and promote spindle formation.   Also, the CDK1-cyclin B1 complex 
will facilitate nuclear envelope break down by phosphorylating the nuclear lamin that would 
otherwise stabilize the nuclear envelope. During prometaphase, the microtubules will attach 
to the kinetochores located at the centromeres of the sister chromatids.  During kinetochore 
attachment, the cells will proceed to metaphase, where the chromosomes will align at the 
metaphase plate [39]. The spindle assembly checkpoint prevents entry into anaphase and 
activation of the anaphase-promoting complex (APC) until there is bipolar attachment of 
mitotic spindle to each sister chromatid and tension is created between the sisters. As the 
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cells approach anaphase, where the sister chromatids are separated and pulled towards 
opposite poles of the cell, APC activity increases.  The APC, a multisubunit E3 ubiquitin-
protein ligase, is responsible for adding ubiquitin chains to its substrates, targeting them for 
degradation.  The APC has two activators, including Cdc20 and Cdh1, which have differing 
substrates.  APCCdc20 targets both securin, the inhibitor of separase, and cyclin B for 
degradation [61].  After metaphase, CDK activity is no longer required, and the degradation 
of cyclin B due to APC Cdc20 ubiquitination turns off CDK activity [60, 61].   Also during 
anaphase, certain CDK1-cyclin A/cyclin B1 substrates must be dephosphorylated.  The CDK 
substrate separase, which is responsible for cleaving the cohesin complex that holds the 
two sister chromatids together, is dephosphorylated and activated.  Additionally, inner 
centromere protein, the regulatory subunit of Aurora B, must be dephosphorylated to allow 
Aurora B to migrate to the spindle midzone and encourage spindle stability.  APCCdh1 
ubiquinates Cdc20 and Plk1 in late anaphase and Aurora kinases A and B in late telophase 
[61].  As the sister chromatids are pulled apart, the spindle poles separate further.  When 
the chromosomes have reached the poles, telophase is initiated, which includes nuclear 
envelope reformation and chromosome decondensation [39].  
Cytokinesis, or the division of the cytoplasm, is the final step in formation of the two 
daughter cells.  Ingression of the cleavage furrow, the site at the cell equator where the 
parent cell will contract, begins in telophase.  The spindle midzone, or the area of 
overlapping centrosomal microtubules, will indicate where the cleavage furrow will form.  
The small GTPase Rho localizes at and contributes to the cleavage furrow by managing 
actin, myosin II and other actin binding proteins.   Kinases Aurora B and Plk1 are required 
for RhoA recruitment and activity at the cleavage furrow [62].  The microtubules will relay 
spatial signals to the cytoskeleton at the cell membrane, or the cell cortex [63]. As 
cytokinesis progresses, the gathering of actin and myosin II at the cell equator pulls together 
like “purse strings” at the cleavage furrow to form a contractile ring [62].   Once the cleavage 
  
14
furrow has completely ingressed, an intracellular bridge with a microtubule midbody forms 
between the two daughter cells [63].  The proteins KIF14 and Citron kinase promote 
abscission of the two daughter cells followed by membrane fusion [62].              
1.3 DEREGULATION OF THE CELL CYCLE IN CANCER 
 One of the hallmarks of cancer is evasion of anti-proliferation signals.  As previously 
described, normal cells have the ability to arrest or undergo apoptosis if there is damaged 
DNA.  However, tumor cells develop the ability to evade cell cycle checkpoints and continue 
to replicate through several mechanisms, including increased expression of cyclin/CDK 
complexes and mutated CKIs (Table 2) [64].  The avoidance of any of the three checkpoints 
(G1/S, inrtra-S or G2/M) can lead to chromosomal and genomic instability, contributing to 
tumor progression. Additionally, tumor cells can undergo unscheduled proliferation, in which 
they will enter the cell cycle without receiving mitogenic signals [65].  This section will 
discuss the mechanisms that allow tumor cells to proliferate continuously.   
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Table 2. Failure in cell cycle regulation and cancer 
Gene/ 
Protein 
Mutation/ 
Defect Cancer Association 
CCND1 Amplification HNSCC, NSCLC, endometrial, melanoma, breast and pancreatic cancer  
Cyclin D1 
Overexpression HNSCC, NSCLC, endometrial, melanoma, breast, pancreatic and colorectal cancer  
Increased nuclear 
localization 
Lymphoma and prostate cancer 
CCNE1 Amplification NSCLC, lymphoma, breast and ovarian cancer 
Cyclin E 
Protein truncation/ 
cytoplasmic 
localization 
Breast and ovarian cancer 
Cyclin B1 
Increased nuclear 
localization 
Breast and oseophageal cancer 
Overexpression Breast, colon, prostate, oral, lung and oseophageal 
cancer 
CDK4 Polymorphism R24C 
Familial melanoma  
CDK4 Amplification Sporadic melanoma, glioblastoma, osteosarcoma, breast and cervical cancer 
Cdc2 Amplification Colon cancer 
CDK2 Amplification Colon cancer 
p16INKA 
Deletion, point 
mutation, 
hypermethylation 
NSCLC, glioma, T-cell ALL, mesothiloma, bilary tract, 
pancreatic and bladder cancer 
p14ARF Deletions Breast, brain and lung cancer 
p53 
Point and missense 
mutations 
Li-Fraumeni syndrome, colon, breast, lung, brain, 
pancreas and stomach cancer 
Viral HPV E6 protein Cervical cancer 
Mdm2 Amplification Leukemia, lymphoma, sarcoma, glioma and breast 
cancer  
Rb 
Mutation, loss of 
function 
Retinoblastoma, NSCLC 
Viral HPV E7 
oncoprotein 
Squamous cell carcinoma and cervical cancer  
ATM Missense, nonsense 
and truncations 
(Ataxia-telangiectasia) Thymic lymphoma, leukemia & 
breast cancer 
ATR Truncation or 
missense mutations 
Stomach, breast, endometrial 
CHK1 Frameshift mutation Colorectal, gastric, endometrial & small cell lung cancer 
CHK2 Truncation or 
missense mutation 
Li-Fraumeni syndrome, breast, bladder, colon, ovary, 
prostate and lung cancer 
AURKA Amplification Breast, colorectal and bladder cancer 
Adapted from: [37, 65-69] 
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CDK-cyclin complexes are often deregulated in cancer.  In melanoma, CDK4 often 
has an R24C mutation that inhibits binding of CKIs, while a variety of cancers have CDK4 
and CDK6 gene amplification.  Increased CDK4/CDK6 activity can cause 
hyperphosphorylation of Rb, allowing tumor cells to bypass the G1 checkpoint [37, 65].  
Cancers such as leukemia, lymphoma, gastric, colorectal, lung, kidney and breast can have 
overexpression of cyclin D1 via gene amplification, rearrangement or translocation [37]. This 
will also increase activity of CDK4/CDK6.  Mouse mammary tumorgenesis induced by 
oncogenes Ras and Neu requires cyclin D1 expression, and up to 70% of breast cancers 
show overexpression of cyclin D1 [66, 70].  While E-type and A-type cyclins are often 
overexpressed and increase activity of CDK2, the CDK2 gene is not typically mutated in 
cancer [37, 65].  Additionally, about 6% of cancers have lost function of the F-box and WD 
repeat domain 7 (FBXW7) protein, which when present ubiquitinates cyclin E and signals for 
proteasome degradation.  However, lack of FBXW7 causes stabilization of cyclin E 
expression in the nucleus.  Aberrant enrichment of nuclear cyclin E can cause chromosomal 
instability and deregulate the loading of DNA licensing proteins onto the ORCs [71, 72].  
CDK1 can have augmented activity in cancers including, breast, colon, lung and prostate, 
due to overexpression of cyclin B1.   
 CDK-cyclin complexes can also be mislocalized.  Mislocalization of CDK-cyclin 
complexes at inappropriate times in the cell cycle can cause early or continuous 
phosphorylation of substrates.  Under normal conditions, cyclin D1 is exported to the 
cytoplasm at the start of S-phase due to glycogen synthase kinase 3β (GSK3β) 
phosphorylation, which reveals a nuclear export signal.  However, a proportion of prostate 
and lymphoma tumor cells show increased cyclin D1 nuclear localization. Increased cyclin 
D-1 nuclear localization has been attributed to GSK3β inhibition by increased KRAS or PI3K 
activity, mutations in the cyclin D1 GSK3β phosphorylation site and mutations in the cyclin-
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D1 ubiquitination domain. Consequences of cyclin D1 mislocalization include increased 
CDK4 activity, chromosome instability and aneuploidy due to DNA re-replication [71].  Cyclin 
E can be post-translationally cleaved by the serine protease neutrophil elastase to generate 
oncogenic forms of cyclin E called low molecular weight cyclin E (LMW-E) [73].  Due to a 
lack of nuclear localization signal, LMW-E is primarily observed in the cytoplasm and has not 
been detected in normal tissue [74-76].  LMW-E has increased binding affinity to CDK2, is 
resistant to CDK inhibition by CKIs, causes aneuploidy and accelerates entrance and exit 
from mitosis, leading to failed cytokinesis and multinucleated cells [77-79].  LMW-E also 
correlates with poor prognosis in breast and ovarian cancer [80, 81].  Additionally, cyclin B1 
can have aberrant localization.  During G2/M, cyclin B1 translocates to the nucleus just prior 
to nuclear envelope breakdown to bind to CDK1.  However, cyclin B1 is detected in the 
nuclei in a high proportion of tumor cells, suggesting early entry into the nucleus. Aberrant 
localization of cyclin B1 in the nucleus is a poor prognostic marker for breast and 
oesophageal cancer [71].                
 Tumor cells can bypass checkpoints by silencing or downregulating CKIs and other 
endogenous cell cycle inhibitors.  The p16 gene is often subjected to deletion or epigenetic 
silencing via hypermethylation of its promoter in many cancers, including pancreatic, 
melanoma, lung, breast and colorectal [35, 67, 82]. Rb can also be mutated or deleted.  
Inhibition of the Rb pathways generally only requires one “hit,” with manipulations of cyclin 
D/CDK4, p16 loss or Rb loss being mutually exclusive.  To induce cell cycle arrest or cell 
death, cells with a deregulated Rb pathway may compensate with increased activity of p53.  
Upstream of p53, ATR can have truncation or missense mutations in stomach, breast and 
endometrial cancers, inhibiting activation of the DNA damage checkpoint.  Additionally, DNA 
damage checkpoint proteins Chk1 and Chk2 can be deleted or mutated, leading to 
increased genomic instability and oncogenesis [37].   
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Over 50% of cancers carry p53 gene mutations, a major regulator of cell cycle arrest 
and apoptosis [67].  Most p53 mutations are missense mutations.  Some mutations will 
cause loss of wild-type function or can generate dominant-negative mutants that inhibit wild-
type p53 protein [83].  The transactivation capacity of p53 is often lost in cancers such as 
colon, breast, lung, brain, pancreas and stomach due to alterations in its DNA binding 
domain [83, 84].  Tumor cells can also inhibit p53 by increasing expression of proteins that 
inhibit its activity, such as MDM2.  Under normal conditions, MDM2 binds to p53 to inhibit its 
transactivation domain, exporting it from the nucleus for degradation and serves as a p53 
ubiquitin ligase [85].   Concordantly, the mdm2 gene is often amplified in sarcomas and 
gliomas [86, 87].  Also, deletions in the p14ARF gene, a negative regulator of MDM2, can be 
found in breast, brain and lung cancers [84].  Viral oncoproteins such as hepatitis B virus X 
protein and human papilloma virus E6 proteins can bind and inhibit p53 function [88, 89]. 
Not all p53 mutations are inactivating, with some mutations causing gain of function (GOF) 
oncogenic activity. GOF Mutant p53 typically has a longer half-life than wildtype p53 and 
can have changes at the transactivation domain that, while still retaining its DNA binding 
ability, may cause it to recognize different sequences [90, 91].  Mutant p53 has been shown 
to affect expression of genes such as c-myc, cyclin D3, epidermal growth factor receptor 
(EGFR) and others [91]. GOF Mutant p53 can bind to some of the same transcription factors 
as the wildtype, including E2F1, but alter or increase their activity to promote oncogenicity 
[90, 92]. Similar to wildtype p53, GOF mutant p53 can also interact with the transcription 
factor NF-Y.  However upon DNA damage, the mutant p53/NF-Y complex activates 
transcription of genes such as cyclin A, cyclin B2, CDK1 and cdc25C.  This is the opposite 
response of the wildtype p53/NF-Y complex after DNA damage [93].  These examples 
demonstrate how loss of function and gain of function p53 mutations have a large impact on 
tumor cells and cell-cycle regulation. 
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1.4 DNA DAMAGE REPAIR PATWAYS 
           To protect the genome, the cell has developed several mechanisms to detect, 
remove and repair DNA damage (Table 3).  The cell can incur DNA damage from 
endogenous sources such as stalled replication forks during DNA replication or exogenous 
sources such as UV radiation, ionizing radiation or DNA damage agents (i.e. 
chemotherapeutics).  In response to DNA damage, a normal cell will arrest and attempt to 
repair the damage.  If repair is impossible, the cell will undergo cell death [49, 50].  The DNA 
damage and repair pathway includes damage detectors, signal transducers and 
downstream effectors [94].   
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Table 3. DNA Damage and Repair 
 Damaging  
Agent Lesion 
Repair 
 Pathway 
Crucial  
Proteins 
SS
B 
ROS, adducts, IR and 
alkylating agents Altered base BER 
DNA glycosylase, APE1 
endonuclease, PARP, 
DNA polymerase β, 
DNA polymerase ε, 
Ligase3, XRCC1, 
PCNA, FEN1   
ROS, UV radiation, 
chemical carcinogens 
Intra-strand 
crosslink (bulky 
adducts) 
NER 
XPC, XPA, RPA, TFIIH 
centrin1, XPG, PCNA, 
EXRCC1-XPF, DNA 
polymerase δ/ ε, RPA, 
RFC, CSA, CSB, ligase 
Replication Error 
Base mismatch, 
insertions, 
deletions 
MMR 
MSH2, MSH3, MSH6, 
MLH1-PMS2, EXO1, 
RPA, PCNA, DNA 
polymerase δ, RFC, 
ligase 
DS
B
 
Replication error, IR, 
chemical agents DSB NHEJ 
Ku70, Ku86, DNA-PKcs, 
Artemis nuclease, DNA 
polymerase-µ, DNA 
ligase IV, XRCC4   
Replication error, 
ROS, chemical 
agents, alkylating 
agents 
DSB HR 
Mre11 nuclease, CtIP, 
Exo1, BLM, DNA2, 
CDK1, BRCA1, BRCA2 
RPA, RAD51, RAD52, 
RAD54, PALB2, DNA 
polymerase 
IC
L 
Lipid peroxidation, 
chemotherapeutics: 
derivatives of nitrogen 
mustards & platinum-
based  
ICL 
NER, HR, or 
Fanconi 
Anemia 
Pathway 
(NER and HR proteins)  
FANCM, FA core 
complex, FAPP24, 
FANCD2, FANCI, BTR 
complex 
Adapted from: [36, 95-97] 
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1.4A SINGLE STRAND BREAKS 
Before the cell can repair DNA damage, it must be able detect it and arrest cell cycle 
progression.  The stalling of DNA polymerases during S phase, reactive oxidative species 
(ROS) and UV radiation can all generate SSBs [36, 48].  During SSB recognition, the single 
strand DNA will become coated by RPA, recruiting ATR and its regulatory subunit ATR-
interacting protein (ATRIP).  RPA will also recruit Rad17, which will load the ring structure 
complex 9-1-1, consisting of Rad9, Hus 1 and Rad1.  ATR will phosphorylate Rad17 and 
911.  ATR will also phosphorylate topoisomerase II binding protein 1 (TopBP1), which is 
required for ATR activation and Chk1 checkpoint activation [36, 48, 98].   
The type of DNA damage determines the mechanism of repair.  The three types of 
repair for SSBs are base excision repair (BER), nucleotide excision repair (NER) and 
mismatch repair (MMR).  Cells rely on BER in response to an aberrant base, ROS, 
chemicals that bind to DNA (adducts), ionizing radiation, and failure in topoisomerase I 
activity or alkylating agents. A glycosylase enzyme usually recognizes the damaged base 
and, combined with the endonuclease APE1, facilitates base removal [36, 95].  The type of 
glycosylase used is dependent upon the substrate that needs to be excised.  For example, 
the uracil DNA glcosylase is required to excise aberrant inclusion of uracil into the DNA, 
whereas DNA glycosylase SMUG1 excises uracil and oxidized pyrimidines [99]. This causes 
a gap in the strand that is “cleaned” by poly (ADP-ribose) polymerase (PARP) and 
polynucleotide kinase to hasten repair [99].  PARP transfers ADP-ribose to form polymer 
chains.  A single nucleotide gap is filled using short-patch repair, while wider gaps require 
long-patch repair. DNA synthesis that occurs during repair is called repair synthesis.  Short-
patch repair relies on DNA pol β to add the required nucleotide, followed by ligation by the 
Ligase3/XRCC1 complex [36]. XRCC1 also serves as a scaffold to recruit other SSB repair 
proteins.  Long-patch repair requires DNA pol β, DNA poly ε and PCNA for repair synthesis.  
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PCNA helps recruit the endonuclease FEN-1, which is required to remove the 5’ blocking 
group that is displaced as a flap.  Finally, ligase 1 seals the DNA backbone [99]. 
NER serves to repair bulkier DNA damage caused by UV radiation (thymidine 
dimers), ROS and chemical carcinogens that interrupt the double helix structure [36, 95].  
During NER, an oligonucleotide fragment of 25-30 nucleotides is excised [100]. NER acts 
through two pathways: global-genome NER and transcription-coupled NER (TCNER) [95].  
During global genome NER, several proteins, including XPC, XPA and RPA, must first 
recognize the damaged DNA.  XPC is in a complex with HHRAD23A (or HHRAD23B) and 
centrin2.  HHRAD23A may not be required for NER, but aids in NER efficiency, while 
centrin2 stabilizes binding between HHRAD23A and XPC.  Following XPC binding, XPA and 
RPA bind to the damaged area.  Due to the extent of damage, some of the double helix 
unwinds, facilitating RPA binding to a single strand.  Following damage recognition, the six-
subunit complex called core transcription factor IIH (TFIIH), which is part of the RNA 
polymerase II transcription systems, binds to the damaged site.  TFIIH is comprised of two 
DNA helicases (XPB and XPD), which unwind the DNA.  The unwinding of the DNA creates 
a bubble.  The proteins p62, p44, p34 and p52 also make up TFIIH and promote bubble 
formation.  Bubble development creates junctions between the unraveled single strand and 
the remaining helix, which are crucial for accurate excision of the damaged bases.  The 3’ 
end of the damaged DNA is cut by XPG, and the 5’ end is cut by the EXRCC1-XPF 
heterodimer.  Similar to BER, repair synthesis requires PCNA along with DNA polymerase δ 
or ε, RPA and replication factor C (RFC), followed by ligase activity to seal the DNA with 
covalent bonds [100].  The mechanism of TCNER, or NER that occurs during transcription, 
is not as defined as global-genome NER.  Since XPC knockout mice can still perform 
TCNER, is it is suggested that damaged bases are recognized due to stalled RNA 
polymerase II activity.  The proteins CSA and CSB are required for TCNER, however, their 
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exact function is unknown.  The events of TCNER following damage recognition require 
TFIIH and are thought to be very similar to global NER [100]. 
MMR, an intricate process, occurs in response to mismatched bases and insertion or 
deletion loops formed by DNA replication errors [95].  Mismatched bases are due to DNA 
polymerase errors that are not detected during proofreading, while insertion/deletion loops 
(IDL) are due to heteroduplex DNA formation.  Heteroduplexes form when two homologous 
strands from different sources, such as a primer and a template, anneal incorrectly [96].  
MMR was first studied in E. coli, where the MutS homodimer was discovered as the error 
detector.  In mammalian cells, the MutS homologs (MSH) MSH2, MSH3 and MSH6 have 
been found to participate in MMR.  The heterodimer MSH2-MSH6 (MutSα) binds and repairs 
base mismatches and IDLs that are 1-2 nucleotides long, while heterodimer MSH2-MSH3 
(MutSβ) repairs base mismatches and IDLs greater than two bases.  MutSα and MutSβ 
interact with the DNA as sliding clamps and can work together [96, 101]. Following binding, 
MutSα or MutSβ recruits the heterodimer MLH1-PMS2 (MutLα), forming a ternary structure.  
ATP-hydrolysis causes a conformational change in the MutSα- MutLα complex, allowing it to 
slide either upsteam or downstream from the damage site.  If they slide upstream, they will 
meet with and displace RFC to allow binding of exonuclease 1 (EXO1) at the 5’ end.  EXO1 
is activated by MutSα and will excise and degrade the damaged strand from 5’ to 3’, leaving 
a single strand gap that is stabilized by RPA.  Following mismatch removal, MutLα inhibits 
EXO1.  PCNA allows binding of DNA polymerase δ, which synthesizes the new strand, 
followed by DNA ligase I mediated ligation [96].  In the event that a MutSα- MutLα complex 
slide downstream towards the 3’ terminus, it will meet a PCNA molecule bound at the 3’ end 
of the strand break.  EXO1 is also recruited here, degrading the damaged strand.  RFC at 
the 5’ end blocks degradation away from the mismatch site in the 5’ to 3’ direction.  Similar 
to the 5’ terminus, EXO1 inactivation is followed by RPA binding, DNA pol δ repair synthesis 
and DNA ligase I sealing with covalent bonds [96].                                 
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1.4B DOUBLE STRAND BREAKS 
DNA damage due to collapsed replication forks, ionizing radiation, ROS, alkylating 
agents and chemotherapeutics can generate DNA DSBs.  The two methods to repair DNA 
DSBs are non-homolgous end joining (NHEJ) and homologous recombination (HR).  NHEJ 
is considered an imperfect, error-prone method of repair since it seals the gaps created by 
DSB, with a few nucleotides at each end are lost [102].  HR, on the other hand, provides 
error-free repair because it uses a sister chromatid as a template to fill the gap [103].  Since 
HR requires a sister chromatid, it is only performed during late S, G2 and M, when a sister 
chromatid is available [104].  NHEJ can occur during any phase of the cell-cycle [95].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2. Schematic of 
DNA double strand breaks, the MRN complex will identify the break and recruit ATM.  ATM 
will phosphorylate CHK2 and H2AX, activating the cell
recruitment of DNA repair foci, respectively. 
However, HR is limited to late S, G2 and M because it requires CDK
resection.   
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In order for repair to occur, the cell-cycle checkpoint must be activated [105].  The 
Rad50/ meiotic recombination 11 (Mre11)/ Nijmegen Breakage Syndrome 1 (NBS1) or MRN 
complex detects and processes DNA DSBs to create single strand DNA (Figure 2) [36, 98, 
105].  MRN also serves as a sensor for ATM, with the C-terminal domain of Nbs-1 and the 
HEAT repeats of ATM mediating the interaction between MRN and ATM [94].  Once 
recruited to the DNA damage site, ATM will separate from its inactive, dimer form and 
autophosphorylate itself at S1981, S367 and S1893 [98, 106, 107].  ATM has many 
substrates, including p53, NBS1, BRCA1 and CHK2 [49, 50].  ATM phosphorylation of Chk2 
will activate the cell-cycle checkpoint (Figure 2) [105].   
Following MRN formation at the DSB and checkpoint activation by ATM, downstream 
effectors will be activated to initiate repair.  ATM will phosphorylate the C-terminus of histone 
H2AX at S139 (γ-H2AX), which serves as a major signal of DNA DBS damage and as a 
recruiter of downstream DNA repair proteins.  H2AX can also be phosphorylated by ATR 
and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs).  Following 
phosphorylation, the BRCA-1 C-terminus (BRCT) region of the mediator damage checkpoint 
protein (MDC1) will bind to γ-H2AX by directly binding to the phosphoepitope of H2AX at the 
C-terminus, enhancing the γ-H2AX signal, and possibly continuing the interaction with ATM 
[98, 108]. MDC1 also binds to NBS1 of the MRN complex, and is required for the interaction 
between MRN and γ-H2AX.  Moreover, MDC1 and γ-H2AX binding is required for the 
recruitment of 53BP1, BRCA1, CHK2 and p53, which can also initiate cell arrest or 
apoptosis [98, 109].  
The first repair protein to bind the damage site during NHEJ is the doughnut-shaped 
heterodimer Ku, composed of Ku70 and Ku86 [110].  Ku will then recruit and activate the 
PIKK DNA-PKcs, forming the trimeric DNA-PK holoenzyme [95, 102, 104].  During NHEJ, it 
is imperative that the two damaged ends are kept near each other, in a process called 
synapsis, to be repaired.  It is unclear how exactly this occurs, but it is believed that Ku and 
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DNA-PKcs play a role [104].  A study using an intermolecular ligation assay reported that Ku 
could stimulate DNA ligation by bridging the DNA ends while still making them DNA ligase-
accessible [111].  Many times the ends of the DNA will be ligated where they, by chance, 
share 1-4 complementary nucleotides, referred to as microhomology.  However, 
microhomology is not required for end-joining. When microhomology occurs, extra 
nucleotides beyond the area of microhomology must be trimmed [104]. Ku will also recruit 
the nuclease Artemis, which is phosphorylated by DNA-PK [110].  Artemis combined with 
DNA-PKcs, acts as an endonuclease at the 5’ and 3’ ends [104].  It is the deletion of these 
nucleotides that can cause a loss of genetic information and an increase in genomic 
instability [103].  Although polymerase activity is not required in many instances of NHEJ, it 
has been suggested that the polymerase-µ may fill in some gaps during repair.  Following 
excision of the damaged ends, DNA-PK recruits the DNA Ligase IV/XRCC4 complex to 
ligate together the blunt ends, completing the process (Figure 2) [104]. 
As previously stated, HR can only occur during late S, G2 and M phases [104].  To 
repair DSBs through HR, end resection is performed to form single-stranded DNA.  Mre11 
nuclease activity combined with CtBP-interacting protein (CtIP) promotes DSB end 
resection, followed by activity from EXO1, Bloom’s syndrome protein (BLM) and DNA2. CDK 
activity is required for strand resection, as CtIP is phosphorylated by CDK1, limiting HR 
strand resection to S and G2 (when CDK1 is active) [112, 113].  Ubiquination of CtIP by 
BRCA1 may also play a role in activating it [114]. MRE11 nuclease activity will stimulate 
RPA recruitment to coat the 3’ ends of the remaining single-stranded DNA. RPA can 
promote checkpoint induction by binding to ATRIP and activating ATR [103, 115].  RPA 
must then be replaced with the recombinase Rad51 with the aid of mediators, including 
BRCA2.  While both BRCA1 and BRCA2 have been shown to colocalize with Rad51, 
BRCA2-Rad51 binding is required for accurate loading of RAD51 at the damage site and 
completion of homologous recombination [116].  BRCA2 has a DNA binding domain that 
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can bind both ssDNA and double stranded DNA (dsDNA) and 8 BRC repeats that bind to 
Rad51 and manage Rad51 filament formation [117].  Rad52 also aids in Rad51 filament 
formation [105].  Following phosphorylation by Chk2, BRCA1 interacts with Rad51 through 
BRCA2 and PALB2 [118, 119].  After Rad51 binding, Rad51 and Rad54 enable the resected 
end of the damaged strand to invade the homologous template, displacing the identical 
strand and forming a displacement loop (D-loop).  Rad51 is disassociated from the single 
strand by the helicase Srs2 to allow for base complementation [102, 103].  Following D-loop 
formation, the single strand is extended via DNA synthesis, with the homologous strand 
serving as the template, causing a D-loop intermediate to form [103]. The intermediate form 
can be resolved either through synthesis-dependent strand annealing (SDSA) or double 
strand break repair (DSBR).  During SDSA, the invading strand is displaced and re-anneals 
to the single strand that it was originally bound to in a non-crossover event, allowing no 
exchange of genetic information. DSBR can be resolved either via crossover or a non-
crossover event.  During DSBR, the invading strand can be captured at both the ends by the 
damaged strand, forming Holliday junctions (HJs).  Here the HJs can be resolved by either a 
crossover or a non-crossover event (Figure 2) [120].  
1.4C INTERSTRAND CROSSLINKS 
 Another form of DNA damage that can be lethal for a cell is interstrand crosslinks 
(ICLs), which are irreversible covalent bonds between bases on opposite strands.  ICLs are 
very damaging because they inhibit the separation of the two DNA strands, which is 
required for transcription and DNA replication.  Chemotherapeutics that are derivatives of 
nitrogen mustards, such as cycolophosphamide and melphalan, and platinum-based drugs, 
such as cisplatin, are known to cause ICLs [97].  As a result, there is a risk of patients 
treated with platinum-based drugs of developing a secondary cancer, especially leukemias 
[121].  High-fat diets and alcoholism can cause lipid peroxidation that can lead to the 
formation of ICLs [122, 123]. ICLs left unrepaired can lead to tumorgenesis, and people that 
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carry germline mutations in the ICL repair pathway are prone to a rare syndrome called 
Fanconi anemia (FA) [97]. While FA will be discussed in greater detail in proceeding 
sections, FA cells have provided a source to elucidate ICL repair.   
The mechanism of ICL repair is cell cycle dependent.  If damage occurs during G1, 
NER can resect some ICLs.  If the ICL damage cannot be repaired via NER, it is carried on 
into S phase.  During S phase the replication fork will stall when it encounters the ICL 
because the DNA will be unable to unwind [97].  The replication fork collapse can be 
stabilized through HR, followed by unhooking of the ICL by nucleases MUS81 and EME1, 
translesion synthesis and then completion through HR [97]. Alternatively, ICL is identified by 
FANCM [124].  FANCM has an ERCC4 nuclease domain that binds to branched DNA and a 
domain that interacts with the FA core complex. The FA core complex is composed of 7 FA 
proteins, including FANCA, FANCB, FANCC, FANCE, FANCF, FANCG and FANCL.  
Forming a heterodimer with FAAP24, which also has an ERCC4 domain, stabilizes FANCM. 
FANCM-FAAP24 recruitment of the FA core complex to the site of damage is restricted to 
cell cycle phases where replication is occurring [97, 124, 125].  The FA core complex 
includes the ubiquitin ligase FANCL, which monoubiquinates FANCD2 and FANCI [126, 
127].  It is believed that monoubiquination of FANCD2 and FANCI stabilizes their binding to 
the ICL site.  Following localization of FANCD2 and FANCI to the ICL site, repair and 
checkpoint proteins such as RPA (activating ATR), BRCA1, BRCA2 and the Bloom’s 
syndrome complex (BTR) proteins are recruited to the ICL site.  BTR is comprised of 
topoisomerase IIIα, RMI1, RMI2 and BLM, which are required for the resolution of Holliday 
junctions.  ICLs are then resolved through HR mediated by BRCA1 and BRCA2. Unresolved 
ICLs can lead to cell death, allowing chemotherapeutics that induce ICL to be effective 
against tumors [97]. 
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1.5 DEREGULATION OF DNA DAMAGE RESPONSE AND CANCER 
 To become malignant, cancer cells must acquire gene mutations to gain survival and 
proliferative advantage while avoiding growth arrest or apoptotic signals [64].  Therefore, 
germline or somatic mutations in DNA damage response (DDR) genes are known to 
contribute to the development of cancer and impact the effectiveness of cancer treatment 
(Table 4).  Furthermore, epigenetic silencing of DDR genes occurs frequently in cancer.  
Cells can compensate for the failure of one DNA repair pathway by upregulating another, 
which can lead to chemotherapy and radiotherapy resistance [128].  The following section 
will detail which DDR genes are mutated in cancer and how this can affect cancer therapy. 
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Table 4. Failure in DDR and Cancer 
Repair 
Pathway Protein 
Mutation/ 
Defect 
Contribution to 
Cancer Ref. 
BE
R
 
APE1 High expression 
Correlated with drug/radiotherapy 
resistance in NSCLC  & cervical 
cancer. Poor prognosis in 
osteosarcoma, medulloblastoma, 
breast and head and neck cancer 
[129, 
130] 
XRCC1 Polymorphism R339Q 
Decreased efficacy in BER, 
predisposed to cancer [131] 
PARP1 Polymorphism V762A 
Decreased activity, predisposed to 
cancer 
[132] 
NE
R
 
XP 
Proteins 
XPA, XPC, XPE, 
XPF & XPG 
Xeroderma pigmentosum: UV 
sensitivity and skin cancer, especially 
squamous cell and basal cell 
carcinoma 
[100] 
XPC gene 
methylation 
Correlated to worse outcome in 
bladder cancer [133] 
SNPs in XPA & 
XPC Correlated to lung and bladder cancer 
[134, 
135] 
SNPs in XPG (& 
XRCC1) 
Associated with response of NSCLC to 
platinum-based chemotherapy [136] 
ERCC1 
SNPs Predictor of response to therapy in lung cancer  
[137, 
138] 
Gene methylation Found in glioma, associated with 
cisplatin sensitivity [139] 
M
M
R MSH2, 
MLH1 & 
MSH6 
Gene promoter 
methylation 
HNPCC (aka Lynch syndrome): early 
onset (<45) of endometrial, gastric, 
renal, ovarian and skin cancer.   
[140] 
DS
B 
re
pa
ir 
NBS1 5 base pair truncation 
Nijmegen breakage syndrome 
(autosomal recessive): early onset of 
cancer, especially lymphoma (median 
age 11) 
[141] 
MRE11 
Point mutations  Associated with ovarian cancer [142] 
Shortening of 
poly(T)11 repeat, 
aberrant splicing 
Found in > 90% of colorectal cancers [143] 
NH
EJ
 
Ku70 
Polymorphism 
A46922G Correlated to breast cancer [144] 
Epigenetic 
silencing 
Correlated with colorectal, breast & 
lung cancer [128] 
Ku80 Gene promoter 
methylation 
Found in > 30% of squamous cell 
carcinoma [145] 
XRCC4& 
Ligase 
IV 
SNPs 
Associated with increased risk of 
glioma [146] 
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HR
 
BRCA1 
& 
BRCA2 
Germline mutation 
of BRCA1 
Increased risk of breast (> 70%) and 
ovarian cancer (>40%) by age 70 [147] 
BRCA1 promoter 
methylation 
Found in spontaneous breast, ovarian 
& lung cancer [148] 
Germline mutation 
of BRCA2 
Increased risk of breast, ovarian, 
colorectal, esophageal, pancreatic, 
stomach and hematopoietic cancer 
[149] 
Rad50 
Frameshift 
mutation, protein 
truncation 
Found in >30% gastrointestinal 
cancers 
[150] 
PALB2 
Monoallelic 
truncations, 
germline 
mutations 
Increased risk of breast cancer 2 – 4 
fold, correlated to pancreatic cancer [32] 
IC
L FANC 
proteins 
FANCA, FANCC, 
FANCG, FANCF, 
FANCE, FANCB, 
FANCD2, & 
FANCI 
High risk of AML (>50% by age 40), 
HNSCC, oesophageal & gynecological 
cancer 
[151] 
Gene methylation 
of FANCF 
Associated with neck squamous cell 
carcinomas, NSCLC, cervical & 
ovarian cancer 
[152-
154] 
Biallelic mutation 
FANCD1 
(BRCA2) 
Increased risk of early onset of 
childhood tumors, including Wilm’s 
tumor & medulloblastoma (mortality by 
5 yrs. of age) 
[155, 
156] 
 FANCN (PALB2) Fanconi anaemia N: early onset of Wilm’s tumor & medulloblastoma [157] 
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Several members of the BER pathway are mutated in cancer.  The R339Q mutation 
in XRCC1 can decrease BER efficiency and can increase the risk of developing cancer 
[131].  Furthermore, a variety of tumors have overexpression of the endonuclease APE1, 
which can protect against radiotherapy and chemotherapeutics, making it a viable target 
[129, 130]. 
 Mutations in the XP proteins, including XPA, XPC, XPE, XPF and XPG, of the NER 
pathway predispose people to the autosomal hereditary disease Xeroderma pigmentosum 
(XP) [158].  Mutations in XP proteins cause defects in the NER pathway that leads to 
sensitivity to UV radiation, leading to cell transformation, with the median age of onset for 
skin cancer at 8 years old [100, 159].  Patients with XP most commonly have basal cell or 
squamous cell carcinoma, but can also have melanoma, keratoacanthomas, angiomas and 
sarcomas [100]. XP patients also have a higher incidence of non-skin cancer malignancies, 
including brain tumors, leukemias and lung cancer [160, 161].  Accordingly, epigenetic 
silencing via methylation and single nucleotide polymorphisms (SNPs) of XPC increases risk 
of bladder cancer [162].  Also, SNPs in ERCC1 are associated with skin cancer and poor 
prognosis in non-small cell lung cancer (NSCLC), further demonstrating the importance of a 
functional NER pathway [161, 162]. 
 Defects in the MMR pathway, due to promoter methylation of MLH1 or mutations in 
MSH2 or MSH6, cause the development of autosomal dominant hereditary nonpolyposis 
colorectal cancer (HNPCC), or Lynch syndrome.  Lynch syndrome increases the risk of 
developing colorectal, stomach, ovarian and endometrial cancer [140].  Moreover, defects in 
the MMR pathway can cause resistance to the chemotherapeutic cisplatin, but are more 
sensitive to other cross-linking agents [163-165]. 
 The failure to detect DSBs due to a mutations or truncations in NBS1 causes 
Nijmegen breakage syndrome.  Nijmegen breakage syndrome is characterized by 
immunodeficiency, ovarian dysgenesis and infertility, chromosome instability, sensitivity to 
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radiation and high risk of developing cancer, especially lymphomas, at a very young age 
[141].  Point mutations in Mre11, another member of the MRN complex, are associated with 
hereditary breast and ovarian cancer [142].  Inactivated and mutated MRE11 is associated 
with MMR-deficient cancers [143]. 
 There are several mutated NHEJ proteins that contribute to cancer development.  
SNPs in Ku70 and Ku80 are correlated with the development of breast cancer, while 
epigenetic silencing of Ku80 correlates with lung cancer and squamous cell carcinoma [128, 
145, 166]. SNPs in ligase IV and XRCC4 are associated with increased risk of developing 
glioma [146].  Due to the importance of NHEJ to repair DSBs, DNA-PKc inhibitors are being 
developed to radiosensitize cancer cells, particularly in B-cell chronic lymphocytic leukemia 
[128]. 
Similar to NHEJ, members are of the HR pathway are often deregulated in tumors, 
allowing them to maintain a higher level of genomic instability that is characteristic of cancer. 
Germline mutations in the BRCA1 and BRCA2 genes are most frequently associated with 
developing HBOC, but are also known to increase the risk of developing prostate, 
pancreatic, melanoma and gastrointestinal tumors [147, 167, 168].  Moreover, even 
sporadic breast and ovarian tumors have been shown to have BRCA1 silencing via 
promoter methylation [148]. PARP inhibitors are being used to target BRCA-deficient 
tumors.  This is based on the premise that PARP inhibition prevents repair of SSBs, 
generating DSBs and forcing cancer cells to rely on HR to resolve DNA breaks; BRCA-
mutated cells are HR-deficient causing them to undergo cell death [169, 170].  Moreover, 
inhibiting HR can sensitize tumors to targeted therapy.  For example, CDK inhibition can 
reduce BRCA1 recruitment, sensitizing BRCA1 wildtype tumors to PARP inhibition [171].  
Most recently, germline truncations, alternative splicing and deletion mutations in PALB2 
were shown to increase the lifetime risk of developing breast cancer, especially in 
premenopausal women [32].  Gastrointestinal cancers with microsatellite instability can carry 
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frameshift mutations in Rad50 and BLM [150].  HR-defective cancers have been shown to 
be sensitive to DSB-inducing agents [172].  Defective HR is paradoxical in that it allows 
cancer cells to accumulate the gene mutations necessary for continued proliferation, while 
providing drugable targets and sensitizing cancer cells to DNA damaging agents. 
Failure in ICL repair due to gene mutations in the FA pathway is characteristic of 
Fanconi anemia, a rare genetic disease that causes decreased fertility, congenital 
abnormalities, bone marrow failure and increased risk of hematological and squamous cell 
cancer [173].  FA is diagnosed via cytogenetic analysis in which lymphocytes are subjected 
to ICL-inducing agents, such as platinum-based chemotherapeutics.  FA-positive cells are 
hypersensitive to ICL-inducing agents, showing increased chromosomal breaks [174].  A 
majority of FA patients suffer from FANCA (65%), FANCC (15%) or FANCG (10%) 
mutations. However, mutations have been found in a variety of FA pathway genes, including 
FANCD2, FANCI and other HR genes [128].  Again, the high prevalence of cancer in 
carriers of FA gene mutations emphasizes the importance of effective DNA repair pathways. 
1.6 MOLECULAR SUBTYPES OF BREAST CANCER 
 Having detailed some of the major causes and deregulated pathways associated 
with cancer, this section will describe the molecular characteristics of breast cancer and how 
they impact treatment strategies.  Breast cancer is a heterogeneous disease due to 
differential gene expression, which affects treatment response and prognosis.  Microarray 
analysis was used to delineate five molecular breast cancer subtypes, including luminal A, 
luminal B, human epidermal growth factor receptor 2 (HER2) positive, basal-like and normal-
like breast cancer (Table 5) [175, 176].  Additionally, a claudin-low subtype and seven 
distinct subtypes within basal-like breast cancer have been identified [177, 178].  The 
subtype of breast cancer determines how the tumor responds to targeted therapy or DNA 
damage inducing treatments, including chemotherapy and radiotherapy.  Molecular 
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subtypes also present differently in the clinic [179].  This section will detail the characteristics 
of all the molecular subtypes and new promising therapies entering the clinic.  
 
 
 
  
Table 5. Molecular sub-types of breast cancer 
 
Expression 
Profile 
Prevalence 
(%) Prognosis 
Treatment 
options 
Normal-like Lo PARP1 and Chk1, hi ALDH 3-10 Good Undetermined 
Luminal A ER+, PR+, HER2-, lo ki67 24-39 Good 
Endocrine 
therapy 
Luminal B 
ER+(low), PR+ 
(low), HER2+, hi 
ki67 
10-18 Poor 
Endocrine 
therapy plus 
chemotherapy 
HER2 positive ER-, PR-, HER2+ 12-25 Poor 
Trastuzumab, 
lapatinib (plus 
chemotherapy) 
Basal-like 
ER-,PR-, HER2-, 
CK 5/6, 14,17, 
EGFR 
15 Poor Chemotherapy, 
surgery 
Claudin-low 
Lo claudin 3,4,7, 
occuldin, lo E-
cadherin, hi 
CD44+/CD24-/low 
12-14 Poor 
Chemotherapy 
(dependent upon 
hormone/HER2 
status)  
Adapted from: [175, 176, 178, 180-182], Lo = low, Hi = high, CK = cytokeratins 
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1.6A NORMAL BREAST-LIKE CANCER 
 Up to 10% of breast cancers are diagnosed as normal breast-like tumors, which are 
composed mostly of normal cells, including stromal cells, and show high expression of 
genes found in adipose tissue [180, 183].  These tumors also have decreased expression of 
proliferation genes compared to Luminal B, HER-2 and basal-like subtypes, while being 
enriched for mesenchymal and extracellular matrix genes [184, 185].  Normal breast-like 
tumors have low expression of PARP1 and Chk1, but have high expression of the stem cell 
marker ALDH1.  ALDH1 expression is also common in stromal cells [185].  Patients with 
normal-breast like tumors show lower overall survival and recur sooner than patients with 
the Luminal A subtype [180].            
1.6B LUMINAL A 
Luminal A breast cancer is more prevalent in post-menopausal women [181].  Both 
luminal breast cancer sub-types are ER-positive.  Immunohistochemistry (IHC) staining is 
used to detect ER expression; as little as 1% of cells staining positive for ER qualifies the 
tumor as ER positive [186].  The ligand estradiol binds to ER, activating ER to go to the 
nucleus where it regulates gene expression [187, 188]. The luminal A subgroup is 
characterized as being HER2 negative and progesterone receptor (PR) positive, with higher 
ER expression and lower expression of the proliferation markers Ki-67 and PCNA than 
luminal B tumors [189-192].  Luminal A tumors also have overexpression of GATA binding 
protein 3, X-box binding protein 1, trefoil factor 3, hepatocyte nuclear factor 3α and estrogen 
regulated LIV-1 [176, 180].  Luminal A tumors often present as histologically low-grade 
tumors with good differentiation [191].  Also, a majority of grade 1 luminal A tumors show 
genomic loss of chromosome 16q, which is correlated with good prognosis [190].  As a 
result, patients with luminal A tumors have a lower probability of developing distant 
metastasis, and have increased overall survival compared to patients diagnosed with other 
subtypes [176]. 
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The treatment breast cancer patients receive is based on the disease stage and 
pathological features, including receptor status and tumor grade.  Patients with luminal A 
breast cancer are often treated with endocrine therapy, including selective estrogen 
response modulators (SERMs), such as tamoxifen and raloxifene, which can bind to ER and 
inhibit its activity in cancer cells [193].  Treatment with tamoxifen is often combined with 
breast conservation surgery, in which a lumpectomy is performed followed by radiotherapy.  
As adjuvant therapy, 5 years of tamoxifen reduces risk of recurrence by 47% and death from 
ER-positive breast cancer by 26% [194].  Tamoxifen and raloxifene are also effective as 
preventive agents for women who are at high risk of developing invasive cancer. 
Unfortunately, tamoxifen is associated with increased risk of developing endometrial cancer.  
However, raloxifene is associated with lower rates of endometrial cancer and can equally 
prevent the development of invasive cancer in high-risk patients [195].  While SERMs have 
efficacy in both pre-menoposual and post-menopausal women, post-menopausal women 
often receive aromastase inhibitors, including anastrozole, letrozole and exemestane [193].  
As described previously, aromatase is an enzyme that converts androgen into estrogen [22].  
A phase III clinical trial found that anastrozole extended time to progression (TTP) in post-
menopausal women with metastatic breast cancer (MBC) to 11.1 months versus 5.6 months 
with tamoxifen treatment [196].  Moreover, letrozole increased TTP to 41 weeks versus 26 
weeks with tamoxifen treatment when used as a first line of therapy in post-menopausal 
patients with advanced ER positive breast cancer [197].  Notably, the multi-center 10-year 
Arimidex tamoxifen alone or in combination study found that while anastrozole significantly 
improved disease-free survival (DFS) and time to recurrence compared to tamoxifen alone 
or in combination, it did not significantly improve overall survival in post-menopausal women 
with hormone positive breast cancer [198].  The efficacy of endocrine therapy as 
neoadjuvant therapy, or therapy given prior to surgery, is still being studied, but initial 
reports suggest improved response of letrozole or anastrozole compared to tamoxifen [193].  
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The anti-ER agent fulvestrant is used as a second-line therapy in post-menopasual patients 
with advanced ER-positive breast cancer, and is effective in tamoxifen refractory MBC 
disease [199].  Overall, due to the development of endocrine therapy and a non-aggressive 
disease, patients with luminal A breast cancer have a good prognosis and fare better than 
patients with other sub-types. 
1.6C LUMINAL B 
          Tumors classified as luminal B have decreased ER positivity, have little or no 
expression of PR, are more likely to be HER2 positive (20% via IHC and mRNA) and have 
higher expression of Ki-67 compared to luminal A tumors.   Although high expression of Ki-
67 has been defined as greater than 13.5% positively stained cells, there have been 
discrepancies in the scoring of Ki-67 via IHC, and the method is not standardized yet [189, 
200, 201].  Microarray data shows increased gene expression of cyclin E, peroxiredoxin, 
squalene epoxidase, gamma-glutamyl hydrolase and nuclease sensitive element binding 
protein 1 are all specific to luminal B tumors [176, 180].  Also, about one third of luminal B 
tumors carry TP53 mutations [202].   Luminal B tumors are distinguished from luminal A 
tumors as being high grade and showing poor differentiation, with patients having increased 
risk of recurrence and distant metastasis primarily to the bone and lung.  Moreover, use of 
the OncotypeDX, a diagnostic program that predicts outcome and optimal treatment based 
on molecular characteristics of the tumors, often gives luminal B breast cancer a high 
recurrence score (RS). The increased risk of metastasis and overall more aggressive 
disease results in a decreased overall survival compared to patients with luminal A breast 
cancer [183, 191, 193, 203].   
 Luminal B breast cancer patients are less responsive to endocrine therapy, and 
benefit from the addition of chemotherapy for treatment [201].  Post-menopausal, ER-
positive breast cancer patients with high RS were at greater risk of developing distant 
recurrence when treated with endocrine therapies anastrozole, tamoxifen or in combination 
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compared to patients with low or intermediate RS [204]. A clinical trial with node-negative, 
ER-positive patients measuring the risk of distant recurrence in low, intermediate or high RS 
patients who received tamoxifen or tamoxifen plus the chemotherapies cyclophosphamide, 
methotrexate and fluorouracil (CMF) or MF found that only high RS patients saw a 28% 
increase in distant recurrence free survival, versus only a 1.1% benefit in low RS patients 
[205].  Moreover, a phase III trial with node-positive, ER-positive post-menopausal patients 
found that 57% of patients that received cyclophosphamide, Adriamycin (doxorubicin) and 
fluorouracil (CAF) prior to or concurrent with tamoxifen had DFS versus 48% of patients who 
received tamoxifen alone during a 10-year follow-up [206].   While the CAF cocktail is 
effective, a trial comparing CAF versus docetaxel, doxorubicin and cyclophosphamide (TAC) 
found that 85.2% of patients with luminal B breast treated with TAC had 3 years of DFS 
versus 79% treated with CAF [207, 208].  Therefore, patients with luminal B breast cancer 
benefit from the combination of endocrine therapy and chemotherapy, but the 
aggressiveness of the disease still calls for more efficient treatment strategies.     
 There are novel therapies being developed to treat luminal B breast cancer that 
would target other pathways involved in proliferation and drug evasion.  For example, 
targeting the mTOR pathway in combination with letrozole has shown to be promising both 
in neoadjuvant and metastatic settings [209, 210].  Combination of the mTOR inhibitor 
everolimus with tamoxifen in patients with aromatase inhibitor pre-treated metastatic disease 
increased progression free survival (PFS) by four months and increased overall survival 
[211].  In a phase II trial, inhibition of fibroblast growth factor receptor (FGFR) in patients 
with luminal metastatic disease that had amplification of FGR1, a known mechanism for 
endocrine resistance, induced either a partial or stable response in patients [201].  Overall, 
new treatment strategies that target pathways known to participate in endocrine resistance 
appear to be promising for patients with luminal breast cancer.   
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1.6C HER-2-POSITIVE BREAST CANCER 
 HER-2, or ERBB2, is a member of the epidermal growth factor (EGF) receptor 
family, which is a subclass of the receptor tyrosine kinases superfamily.  The fours receptors 
within the EGF family are EGFR/ERBB1, ERBB2 (HER-2), ERBB3 and ERRB4, all of which 
are transmembrane proteins with extracellular ligand binding domains and cytoplasmic 
tyrosine kinase domains [212].  All of the EGF receptor family members, except HER-2, 
have specific ligands that cause receptor activation.  HER-2 has no soluble ligand, but is the 
preferred partner to form heterodimers with other activated EGF receptors [213]. Receptor 
activation leads to homodimer or heterodimer formation, followed by phosphorylation of the 
cytoplasmic tail, which acts as docking site for other proteins to activate downstream 
signaling [212]. Downstream pathways activated by HER-2 signaling include the mitogen-
activated protein kinase (MAPK) pathway and the PI3K pathway [214, 215].  HER-2 can 
also sequester the CDK inhibitor p27, preventing it from inhibiting CDK2 activity, promoting 
proliferation [216].     
 HER-2 gene amplification and overexpression, detected through either fluorescence 
in situ hybridization or IHC, occurs in 12 to 25 percent of breast cancers [183, 217].  HER-2 
overexpression has also been detected in ovarian, gastric and salivary tumors [212, 218, 
219]. The HER-2 pathway is constitutively active when HER-2 is overexpressed, as it can 
form homodimers with itself [212].  Patients with HER-2 positive breast cancer have a poor 
prognosis and decreased overall survival compared to non-HER-2 positive breast patients, 
with a majority of tumors being poorly differentiated and high-grade [181, 218].  HER-2 
positive breast cancer preferentially metastasizes to the liver, brain and bone [203].  
 However, targeted therapies have been developed to treat HER-2 positive breast 
cancer.  The recombinant, humanized monoclonal antibody trastuzumab (Herceptin) binds 
to the extracellular domain of HER-2, inhibiting its activity and sequestering it away from 
other EGF receptors [193].  Since, trastuzumab had an objective response rate (RR) of 35% 
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in HER-2 overexpressing MBC patients, it was initially only approved as a single agent 
[220].  However, subsequent trials evaluated the combination of trastuzumab with an 
anthracycline (either doxorubicin or epirubicin) and cyclophosphamide or paclitaxel (in 
patients who had previously received anthracycline chemotherapy) in HER-2-positive MBC 
patients.  When comparing trastuzumab plus chemotherapy versus chemotherapy alone, 
time to disease progression increased to 7.4 months versus 4.6 months, with median 
survival increasing to 25.1 months versus 20.3 months.  Unfortunately, 27% of patients who 
received an anthracycline with trastuzumab had cardiac dysfunction [221].  As a result, 
trastuzumab is only used in combination with non-anthracycline chemotherapies [193].  
Moreover, trastuzumab has been approved to be included in adjuvant therapy in patients 
with localized breast cancer, due to a 52% decrease in risk of disease recurrence and 
91.4% overall survival compared to 86.6% of the control group with a 24 month follow-up 
[222].  The small molecule inhibitor lapatinib binds to and inhibits the tyrosine kinase domain 
of EGFR and HER-2 [193].  The addition of lapatinib to capectiabine versus capecitabine 
alone increased time to progression to 8.4 months versus 4.4 months in HER-2 positive 
MBC patients who previously received anthracyclines, taxanes and trastuzumab [223].  A 
randomized, open-label phase III trial examined lapatinib alone, trastuzumab alone, or in 
combination in HER-2 positive breast cancer patients, and found that 51.3% of combination 
treated patients had pathological complete response (pCR) versus only 29.5% of 
trastuzumab treated patients [224].  Inhibition of EGFR alone via gefitinib, or in combination 
with trastuzumab, has not been effective in breast cancer patients [193].  While HER-2 
positive breast cancer is an aggressive disease, these patients can benefit from targeted 
therapy as single agents or in combination with chemotherapy.   
1.6D BASAL-LIKE BREAST CANCER            
 About 15% of breast cancers are classified as the aggressive subtype basal-like 
breast cancer (BLBC).  Forty percent of BLBC patients are premenopausal African American 
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women [181].  BLBC is characterized through gene-expression profiling as having 
expression of high-molecular weight basal cytokeratin (CK) 5/6, CK14 and CK17 and 
expression of EGFR, with 15-35% of BLBC tumors having EGFR gene amplification. 
Frequently, BLBC is ER and PR negative and HER-2 negative/low and have high Ki-67 
expression by IHC, characteristics that overlap with triple-negative breast cancer (TNBC) 
[225, 226].  However, since not all BLBC are hormone receptor and HER-2 negative, BLBC 
is not synonymous with the clinical diagnosis of TNBC [226].  Up to 82% BLBC have been 
found to have TP53 gene mutations [180].  The similarities between sporadic BLBC and 
breast cancer due to germline mutations in BRCA1 have become increasingly recognized.  
A majority of BRCA1 mutation breast cancers are also negative for hormone receptors and 
HER-2 and carry TP53 mutations [28, 227].  BRCA1 mRNA has been found to be lower in 
BLBC sporadic tumors compared to non-BLBC sporadic tumors [228].  Moreover, both 
BRCA1 tumors and sporadic BLBC tumors present as high-grade tumors that have high 
expression of EGFR, Skp2 and cyclin E and low expression of cyclin D1 and p27 expression 
[28, 229].  Therefore, women carrying BRCA1 mutations who are at high risk of developing 
breast cancer are more likely to develop BLBC. 
 Patients with BLBC have a poor prognosis, with decreased overall survival and 
decreased relapse-free survival, especially during the initial 3-5 years after diagnosis, 
compared to the other subtypes [180, 230]. Unlike non-BLBC tumors, BLBC preferentially 
metastasizes to the brain and lung, with patients dying within 5-8 years of diagnosis [203, 
226].  Moreover, the basal-like phenotype predicts aggressive disease and low survival after 
the development of metastasis [231].   
 Since BLBC tumors can be ER, HER-2 low or triple-negative, BLBC status does not 
currently denote a specific type of treatment regimen.  Therefore, patients with ER-positive 
or HER-2 positive BLBC tumors receive endocrine therapy and trastuzumab, respectively.  
However, most BLBC tumors are triple-negative, which cannot benefit from currently 
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available targeted therapies, and only receive chemotherapy [226].  Treatment of TNBC will 
be discussed in greater detail in the following section.  Therefore, BLBC is an aggressive 
disease with high risk of recurrence, and the therapies used to treat this subtype are based 
on hormonal and HER-2 status. 
1.6E CLAUDIN-LOW BREAST CANCER 
 The claudin-low subtype is a more recently identified subtype using gene-expression 
analysis of human breast tumors and murine mammary tumors from transgenic mouse 
models [178].  Claudin-low tumors have low expression of the tight junction proteins claudin 
3,4,7 and occuldin and the epithelial marker E-cadherin.  Claudin-low tumors share some 
characteristics of basal-like tumors, including low expression of HER2 and luminal markers 
[178, 184].  These tumors have high expression of immune response genes, including 
genes that are typically expressed by B-cell and T-cell lymphocytes.  The presence of 
lypmphocyte proteins indicates immune cell infiltration; however, the expression CXCL2 
most likely occurs within the tumor cells [185].  Claudin-low tumors are also enriched for 
cells that express the tumor initiating stem cell markers CD44+/CD24-/low [232].  Additionally, 
these tumors have high expression of mesenchymal and stem cell markers N-cadherin and 
vimentin [184]. Moreover, tumor expression of CD44+/CD24-/low was more enriched in the 
claudin-low subtype following endocrine and chemotherapy treatment [233].              
 Only about 12-14% of breast cancers are classified as claudin-low tumors.  Claudin-
low tumors are predominantly triple negative, with only up 25% being hormone-receptor 
positive.  Patients with claudin-low tumors recurred sooner than the luminal A subtype and 
have lower overall survival than either luminal A or luminal B [184, 234]. There are currently 
no specific therapies to treat the claudin-low sub-type.  Similar to basal-like tumors, these 
tumors receive treatment based on their hormone-receptor and HER2 status.   
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1.7 TRIPLE-NEGATIVE BREAST CANCER 
 TNBC is a clinical diagnosis given to patients with breast tumors that lack expression 
of ER, PR or HER-2 amplification [177].  Up to 10- 20% of breast cancers are TN, with 
patients predominantly consisting of premenopausal, African American patients.  In fact, 
20.8% of African American patients with breast cancer are triple-negative, versus only 
10.4% of Caucasian patients [235].  TN tumors are aggressive with patients presenting at an 
advanced stage at time of diagnosis, with large, high-grade tumors that have metastasized 
to the lymph nodes [236].  Moreover, TNBC patients have a poor prognosis due to an 
increased rate of distant metastasis within the first five years of diagnosis, peaking at 3 
years, compared to patients with other subtypes who remained constant throughout.  Less 
than one third of women with metastatic TNBC survive 5 years [237, 238].  Similar to BLBC, 
TNBC preferential metastatic sites include, lung (40%), brain (30%), liver (20%) and bone 
(10%), differing from non-TNBC [239, 240]. As previously described, 70% TNBC tumors are 
classified as BLBC sub-type, with the remaining tumors falling into other subtypes [241]. 
TNBC tumors are more likely to occur in women with BRCA1 gene mutations, with 80% of 
breast cancer patients with BRCA1 mutations diagnosed as TN [227, 241, 242].  Over half 
of TNBC tumors have EGFR overexpression, which is correlated with poor prognosis [243].  
Additionally, TNBC tumors frequently have deregulated cell cycle machinery, including high 
expression of cyclin E, low expression of cyclin D and aberrant expression/ mutations in the 
tumor suppressor p53 [80, 244-246].  Also, a majority of TNBC tumors have loss of Rb, but 
this is correlated with a good prognosis [247].  Overall, TNBC tumors differ both molecularly 
and clinically from non-TNBC tumors (Table 6). 
  
  
46
Table 6. Comparison of TNBC and non-TNBC tumors 
 
TNBC non-TNBC 
Mean age at diagnosis (yrs.) 53 57.7 
Age < 40 at diagnosis (%) 12.2 5.7 
Tumor size at diagnosis (cm) 3 2.1 
Lymph node mets. (%) 54.4 45.6 
Grade III tumors (%) 66 28.3 
Poorly differentiated (%) 71.1 26.5 
Sites of distant metastasis 
(most likely to least likely) Lung, brain, liver, bones Bones, liver, lung, brain 
Basal cyotkeratins (%) 71 6.3 
EGFR (%) >60 2-16.5 
p53 mutation (%) 54-82 13 
Mitotic index High Sub-type specific 
Rb loss (%) 64.5 6.5-22.6 
Adapted from: [237], [240], [245, 247, 248] 
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              The heterogeneity of TN tumors was illustrated in gene expression analysis that 
generated 6 subtypes within TNBC, including basal like 1 (BL1), basal like 2 (BL2), 
immunomodulatory (IM), mesenchymal (M), mesecnchymal stem-like (MSL) and luminal 
androgen receptor (LAR) [177]. To determine if these subtypes could predict response to 
treatment, breast cancer cell lines used in the laboratory were also subtyped. The BL1 
subtype is enriched in cell cycle and cell division genes and the DNA damage ATR/BRCA 
pathway genes.  BL2 tumors have high expression of the EGF, WNT and IGF1R pathway 
genes.   Both BL1 and BL2 tumors have higher Ki-67 expression compared to the other 
subtypes.  Cell lines within the BL1/BL2 classification were much more sensitive to the 
chemotherapeutic Cisplatin compared to other subtypes.  However, not all cell lines 
responded equally to the PARP inhibitors veliparib and olaparib.  IM tumors are enriched for 
immune response genes, including the IL-12, IL-7, B cell receptor and natural kill cell 
pathways as well as the TNF and JAK/STAT signaling pathways. Genes involved in cell 
motility characterize the M subtype, including the Rho pathway, as well as extracellular 
matrix receptor interaction genes, including WNT, ALK and TGF-β pathways. In addition to 
Rho, TGF-β and ALK pathways, MSL tumors are enriched for EGFR, PDGF and ERK1/2 
pathway genes.  Both M and MSL tumors have higher expression of EMT genes, including 
MMP2, TWIST1 and ZEB1.  Compared to M tumors, MSL tumors have lower proliferation 
along with higher expression of stem cell genes.  Cell lines within this subtype are more 
sensitive to dasatinib, an inhibitor of the cell migration protein Src, than the LAR cell lines.  
Tumors within the LAR subgroup are enriched for androgen and estrogen metabolism, 
steroid biosynthesis, TCA cycle and sucrose and fatty acid metabolism genes [177]. LAR 
and a subset of MSL cell lines were sensitive to the AR antagonist bicalutamide, whereas 
basal-like cell lines had IC50 values greater than 500 um [177].  The identification of TNBC 
tumor subtypes could potentially lead to more personalized care for these patients.  
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 In contrast, a recent paper that employed RNA and DNA profiling analysis on TNBC 
tumors identified 4 TNBC subtypes, including Luminal-AR (LAR), Mesenchymal (MES), 
basal-like immune suppressed (BLIS) and basal-like immune activated (BLIA) [249].  The 
conflicting results between the Lehman et al. study and the Burstein et al. study may be due 
to the method used to confirm the TN status of tumors analyzed.  The LAR subtype is 
characterized by increased gene expression of cyclin D1, dehydrogenase/reductase 
member 2, prolactin-induced protein and androgen receptor.  Possible druggable targets 
against the LAR tumors include ER, PR and mucin 1 cell surface receptor.  The MES 
subtype shows high expression of EGFR and alcohol dehydrogenase 1B, with possible 
druggable targets including neurotrophic tyrosine kinase receptor type 2, endothelin receptor 
type B and interleukin 1 receptor.  The BLIS subtype is characterized by increased 
expression of fibroblast growth factor receptor 2 (FGFR2) and E74-like factor 5.  Patients 
with BLIS tumors show decreased disease-free survival compared to the other subtypes. 
Overexpression of FGFR2 provides a potential target for treatment of the BLIS subtype.  
Tumors in the BLIA subtype have gene amplification of CDK1, chemokine ligand 9 and 
topoisomerase II alpha.  In addition to topoisomerase II, possible drug targets against BLIA 
are chemokine ligand 10 and proteasome subunit beta type 9.  Overall, patients with BLIA 
tumors have a good prognosis and have increased disease-free survival compared to the 
other subtypes [249].  Further validation will most likely be required to consolidate the 
findings of both TNBC subtype studies.  In any case, the subtyping of TNBC will hopefully 
lead to the development of more targeted therapies.          
Since TN tumors do not express ER or HER2, they do not respond to current 
targeted therapies, including tamoxifen and trastuzumab.  As a result, TNBC patients 
receive chemotherapy and surgery for treatment [248].  There is no standard of care for 
TNBC patients, with patients receiving a variety of chemotherapeutics including 
anthracyclines, fluropyrimidines, taxanes and platinum-based drugs (Table 7).  The 
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alkyating agent cyclophosphamide, which forms interstrand and intrastrand crosslinks, is 
often added to anthraycline-based therapy to increase therapeutic benefit [250].  TNBC 
patients can also receive platinum-based chemotherapy both as a single agent and in 
combination therapy, with TNBC patients responding better to platinum based therapy 
compared to non-TNBC patients [251].  TNBC tumors are more likely to have pCR 
compared to ER positive tumors (22% vs 11%) to neoadjuvant chemotherapy.  A study that 
monitored patients treated with paclitaxel followed by treatment with 5-fluorauracil, 
doxorubicin and cyclophosphamide (FAC), found that TNBC patients had a higher rate of 
pCR of 45%, compared to only 6% in luminal tumors [179].  The delivery method of 
combination treatments can impact treatment efficacy.  For example, simultaneous 
administration of doxorubicin and paclitaxel in metastatic patients increased RR to 47% 
compared to 36% and 34% of doxorubicin or paclitaxel alone, respectively.  Interestingly, 
there was not significant benefit when drugs were administered sequentially [252].  
However, TNBC patients who do not achieve pCR in response to therapy, and have 
residual disease, have decreased overall survival compared with non-TNBC patients who 
had residual disease. Specifically, TNBC patients have decreased PFS and overall survival 
within the first 3 years of diagnosis [253].  Overall, drug combinations have greater efficacy 
over single-agent treatment, but can be associated with increased toxicity, compared to 
single agent therapy [193, 194].  Therefore, although TNBC patients initially respond well to 
chemotherapy, their poor prognosis and increased risk of recurrence forces a search for 
novel therapies.    
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Table 7. Chemotherapy options for TNBC patients 
Drug Family Mechanism of 
action Drugs 
Response as single 
agent in breast 
cancer patients 
Anthracyclines 
Intercalates with 
DNA, inhibits 
topoisomerase II 
activity 
Doxorubicin  10-50% 
Epirubicin 13-48% 
Etoposide 15-35% 
Anti-metabolites 
Nucleoside 
analogs, disrupt 
RNA and DNA 
synthesis 
5-fluorouracil  25-54% 
Capecitabine 20-35% 
Gemcitabine 12-37% 
Taxanes 
Microtubule 
stabilizer by 
binding to β-
tubulin 
Doxetaxel 21 days: 18-68% 7 days: 33-50% 
Paclitaxel 21 days: 16-62% 7 days: 22-53% 
Abraxane 33-48% 
Vinca-alkaloids 
Inhibit 
microtubule 
formation 
Vinorelbine 25-50% 
Platinum-based 
Covalent binding 
to DNA purine 
bases 
Cisplatin, carboplatin 9-51% 
Adapted from: [193], [254-261] 
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Several novel targeted therapies against TNBC are in clinical trials.  PARP inhibitors 
are proving to be very promising against BRCA1/BRCA2 mutation derived tumors.  PARP 
repairs SSBs via BER, with PARP inhibition leading to a collapse of replication forks.  This 
causes SSBs to develop into DSBs that would require HR for repair.  However, studies 
found that cancer cells with BRCA1/BRCA2 genes are deficient in HR, sensitizing cells to 
PARP inhibition [170, 262]. Since most BRCA-derived tumors are diagnosed as TN and TN 
tumors have many of the same DNA-repair deficiencies as BRCA tumors, PARP inhibitors 
became an obvious treatment strategy for TNBC.  PARP inhibitors are also being evaluated 
for serous ovarian cancer.  There are currently six PARP inhibitors being examined in the 
clinic, including olaparib, veliparib, rucaparib, BMN-673, CEP-9722 and niraparib [263].  As 
a single agent, PARP inhibitors have anti-tumor activity in BRCA-mutation carriers and non-
carriers (Table 8).  A phase II study in BRCA-mutation carriers with refractory disease found 
that olaparib monotherapy had a RR of 31.1% and 12.9% in ovarian and breast cancer 
patients, respectively [264].  Several trials have combined PARP inhibitors with 
chemotherapeutics, aiming to maximize DNA damage and tumor cell death (Table 8).  
Ongoing phase II/III trials, including combining rucaparib with cisplatin in TNBC patients with 
BRCA-mutations, will further illuminate the utility of PARP inhibitors in the clinic [263].       
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Table 8. Sample of clinical trials with PARP inhibitors 
Clinical trials independent on BRCA status 
NCT Identifier Regimens Setting Major Findings Ref. 
NCT007535451 Olaparib: 
single agent 
Randomized, double 
blind placebo-controlled 
phase II study for 
maintenance of recurrent 
platinum sensitive serous 
ovarian cancer 
Well tolerated; PFS 
improved of 8.4 
months vs. 4.8 
months [265] 
NCT00679783 Olaparib 
Phase II study in TNBC 
and serous ovarian 
cancer 
OR in 41% of BRCA 
patients vs. 24% in 
non-BRCA patients 
(ovarian); no OR in 
BC patients 
[266] 
NCT00707707 Olaparib with Paclitaxel 
Phase I study in 
metastatic TNBC patients 
Diarrhea, nausea and 
neutropenia.  37% 
partial response 
[267] 
Clinical trials dependent on BRCA status 
NCT00628251 
Liposomal 
doxorubicin 
and olaparib 
Phase II study BRCA-
patients with relapsed 
ovarian cancer 
No statistical 
difference in 
treatment groups 
[268] 
NCT0144518 Carboplatin 
and olaparib 
PhaseI/IIb study in 
BRCA-patients with 
breast and ovarian 
cancer 
Well tolerated; 50% 
partial response, 1 
patient pCR [269] 
NCT00749502 Niraparib 
Phase I study (24/100 
with BRCA mutations) 
Well tolerated; 40% 
OR in BRCA-patients 
with ovarian cancer, 
50% OR in BRCA-
patients with BC 
[270] 
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EGFR has become an attractive target against TNBC.  Some studies have found up 
to 64% of TNBC tumors having overexpression of EGFR protein; with 33% of tumors having 
high EGFR gene copy number, correlating to poor outcome [271].  In vitro studies 
demonstrated increased sensitivity of BLBC cells to the monoclonal antibody cetuximab 
compared to luminal cells, with combination therapy of carboplatin followed by cetuximab 
being synergistic [272].  A randomized phase II study examining cetuximab alone versus 
cetuximab with carboplatin in TN MBC patients found that while cetuximab was well 
tolerated, it showed low activity against the tumor.  However, combination therapy had an 
18% RR, with 27% of patients showing clinical benefit [273].  However, more clinical trials 
are needed to validate the efficacy of targeting EGFR as both single-agent and combination 
therapy.   
 The vascular endothelial growth factor (VEGF) family and their receptors (VEGFR) 
are required for angiogenesis and have been linked to tumor growth and metastasis in 
variety of tumors, including breast cancer [193, 274].  As single-agent therapy, bevacizumab 
(Avastin), a humanized recombinant antibody against VEGF-A, had a RR of 6.7% in a 
phase I/II trial in MBC patients, with 22% of patients experiencing hypertension [275]. 
However a phase III trial in metastatic breast cancer patients found that paclitaxel plus 
bevacizumab versus paclitaxel alone increased PFS to 11.8 vs. 5.9 months and RR to 
36.9% vs. 21.2%, respectively [276]. Moreover, a randomized study in TNBC patients with 
primary tumors found treatment with epirubicin and cyclophosphamide followed by 
docetaxel with and without the addition of bevacizumab increased pCR to 39.3% versus 
27.9%, respectively [277].  Therefore, inhibition of angiogenesis can increase the response 
to chemotherapy in TNBC patients.    
1.8 GAP IN KNOWLEDGE  
 The molecular and clinical characteristics of TNBC demonstrate that TNBC patients 
cannot benefit from currently approved targeted therapy.  Initial sensitivity to 
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chemotherapeutics has not been able to greatly improve the overall survival and prognosis 
of TNBC patients. While novel treatments are in development, current studies do not 
investigate how targeting the deregulated TNBC cell-cycle checkpoints could be 
synthetically lethal with chemotherapeutics.  In order to generate a novel treatment strategy 
the following questions must be answered:       
• Would the deregulation of the cell cycle sensitize TNBC cells to cell cycle inhibitors; 
would non-TNBC and non-transformed cells respond differently? 
• Can a synthetic lethal combination of cell-cycle inhibition and chemotherapeutics 
specifically target TNBC cells, without inflicting harm to non-transformed cells? 
• Will combination cell cycle targeted therapy be an effective method in a pre-clinical 
model? 
• What affect would combination therapy have on the cell cycle of TNBC cells 
compared to non-transformed cells? 
•  Is there a molecular target/pathway that can be used as a marker to predict 
combination treatment response? 
• Can combination treatment augment the DNA damage inflicted by 
chemotherapeutics explicitly in TNBC cells? 
The following chapters of this dissertation will address these questions.  The overall 
hypothesis of this dissertation is that TNBC cells are sensitive to cell cycle-targeted 
combination therapy, leaving non-transformed cells unharmed.  The examination of 
these questions, potentially leading to the generation of a novel targeted therapy treatment 
strategy, could greatly improve the care of TNBC patients.   
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CHAPTER 2: SEQUENTIAL ADMINSTRATION OF ROSCOVITINE FOLLOWED BY 
DOXORUBICIN INDUCES SYNERGISTIC CELL DEATH IN TNBC CELLS 
2.1A DEREGULATION OF THE CELL CYCLE IN BREAST CANCER 
As with all tumor cells, breast cancer cells possess the ability to proliferate 
continuously due to gene amplifications of cycling promoting factors, mutations in CKIs and 
alterations in protein expression.  About 15% of breast cancer tumors have gene 
amplification at chromosome 11q13, where CCND1 is located [278].  Moreover, 50% of 
breast cancers have high cyclin D1 expression at both the mRNA and protein level, 
contributing to Rb inhibition [279, 280].   Also, there is a positive correlation between ER 
positivity and cyclin D1 expression, with ER activity inducing cyclin D1 transcription [281, 
282].  Unlike cyclin D1, cyclin E is seldom amplified in breast cancer.  However, over 40% of 
breast tumors have cyclin E overexpression at the protein level, contributing to CDK2 
overactivation [80, 283].  Cyclin E protein overexpression is a poor prognostic marker in 
breast cancer, and is associated with negative ER and PR status [80, 284].  As previously 
described, cytoplasmic localization of LMW-E is oncogenic in breast cancer, and has been 
shown to specifically enable ER positive breast cancer cells to bypass letrozole-induced G1 
arrest [76, 285]. High expression of cyclin B1 in either the cytoplasm or the nucleus 
correlated with poor overall survival in breast cancer, suggesting that any increase in cyclin 
B1 expression can increase the aggressiveness of the tumor [286].  In addition to aberrant 
cyclin expression, CKIs can also be deregulated in cancer.  The CKI p27 has decreased 
expression and irregular cytoplasmic localization in breast cancer cells.  Moreover, 
decreased nuclear p27 expression correlated with high tumor grade, negative ER status and 
could serve as predictor of decreased disease free survival in breast cancer [287, 288].  
About 20-30% of breast cancers have promoter hypermethylation, leading to epigenetic 
silencing of the CKI p16INK4A gene [289].  Whereas p21 is rarely mutated in breast cancer, 
the p21 transcription factor p53 is mutated in 54-82% of BLBC and TNBC [180, 290, 291].  
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Activity of kinases that participate in chromosome segregation can also be augmented in 
breast cancer.   Aurora A kinase, required for chromosome segregation, is often 
overexpressed in breast cancer due to gene amplification, leading to chromosomal 
instability [292].  Importantly, microarray analysis on breast cancer tumors from patients 
under the age of 55 revealed that expression of several cell cycle genes, such as cyclin E2, 
cyclin B2, CDC25B, and Bub1, comprise a poor prognosis gene signature that predicts 
metastasis in less than 5 years [234].  Therefore, targeting the cell cycle is a viable 
treatment option for breast cancer, especially to target more aggressive tumors.   
2.1B CYCLIN AND CDK KNOCKOUT MICE 
Cyclin and CDK knockout mice were generated to investigate the role of each protein 
during development and to examine compensatory mechanisms within the cell cycle (Table 
9).  For example, cyclin A1 knockout mice are viable, with only male mice suffering from 
sterility.  This suggests that cyclin A2 can compensate for cyclin A1, and that cyclin A1 is 
only required for spermatogenesis [293].  However, cyclin A2 knockout mice are embryonic 
lethal [294].  Similarly, while cyclin B1 knockout mice are embryonic lethal, cyclin B2 are 
viable, indicating that cyclin B1 can compensate for cyclin B2 during development.  
Knockout of other cyclins show abnormalities in specific tissues, indicating their participation 
in tissue-specific development (Table 9).  Cyclin A and B are required to activate CDK1, with 
CDK1 knockout mice also being embryonic lethal [295].  Moreover it was found CDK1 could 
bind to cyclin E in CDK2-deficient MEFs and, in the absence of all interphase CDKS, can 
phosphorylate Rb to complete the cell cycle [295, 296].  Together, these studies indicate 
that CDK1 activity can drive the entire mammalian cell cycle in the absence of other CDKs 
[295].  However, the compensatory mechanisms observed in in vivo model systems do not 
always translate to CDK inhibition studies in vitro.  This may be because CDK inhibition 
does not automatically make their cyclin subunits accessible to bind to other CDKs.   
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Therefore, in vitro systems are often preferred for development of CDK inhibitors as 
opposed to transgenic models [33].      
Table 9. Phenotypes of cyclin and CDK knockout mice 
Cyclin/CDK Phenotype Ref.  
Cyclin A1 Viable, no abnormalities.  Only male mice sterile [293] 
Cyclin A2 Embryonic lethal at E5.5 [294] 
Cyclin B1 Embryonic lethal at E10.5 [297] 
Cyclin B2 Viable, no abnormalities, both genders fertile.   [297] 
Cyclin D1 
Viable, reduced body size, neurological abnormalities, 
hypoplastic retina, mammary gland defects (inability to 
lactate during pregnancy) 
[298, 299] 
Cyclin D2 
Viable, females sterile and males with hypoplastic testes.  
Defects in B-lymphocyte proliferation, pancreatic β-cell 
proliferation, hypoplastic thymus and abnormalities in 
cerebellar development and adult neurogenesis  
[300-302] 
Cyclin D3 Viable. Defects in T-lymphocyte development [303] 
Cyclin D1/D2 Reduced body size, hypoplastic cerebella, mortality 3 
weeks after birth [304] 
Cyclin D2/D3 Megaloblastic anemia, embryonic lethal at E17.5 [304] 
Cyclin 
D1/D2/D3 
Proliferative defects in hematopoietic cells and cardiac 
myocytes, embryonic lethal at E16.5 [305] 
Cyclin E1 Viable, no abnormalities [306] 
Cyclin E2 Viable, no abnormalities, reduced male fertility [307] 
Cyclin E1/E2 Defects in extraembryonic tissues, embryonic lethal at E11.5 [307] 
CDK1 Embryonic lethal E2.5 [295] 
CDK2 Reduced body size, impaired neural progenitor cell proliferation, both genders sterile [308, 309] 
CDK4 Reduced body size, insulin deficient, diabetes caused by 
reduced pancreatic β-cells,  [310] 
CDK6 Hypoplasia and defects of thymus and spleen  [311] 
CDK2/4 Heart defects, embryonic lethal at E15.5 [312] 
CDK2/6 Reduced body size, hematopoietic defects, both genders 
sterile [311] 
CDK4/6 Severe anemia, embryonic lethal at E14.5-E18.5 [311] 
CDK2/4/6 Heart defects, hematopoietic defects, embryonic lethal at E13.5 [295] 
CDK5 Severe neurological defects, mortality immediately following birth [313] 
CDK11 Embryonic lethal at E3.5 [314] 
Adapted from: [33] 
            
2.1C CDK INHIBITORS IN CANCER
 CDK inhibitors have been developed
cycle in cancer.  The two main 
non-ATP inhibitors.  ATP-competitive inhibitors bind to the CDK catalytic ATP
preventing CDK activation.  ATP
including natural products (i.e. flavon
pyrazoles and thiaozoles (Table 10
CDK inhibitors that have been
 
 Table 10.  Clinically examined
Drug 
(Company) 
Drug  
Family 
Flavopiridol 
(Sanofi-
Aventis) 
Flavone 
Palbociclib 
(Pfizer) Pyridopyrimidine
Dinaciclib 
(Merck) 
Pyrazolo-
pyrimidine 
Roscovitine 
(Cyclacel) Purine 
Adapted from: [315] Chemical structures adapted from Sigma
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 to target the consistent deregulation of the cell 
types of CDK inhibitors are ATP-competitive inhibitors and 
-competitive inhibitors consist of heterocyclic families, 
es and staurosporine), purines, pyrimidines
) [315].  The following section will detail ATP
 extensively examined clinically (Table 11).   
 CDK inhibitors 
Structure 
 
CDK1, CDK2, CDK4, 
CDK6, CDK7 & CDK9
 
 
CDK4/CDK6
 
CDK1, CDK2, CDK5 & 
 
CDK1, CDK2, CDK5, 
CDK7, & CDK9
-Aldrich and Selleckchem 
-site, 
, indoles, 
-competitive 
Target 
CDKs 
 
 
CDK9 
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Table 11. Clinical trials with CDK inhibitors  
Drug Trial  Phase Results Ref. 
Flavopiridol 
I Solid tumors: complete response/partial response in 5/27 patients, stable disease in 10/27 patients (C) [316] 
I CLL: partial response in 40% of patients, PFS of 12 
months (M) [317] 
II Malignant melanoma: no clinical significance (M) [318] 
II NSCLC: No OR, disease progression in 4/20 patients (M) [319] 
II 
AML: With cytrabine and mitoxantrane increased 
complete remission compared to standard of care 
(C)  
[320] 
Palbociclib 
I 
Advanced Rb-positive solid tumors: In a 28-day 
cycle (3 weeks on, 1 week off), 125 mg/daily is 
MTD.  SD in 35% of patients (M) 
[321] 
II 
Advanced Rb-positive BC: 38% of patients had SD 
for over 6 months, with 19% of patients having 
some clinical benefit.  Over 50% of patients had 
dose reduced because of cytopenia (M) 
[322] 
II 
Advanced ER-positive BC: Improved PFS from 10.2 
vs. 20.2 months comparing letrozole vs. letrozole 
plus palbociclib, respectively (C vs. M) 
[323] 
III ER positive BC: on-going with letrozole (C vs. M) NCT01740427 
Dinaciclib 
I 
10/48 patients, including (NSCLC, prostate cancer 
sarcoma, melanoma, esophageal carcinoma, 
gastrointestinal stromal tumor, adenoid cyst 
carcinoma and pseudomxyoma peritonei) achieved 
SD for at least four 28-day treatment cycles (M) 
[324] 
II 
Advanced breast cancer: 2/7 patients had PR, no 
benefit compared to capecitabine (TTP 2.73 vs. 
4.17 months) (M) 
[325] 
II 
NSCLC: TTP 1.49 vs. 1.58 months, dinaciclib vs. 
erlotinib, respectively. Adverse effects included 
neutropenia, leukopenia, vomiting and diarrhea (M) 
[326] 
III CLL: dinaciclib vs. Ofatumumab, on-going (M) NCT01580228 
Roscovitine 
I Nasopharyngeal cancer: 50% of patients had tumor 
reduction (M) [327] 
I 
NSCLC: In combination with gemcitabine and 
cisplatin.  Patients showed PR (6/27), SD (7/27) 
and disease progression (1/27). MTD 800 mg (C) 
[328] 
I 
Advanced solid tumors: Sequential combination 
treatment sapacitabine and roscovitine induced PR 
2 patients with breast and pancreatic cancer and 
SD in 6 patients.  Germline BRCA mutation 
suggested as marker to response (C) 
[329] 
M = monotherapy, C = combination therapy 
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Flavopiridol is a semisynthetic flavone analog of an Indian plant rohutkine.  
Flavopiridol has shown to have activity against CDK1, CDK2, CDK4, CDK6, CDK7 and 
CDK9 at nanomolar concentrations and has also been shown to decrease cyclin D1 mRNA 
expression.  Flavopiridol is administered intravenously [290, 330].  In vitro studies performed 
on multiple myeloma cell lines found that flavopiridol induces apoptosis while reducing 
mRNA and protein levels of the anit-apoptotic protein MCL-1 [331].  However, this CDK 
inhibitor has shown mixed results in the clinic (Table 11). Untreated metastatic melanoma 
patients enrolled in a phase II study showed no significant clinical benefit with single-agent 
flavopiridol. Although flavopiridol was relatively well tolerated, over 80% patients suffered 
from diarrhea [318].  Similarly, a phase II trial in NSCLC patients showed no objective 
response, with some patients progressing during treatment [319].  Phase II studies in 
patients with acute myeloid leukemia who were treated with flavopiridol followed by 
cytarabine and mitoxantrone had increased complete remission rates compared to patients 
treated with cytarabine and danurubicin [320].   Moreover, a phase I trial in patients with 
solid tumors found that combination of docetaxel followed by flavopiridol induced complete 
response or partial response in 5/27 patients and stable disease (SD) in 10/27 patients 
[316].  These studies illustrate the clinical potential of flavopiridol in combination therapy.  
Although flavopiridol has shown promising results in leukemias, its manufacturer, Sanofi-
Aventis, is no longer developing it for cancer treatment [315].     
Palbociclib is a potent CDK4/CDK6 inhibitor that has promising therapeutic potential 
in breast cancer [332].  While other CDK4/CDK6 inhibitors, such as LEE011 and LY283519 
have been clinically examined, palbociclib is the focus here due to the success and efficacy 
it has made in breast cancer (Table 11) [333]. An in vitro study that examined the response 
of forty-four human breast cancer cell lines and three immortalized cell lines to palbociclib 
treatment found that luminal ER positive (including HER2 amplified) cells were the most 
sensitive to treatment compared to BLBC or cells that had undergone epithelial to 
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mesenchymal transition.  Growth inhibition was measured via cell counting, as no 
cytotoxicity was detected.  Moreover, sensitive cells had elevated gene expression of Rb 
and cyclin D1 and decreased levels of p16.  Palbociclib treatment reduced phospho-Rb 
specifically in sensitive cell lines, causing a G0/G1 arrest.  Additionally, palbociclib increased 
the growth inhibitory affect of tamoxifen and trastuzumab treatment in ER-positive and 
HER2 amplified cell lines, respectively [334].   When examined in drug resistant cell lines, 
palbociclib treatment re-sensitized cells to tamoxifen and induced growth arrest and 
senescence in cells resistant to endocrine therapy [334, 335].  A phase I study that enrolled 
patients with Rb-positive advanced solid tumors refractory to standard treatment examined 
treatment with palbociclib in a 3 weeks on, 1 week off schedule, found that 125 mg once 
daily was the maximum tolerated dose (MTD) and induced SD in 13/41 [321].  A phase II 
trial enrolled 37 women with advanced breast cancer with confirmed Rb-positive protein 
expression also examined the dose of 125 mg/daily 3 weeks on, 1 week off schedule.  Fifty-
one percent had dose reductions due to cytopenia.  Thirty eight percent of patients had SD 
for over 6 months, with 19% of patients having some clinical benefit.  However, Rb nuclear 
expression, percent Ki-67, cyclin D gene amplification and p16 loss did not correlate to a 
positive response, indicating that further investigation is required for predictive response 
marker [322].  A randomized phase II study investigated the safety and efficacy of letrozole 
versus letrozole plus palbociclib in treatment-naive postmenopausal women with advanced 
ER positive (HER2 negative) breast cancer.  Letrozole was administered continuously at 2.5 
mg daily, while palbociclib was administered 125 mg daily for 3 weeks on, 1 week off.  This 
study found that combination treatment significantly improved the median PFS from 10.2 
versus 20.2 months comparing the letrozole group versus the letrozole plus palbociclib, 
respectively. For toxicity, 1% versus 54% of patients had neutropenia, and none versus 19% 
had leucopenia with letrozole alone versus letrozole plus palbociclib, respectively.  Similar to 
other studies, this trial did not find any correlation between cyclin D1 and p16 status and 
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response [323].  Based on the significant phase II results, phase III trials on palbociclib in 
combination with letrozole are currently ongoing in ER-positive breast cancer [336].   
Dinaciclib, or SCH727965, is a potent pyrazol-pyrimidine derivative that inhibits 
CDK1, CDK2, CDK5 and CDK9 in the nanomolar range [330].   Dinaciclib has shown activity 
against a broad range of malignancies in pre-clinical settings.  In vitro studies with ovarian 
cancer cells found that dinaciclib was more effective at reducing phospho-Rb (S807/811) 
expression while inducing apoptosis measured by cleaved PARP1 expression at >6.25 nM 
compared to 1µM flavopiridol [337].  A human ovarian cancer xenograft in a mouse model 
system found that dinaciclib had a higher MTD of 60 mg/kg versus <10 mg/kg of flavopiridol 
(based on 20% weight loss) [337].   Furthermore, dinaciclib induced a 50% reduction in 
tumor growth at 5 mg/kg after 7 days of treatment, versus 10 mg/kg of flavopiridol.  
Additionally, dinaciclib decreased pancreatic cancer cell viability and migration capacity in 
vitro.  Human pancreatic cancer xenograft studies revealed that dinaciclib reduced tumor 
growth both as a single agent and in combination with gemcitabine [338].  Since flavopiridol, 
which showed promise in leukemia, was discontinued, dinaciclib was examined in a 
preclinical model against CLL cells.   A 2hr exposure of a clinically achievable dose of 
dinaciclib induced apoptosis in CLL cells isolated from patients, including high-risk patients 
[339]. Dinaciclib has also been investigated in clinical trials (Table 11). A phase-I dose 
escalation study in patients with solid tumors found the maximum administered dose to be 
14 mg/m2, recommending a phase II dose of dinaciclib to be 12 mg/m2.  In this study, 10/48 
patients, including patients with NSCLC, prostate cancer, sarcoma and melanoma, achieved 
disease stabilization for at least four 28-day treatment cycles [324].  A phase II open-label 
study comparing standard of care treatment erlotinib to dinaciclib in NSCLC patients found 
that time to progression (TTP) was 1.58 months for erlotinib versus 1.49 months for 
dinaciclib.  These patients experienced neutropenia, leukopenia and vomiting [326].  
Furthermore, a phase II study in patients with advanced breast cancer found that dinaciclib 
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treatment of 50 mg/m2 once every 21 days caused a partial response in 2/7 patients.  
However, dinaciclib treatment had earlier TTP compared to capecitabine treatment (2.73 vs. 
4.17 months), and the study concluded after 30 days ([325]. While showing limited efficacy 
in solid tumors, the safety and efficacy of dinaciclib compared to ofatumumab (a monoclonal 
antibody against CD20) is being investigated in a phase III trial in refractory CLL patients 
(NCT01580228) [336].  Similar to other CDK inhibitors, the narrow efficacy of dinaciclib as 
single-agent therapy against solid tumors could indicate that it could be more efficacious in 
combination therapy.            
Roscovitine, also known as selicicib or CY-202, is also a pan-CDK inhibitor that has 
activity against CDK1, CDK2, CDK5, CDK7 and CDK9 at micromolar concentrations 
according to in vitro kinase assays [330].  Roscovitine has been used in combination in 
multiple pre-clinical models.   In p53 mutant breast cancer cells roscovitine increased 
accumulation in G2 and augmented ionizing radiation (IR)-induced growth inhibition.  
Moreover, concomitant treatment of roscovitine (100mg/kg) and IR (7.5Gy) significantly 
reduced tumor volume compared to either treatment alone in a xenograft model system.  
Here, it was suggested that combination treatment reduced the ability of cells to undergo 
NHEJ [340].   Combination treatment of roscovitine and IR also significantly increased 
apoptosis of NSCLC cells in vitro.  Moreover, combination treatment reduced expression of 
NHEJ proteins Ku70 and Ku80, again suggesting that roscovitine can inhibit DNA repair 
[341].   Roscovitine also synergized with IR in nasopharyngeal cancer cells by increasing 
apoptosis and inducing a G2/M cell cycle arrest, while retarding tumor growth in a xenograft 
model [342].   In addition to IR, roscovitine has been examined in combination with 
chemotherapeutics.  Our lab has found that roscovitine synergizes with doxorubicin to 
induce cytotoxicity in sarcoma cell lines in vitro [343].  
Roscovitine has been investigated clinically where it was administered orally (Table 
11) [315].  A phase I study that examined treatment with roscovitine, gemcitabine and 
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cisplatin in NSCLC patients found that the maximum tolerated dose of roscovitine was 800 
mg twice daily (with 1000 mg/m2 gemcitabine and 75mg/m2 cisplatin). In this study, 6/27 
patients had a partial response, 7/27 had SD and 1/27 patients had disease progression 
[328].  In a phase I study of nasopharyngeal cancer, roscovitine was administered at either 
400 mg or 800 mg twice daily on days 1 to 3 and 8 to 12.  While patients receiving 400 mg 
did not have significant toxicities, patients receiving 800 mg had liver toxicity and vomiting.  
However, despite being only briefly exposed, 50% of evaluable patients showed tumor 
reduction; with IHC analysis revealed increased apoptosis and necrosis and decreased 
cyclin D1, MCL1 and phospho-Rb [327].  Moreover, a phase I study examined the toxicity 
and efficacy of sequential administration of sapacitabine and roscovitine in patients with 
advanced solid tumors [329].  Sapacitabine is a prodrug of the nucleoside analog 2′-C-
cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC), that can induce SSBs that 
develop into DSBs [344].  These patients received sapacitabine daily for days 1-7, 
roscovitine days 8-10, followed by 11 days off.  Here the MTD for roscovitine (in combination 
with sapacitabine) was found to be 1200 mg, with dose limiting toxicities being reversible 
neutropenia and increased transaminase levels. Of the 27 patients, two patients with either 
breast or pancreatic cancer, both BRCA mutation carriers, had a partial response.  
Additionally, 6 patients had SD for at least 12 weeks, including a BRCA mutation carrier 
patient with ovarian cancer for over 24 weeks.  It was suggested that BRCA mutations could 
be a marker for response to the sapacitabine and roscovitine combination [329].  Overall, 
more studies are needed to confirm the clinical efficacy of roscovitine, especially in 
combination with DNA damaging agents.   
2.1D HYPOTHESIS AND SPECIFIC AIMS 
Despite showing encouraging results when combined with DNA-damaging agents 
(and targeted therapies), little has been done to develop a combination treatment strategy in 
TNBC with CDK inhibitors.  While others have shown that over-activation of the oncogene 
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Myc causes sensitivity to CDK inhibition in TNBC cells, this strategy again only examines 
CDK inhibition in a monotherapy setting [345].  As previously described, due to defects in 
cell cycle regulation, cancer cells continuously proliferate even in the presence of DNA 
damage, with TNBC tumors initially responding to chemotherapeutics (Table 2).  
Anthracyclines, including topoisermase II inhibitors doxorubicin and epirubicin, are used in 
the standard of care of TNBC and are often used in combination therapy (Table 7) [179]. 
Therefore, we hypothesized that combining CDK inhibitor roscovitine with the 
chemotherapeutic doxorubicin would cause increased cell death only in TNBC cells.   To 
address this hypothesis the following, specific aims were examined: 
• Determine the cell cycle response of HMEC, ER positive and TNBC cells to 
roscovitine treatment. 
• Investigate the inhibitory effect of combination treatment of roscovitine and 
doxorubicin on HMEC and TNBC cells. 
• Examine combination-induced cytotoxicity in TNBC and HMEC cells. 
• Establish combination treatment in a pre-clinical in vivo model system.  
Overall, the data presented in this chapter demonstrates that roscovitine treatment induced 
a significant G2/M arrest specifically in TNBC cells.  Analysis using the Chou-Talalay 
method revealed that only sequential administration of roscovitine followed by doxorubicin 
induced synergistic cell inhibition only in TNBC cells, not in HMEC cells [346].  Moreover, 
administration of roscovitine prior to doxorubicin increased apoptosis only in TNBC cells 
compared to single drug treatment.  Finally, a xenograft model of TNBC cells found that 
combination treatment was well tolerated and significantly decreased tumor growth and 
increased overall survival compared to single agent treatment.    
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2.2 MATERIALS AND METHODS 
2.2A CELL CULTURE 
 The immortalized human mammary epithelial (HMEC) cell lines 76NE6 and 76NF2V 
were obtained from Dr. V. Band (University of Nebraska Medical Center) and MCF10A cells 
were obtained from the American Type Cell Culture Collection (ATCC; Manassas, VA).  
These cells were maintained in DCFI-1 medium in culture as described previously [347]. The 
breast cancer cell lines MDA MB 157, MDA-MB-231 and HCC1806 cells were obtained from 
the ATCC and maintained in complete alpha medium [347].  The breast cancer cell lines 
MCF-7, ZR75-1, T47D and MDA MB 468 was obtained from the ATCC and maintained in 
complete Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal calf 
serum (FCS).  All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless 
stated otherwise. All cells were kept in a humidified incubator in a 6.5% CO2 atmosphere at 
37°C. All cells were tested for mycoplasmal contamination, and their identities were verified 
via karyotype analysis. Breast cancer cell line hormone receptor, HER2 and p53 and Rb 
status are available in Table 12. 
 
Table 12. Breast cancer cell lines examined 
Cell Line ER PR HER2 p53 status Rb status 
MCF10A - - - WT WT 
76NE6 -  - Degraded by HPV-6 WT 
76NF2V - - - WT WT 
HCC1806 - - - Mutant Functionally inactive 
MDA MB 157 - - - Mutant Functionally inactive 
MDA MB 231 - - - Mutant Functionally inactive 
MDA MB 468 - - - Mutant - 
MCF7 + + - WT WT 
T47D + + - Heterozygous Mutant WT 
ZR75-1 + - + WT WT 
Adapted from: [347, 348] 
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2.2B DRUGS 
 Roscovitine, provided by Dr. Laurent Meijer (National Center for Scientific Research, 
Paris France), was diluted to 10 mM in dimethyl sulfoxide (DMSO).  Doxorubicin-HCl 
(Bedford Laboratories, Bedford, OH) was reconstituted in a 0.9% sterile saline solution at 2 
mg/mL and shielded from light.  Staurosporine (Sigma-Aldrich) was diluted to 2.14 mM in 
DMSO.  
2.2C FLOW CYTOMETRY 
 Cells were seeded in 10 cm dishes at 3.5 x 105 cells per plate to examine cell-cycle 
phases in response to drug treatment. Cells were then treated with roscovitine at 20 µM for 
24 hours.  Following treatment, cells were fixed and stained to measure their DNA content 
as described previously [285]. Briefly, cells were resuspended and fixed in 1.5 mL of cold 
phosphate-buffered saline (PBS) and 3.5 mL of cold ethanol overnight. Cells were then 
washed with PBS, resuspended in PBS containing 10 µg/mL propidium iodide, RNase A, 
Tween 20, and bovine serum albumin and incubated at 4°C overnight. Prior to measuring 
their DNA content, cell samples were incubated for 1 hour at 37°C. Samples were analyzed 
at The University of Texas MD Anderson Cancer Center Flow Cytometry and Cellular 
Imaging Facility using a Beckman Coulter Gallios Flow Cytometer (Indianapolis, IN) 
equipped with the Kaluza software program (Beckman Coulter). 
2.2D HIGH-THROUGHPUT SURVIVAL ASSAY 
 To assess the effect of combination drug treatment on HMEC and TNBC cell lines, 
cells were subjected to a high-throughput survival assay (HTSA) as described previously 
(Figure 3) [349]. Briefly, for all combinations cells were seeded in 96-well plates (Table 13).  
We administered the roscovitine and doxorubicin combination drug treatment 
simultaneously and sequentially, in both directions (Figure 3 A, B).  For concomitant drug 
administration, cells were treated for 72 hours with roscovitine and doxorubicin 
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simultaneously (Table 14, R+D). For sequential drug administration, cells were treated with 
drug A at the 10% inhibitory concentration (IC10), IC25, and IC50 for 24 hours. Following drug 
A treatment, the medium was removed from the wells, and cells were treated with drug B at 
the IC10 to the IC50 for 48 hours, equaling 72 hours of total drug treatment (Table 14, D R, 
RD). Following the completion of 72 hours of drug treatment, the medium in the wells was 
replaced with fresh-drug free medium. Every 96-well plate contained cells that remained 
untreated as controls. Controls for treatment with drug A or drug B only were also included. 
The drug-free medium was changed every 48 hours for 9 days. Nine days after the removal 
of drug B, the plates were subjected to a (3-(4, 5)-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) assay (2.5 mg/mL; Sigma-Aldrich), incubated for 4 hours 
at 37°C, and solubilized (0.04 N HCl and 1% sodium dodecyl sulfate [SDS], in isopropyl 
alcohol). Absorbance was read at 590 nM using Epoch microplate spectrophotometer with 
the Gen5 software program (BioTek, Winooski, VT). Isobolograms and combinational 
indices were generated using the CalcuSyn software program (Biosoft, Cambridge, UK).  
 
Table 13. Cell number/well seeded for HTSA 
Cell Line Cells/well 
MCF10A 1000 
MDA MB 157 3500 
MDA MB 231 1500 
MDA MB 468 2000 
  
Table 14. Drug concentrations used for combination treatment 
 
R+D DR RD 
Cell Line 
R 
(µM) 
IC10, 25, 50 
D 
(nM) 
IC10-IC50 
D 
(nM) 
IC10, 25, 50 
R 
(µM) 
IC10-IC50 
R 
(µM) 
IC10, 25, 50 
D 
(nM) 
IC10-IC50 
MCF10A 7,10,18 6-13 12,22,30 1-12 9, 11, 13 1-20 
MDA 
MB157 5,9,15 4-8 9.5,12,17.5 4-26 8, 22, 32 1-15 
MDA MB 
231 5,18, 25 5-18 1,3,6 2-20 6, 18, 24 5-42 
MDA MB 
468 10,12,15 5-9 1, 22, 25 1-16 1, 10, 24 2-21 
  
Figure 3.  Schematic illustrating the HTSA using both simultaneous (A) and 
sequential (B) drug administration
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2.2E DYE-EXCLUSION ASSAY 
 To examine cell viability, cells were subjected to a dye-exclusion assay. Cells were 
seeded at 3.5 x 105 cells per plate and treated with roscovitine for 24 hours, followed by 
doxorubicin for 48 hours at IC50 concentrations (Table 14).  Roscovitine and doxorubicin only 
treated cells were used as single drug controls. Untreated and staurosporine-treated cells 
served as negative and positive controls, respectively. Cells were harvested at indicated 
times, and cell pellets were washed with cold PBS. Following centrifugation, pellets were 
resuspended in PBS, and propidium iodide was added to each harvested sample at a final 
concentration of 2 µg/mL prior to flow cytometric analysis using an LSR II flow cytometer 
equipped with the CellQuest Pro software program (BD Bioscience). 
2.2F CASPASE ACTIVITY LUCIFERASE ASSAY  
 A Caspase-Glo 3/7 (Promega, Madison, WI) assay was used to measure caspase 
activity in HMEC and TNBC cells in response to single and combination drug treatment.  
Cells were seeded in 96-well white-walled plates (Table 13). After 24 hours, cells were 
treated with roscovitine and doxorubicin at the IC50 concentrations for 24 and 48 hours, 
respectively (Table 14). Caspase 3/7 activity of the cells was measured after single 
(roscovitine or doxorubicin) and combination (roscovitine followed by doxorubicin) treatment 
according to the assay manufacturer’s protocols. The luciferase activity was deteced using a 
Synergy H4 hybrid microplate reader equipped with the Gen5.1.1 software program 
(BioTek). Readings of wells containing media only were subtracted from all experimental 
values.  
2.2G WESTERN BLOT ANALYSIS  
 To extract protein lysates from cells for Western blot analysis, cells were harvested 
following indicated treatments. Cells were washed with cold PBS, trypsinized (0.25%), and 
centrifuged. Next, cell pellets were washed with cold PBS and centrifuged again. Cell pellets 
were lysed with RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.3, 0.1% SDS, 1% Triton X-
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100, 1% deoxycholate, and 5 mM ethylenediaminetetraacetic acid) containing protease 
inhibitors, with occasional vortexing. Cell pellets were centrifuged at 16,000 rpm for 60 
minutes, with supernatant containing protein lysates. Western blot analysis was performed 
to examine protein expression in HMEC and TNBC cells as described previously [350]. 
Briefly, the protein lysate was subjected to electrophoresis on an SDS-polyacrylamide 
electrophoresis gel and transferred to Immobilon-P membranes overnight at 4°C at 35 mV. 
Blots were blocked with BLOTTO milk for 1 hour at room temperature and incubated with 
primary antibody overnight at 4°C. Antibodies against PARP-1 (Cell Signaling Technology, 
Beverly, MA) and actin (EMD Millipore, Billerica, MA) were used to probe for protein 
expression.  Blots were incubated with goat anti-rabbit or goat anti-mouse immunoglobulin-
horseradish peroxidase-conjugates at a dilution of 1:5000 in BLOTTO for 1 hour (Pierce, 
Rockford, IL). Blots were then washed and developed using a Renaissance 
chemiluminescence system (Perkin Elmer Life Sciences, Inc., Boston, MA) as directed by 
the manufacturer.  Image J was used to perform densitometry analysis.   
2.2H TRANSFECTION  
 To generate transient knockdown cells, HMEC and TNBC cells were seeded for 96-
well plates for survival analysis or 6-well plates for flow cytometry or Western blot analysis 
according to manufacture protocols (Thermo Scientific Transfection Dhramafect siRNA 
Transfection Protocol).   Thermo Scientific siGENOME smart pool siRNA, including siControl 
pool #1, siCDK1 and siCDK2, were resuspended according to the manufacture’s protocol at 
100 µm.  Cells were transfected with siRNA targeting CDK1, CDK1 or both using the 
transfection reagent Dharmafect formulation 1 according to the manufacture’s protocol 
(Thermo Scientific). Non-coding siControl pool #1 was used as a negative control.  Cells 
were harvested 48 hours post transfection or as indicated for Western blot analysis and flow 
cytometry.  Cells were subjected to MTT for survival analysis 9 days after removal of 
doxorubicin.     
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2.2I XENOGRAFT MODEL 
To develop a pre-clinical model, four-week old nude mice were injected with 4.5 million MDA 
MB 468 cells in a 1:2 ratio with matri gel (BD Bioscience) into mammary fat pads four and 
nine of the mouse.  Once the tumor reached a volume (L x W2 /2) of 100-150 mm3, mice 
were treated with vehicle + vehicle, roscovitine (50 mg/kg) 4 days on/3 days off, doxorubicin  
(2mg/kg) once a week, or 4 days of roscovitine followed by one day of doxorubicin for four 
cycles.  All drugs were administered i.p.  Roscovitine was diluted at 100 mg/ml in DMSO and 
then further diluted to 10 mg/ml in a carrier solution consisting of 10% Tween 80 (Sigma 
Aldrich), 20% N-N-dimethylacetamide (Acros Organics, Geel, Belgium) and 70% 
polyethylene glycol 400 (Sigma-Aldrich) [351].  Tumor volume and weight were measured 
twice a week.  Mice were sacrificed if their total tumor burden reached 1500 mm3, tumors 
became ulcerated or inhibited mouse movement or if mice loss 20% of initial body mass.  
Mice were housed five per cage in sterilized micro-isolator cages (Lab Products, Seaford, 
DE) furnished with corncob bedding.  Mice received care in accordance with the Animal 
Welfare Act, the National Institutes of Health “Guide for the Care and Use of Laboratory 
Animals,” and the institutional guidelines of the MD Anderson Cancer Center. 
2.2J WESTERN BLOT ANALYSIS OF TUMOR TISSUE 
 Following surgical resection, tumors were snap frozen in liquid nitrogen.  Protein 
lysates were extracted via sonication in a protease inhibitor solution as previously described 
[352].  Homogenates were centrifuged at 45,000 g for 45 minutes.  Supernatants were 
subjected to Western blot analysis.  Blots were probed with anti-PARP1 antibody (Cell 
Signaling Technology, Beverly, MA).    
2.2K STATISTICAL ANALYSIS  
 The Student t-test with a 95% confidence interval was performed to determine p 
values. P values less than 0.05 were considered significant. Survival analysis was 
performed using the Mantel-Cox test.  
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2.3 RESULTS 
2.3A ROSCOVITINE INDUCES A G2/M ARREST IN TNBC CELLS  
To investigate how breast cancer subtype and G1 checkpoint status (Table 12) 
would affect response to CDK inhibition, the HMEC cell line MF10A, the ER positive cell line 
MCF7 and the TNBC cell line MDA MB 231 were treated with roscovitine for 24 hours 
followed by cell cycle analysis via flow cytometry.  p53 wildtype HMEC and ER positive cells 
had 70 or 60% of cells in G1, respectively.   However, over 60% of p53 mutant MDA MB 231 
cells accumulated in the G2/M phase (Figure 4A).  To examine the effect of CDK inhibition 
on G2/M accumulation, a wide panel of HMEC (MCF10A, 76NF2V and 76NE6), ER positive 
cells (MCF7, T47D and ZR75-1) and TNBC (MDA MB 157, MDA MB 231, MDA MB 468 and 
HCC1806) cells were treated with roscovitine for 24 hours followed by cell cycle analysis.  
Roscovitine induced a 10 percent or less increase in G2/M phase in HMEC cells MCF10A 
and 76NF2V.  However, roscovitine caused a significant (p- 
value < 0.001) 20% increase in the p53 inactive 76NE6 cells (Figure 4A, B).  Similar to 
HMEC cells, roscovitine induce a 10% or less increase in G2/M of ER positive cells. In 
comparison, all four TNBC cell lines exhibited a significant (p-value < 0.05) increase in the 
G2/M phase in response to treatment, with MDA MB 231 cells having over a 25% increase 
in cells in G2/M (Figure 4B, C).  Roscovitine treatment enriched the G2/M population of the 
TNBC cell lines examined to 40-60 percent, compared to the non-TNBC cells with 30 
percent or less accumulating in G2/M (Figure 4C).  76NE6 cells were the exception to the 
trend detected in HMEC cells, with 60% of cells accumulating in the G2/M phase following 
roscovitine treatment (Figure 4C).  These data suggests that the roscovitine-induced G2/M 
arrest is subtype and p53 mutant status specific.   
 
 
 
  
 
Figure 4. Roscovitine-induced G2/M accumulation is cell
A, HMEC, ER-positive and TNBC cells were treated with roscovitine
followed by cell cycle analysis via flow cytometry
Percent change in G2/M phase cells due to roscovitine treatment.  C, Cell cycle analysis of
panel of HMEC, ER positive and TNBC cells in response to roscovitine
G2/M phase plotted.  Mean ± SD. 
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2.3B SEQUENTIAL ADMINSTRATION OF ROSCOVITINE FOLLOWED BY 
DOXORUBICIN INDUCES SYNERGISTIC CELL INHIBITION ONLY IN TNBC CELLS 
To investigate if the roscovitine-induced G2/M arrest in TNBC cells can be exploited 
to develop combination therapy, we subjected TNBC and HMEC cells to HTSA.  We 
combined the clinically available chemotherapeutic doxorubicin with roscovitine both 
concomitantly and sequentially (Figure 3A, B). CalcuSyn, which quantifies synergy using the 
Cho-Talalay method, generates combination indices (CI) that determine if a combination is 
antagonistic (CI >1), additive (CI = 1) or synergistic (CI<1) [346].  The CI values 
demonstrated that concomitant treatment induced an antagonistic response in all cell lines 
(Figure 5A, left panel).   Sequential administration of doxorubicin treatment prior to 
roscovitine also induced antagonism in all cell lines (Figure 5A, middle panel). Strikingly, 
administration of roscovitine prior to doxorubicin induced synergism in TNBC cell lines, but 
antagonism MCF10A cells (Figure 5A, right panel).  Sequential administration of roscovitine 
and doxorubicin had a significantly lower (p-value < 0.05) CI value in all TNBC cell lines 
compared to simultaneous treatment or administration of doxorubicin prior to roscovitine 
(Figure 5A). Therefore, combination treatment can specifically inhibit TNBC cells and not 
HMEC cells. 
 Since roscovitine can inhibit multiple CDKs, we examined whether inhibition of 
CDK1, CDK2 or both CDKs simultaneously was required for synergism with doxorubicin 
treatment.  MCF10A and MDA MB 468 cells were transiently transfected with siRNA against 
either CDK or both, with non-targeting siRNA used as a control.  Cell viability was assessed 
on day 12 with MTT.  While knockdown of CDK1 or both CDKs reduced cell viability in 
MCF10A cells by 60%, there was no further reduction in viability with the addition of 
doxorubicin. Knockdown of CDK2 did not decrease percent viability, however the addition of 
doxorubicin again reduced viability by 60% in MCF10A cells (Figure 5B).  Transient 
knockdown of CDK1 or both CDKs simultaneously reduced viability by about 50% in MDA 
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MB 468 cells, whereas knockdown of CDK2 caused only 20% cell inhibition.  However, the 
addition of doxorubicin to CDK1 or CDK1/CDK2 knockdown caused 90% cell inhibition in 
MDA MB 468 cells (Figure 5B).  This suggests that inhibition of CDK1 combined with 
doxorubicin treatment is sufficient to induce synergistic cell inhibition in TNBC cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 5. Sequential administration of roscovitine (R) and doxorubicin (D) induces 
synergistic cell inhibition only in TNBC cells. 
with R and D simultaneously (R+D, left), D preceding R (D
(R D, right).  Isobolograms and CI values were generated using CalcuSyn. B, MCF10A 
and MDA MB 468 cells were transfected with either non
targeting CDK1, CDK2 or both. Western blot analysis confirmed knockdown (left). Perce
viability with and without doxorubicin treatment was assessed 
Mean ± SD.   
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A, MCF10A and TNBC cells were treated 
R, middle) or R preceding D 
-targeted siRNA (siControl) or siRNA 
by MTT on day 12 (right).
nt 
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2.3C COMBINATION TREATMENT INCREASES APOPTOSIS SPECIFICALLY IN TNBC 
CELLS 
We used a luciferase caspase 3/7 assay to examine the apoptotic response of 
HMEC and TNBC cells to single and combination treatment. No increase in caspase 3/7 
activities was detected in MCF10A cells. While doxorubicin and combination treatment did 
significantly increase caspase activity in TNBC cells compared to untreated cells (p-value < 
0.05), there was no significant difference between the caspase activities of doxorubicin 
versus combination treated TNBC cells (Figure 6). These data suggested that both single 
and combination treatment induced apoptosis, but does not account for the synergistic cell 
inhibition measured only in TNBC cells  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Doxorubicin and combination treatment induce caspase 3/7 activity.  HMEC 
and TNBC cells were treated with single or combination drug treatment and 
subjected to a luciferase assay to measure caspase 3/7 activity. 
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Since caspase activity during drug treatment could not account for the synergistic 
response of combination treatment in TNBC cells, cell death was examined in TNBC and 
HMEC cells using a dye-exclusion assay in response to single and combination treatments 
both during and following drug treatment.  Cells were subjected to a dye-exclusion assay 
with propidium iodide (PI). PI positivity is detected via flow cytometry when the cell 
membrane is compromised, a characteristic of apoptosis [353].  Roscovitine-induced PI 
positivity peaked at 24 hours post drug exposure (Figure 7A, left).  Doxorubicin treatment 
steadily reduced cell viability over time; with MDA MB 157 cells showing over 30% PI 
positivity on day 12 (Figure 7A, right).  When the drug was present, combination treatment 
induced 15% PI positivity in MCF10A cells, but induced 45% and 30% PI positivity in MDA 
MB 157 and MDA MB 468 cells, respectively (Figure 7, right). Moreover, only TNBC cells 
continued to exhibit decreased cell viability, or PI positivity, after release from treatment.  
MDA MB 157 cells had over 50% PI positivity 72 hours after being released from treatment, 
while MDA MB 468 cells had over 25% PI positivity 120 hours after being released from 
treatment (Figure 7A).   These data demonstrate that the combination treatment inhibited 
TNBC cell recovery, causing the cells to continue to die after treatment and to a greater 
extent than HMEC cells.  
Western blot analysis was performed to detect PARP-1 cleavage, a marker of 
apoptosis.  Densitometry analysis was used to measure the ratio of cleaved PARP-1 to full 
length PARP-1.  Staurosporine treatment, used as a positive control, induced PARP-1 
cleavage in HMEC and TNBC cells (Figure 7B). MCF10A cells did not induce PARP-1 
cleavage in response to treatment above basal levels.  TNBC cells expressed cleaved 
PARP-1 both during and after release from combination treatment.  MDA MB 157 cells had 
the highest ratio of PARP-1 cleavage at 48 hours into combination treatment, and 
maintained cleaved PARP-1 expression until 72 hours post release (Figure 7B).  MDA MB 
468 cells had the highest ratio of PARP cleavage 24 hours into combination treatment, and 
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also had a sustained apoptotic signal until 72 hours post release (Figure 7B).  The 
persistence of cleaved PARP-1 expression, similar to the continuous PI positivity, indicates 
that TNBC cells continued to undergo apoptosis after treatment.  These data demonstrate 
that combination treatment inhibits cell recovery, leading to a persistent apoptotic signal only 
in TNBC cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 7. Combination treatment induces prolonged apoptosis only in TNBC cells.  
HMEC and TNBC cells were treated with roscovitine
hours, or roscovitine preceding doxorubicin
(S) treatment was used as a positive control. Cells were harvested at indicated times and 
subjected to a dye-exclusion assay using propidium iod
were treated with R, D or R preceding 
analysis was used to detect full
PARP-1 bands were quantified with Image J (ratio = cl
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 (R) for 24 hours, doxorubicin
 (RD) at IC50 concentrations.  Staurosporine 
ide (PI). B, HMEC and TNBC cells 
D and harvested at indicated times. Western blot 
-length and cleaved PARP1. Full PARP-1 and cleaved 
eaved/full PARP-1). 
A, 
 (D) for 48 
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To determine if inhibition of CDK1, CDK2 or both is required for inducing apoptosis 
with doxorubicin, MCF10A and MDA MB 468 cells were transiently transfected with siRNA.  
Samples were harvested immediately after treatment and 48 hours post treatment.  Cleaved 
PARP-1 expression was detected in all conditions in MCF10A cells immediately after 
treatment; however, the addition of doxorubicin to CDK knockdown did not increase cleaved 
PARP-1 expression.  Indeed, simultaneous CDK1 and CDK2 knockdown plus doxorubicin 
had the least PARP cleavage in MCF10A cells (Figure 8A).  In contrast, knockdown of 
CDK1, CDK2 or both increased PARP-1 cleavage in MDA MB 468 cells compared to 
siControl transfected cells.  Moreover, the addition of doxorubicin to CDK knockdown 
increased cleaved PARP-1 expression (Figure 8C). Forty-eight hours post treatment, 
MCF10A knockdown and combination treated cells showed complete recovery, expressing 
only full-length PARP (Figure 8B).  However, MDA MB 468 cells had persistent cleaved 
PARP1 expression in both transient knockdown cells and in cells that had CDK knockdown 
with doxorubicin 48 hours post treatment (Figure 8D).  These findings reveal that TNBC cells 
cannot recover from potent CDK inhibition or CDK inhibition combined with doxorubicin, 
leading to an enduring apoptotic signal.   
 Figure 8.  TNBC cells cannot 
MCF10A and (C, D) MDA MB 468 cells were transfect
doxorubicin treatment.  Cells were harvest
post treatment (B, D).  Western blot analysis was used to detect PARP1. 
cleaved PARP bands were quantified with Image J (ratio = cleaved/full PARP).
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recover from CDK inhibition plus doxorubicin.  
ed with siRNA with or without 
ed directly after treatment (A, C) and
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2.3D ROSCOVITINE-DOXORUBICIN COMBINATION INHIBITS TUMOR GROWTH AND 
INCREASES SURVIVAL  
 To examine combination treatment in a pre-clinical model, MDA MB 468 cells were 
used to generate human xenograft tumors in nude mice.  There were four treatment arms: 
vehicle, roscovitine (50 mg/kg) for 4 days on 3 days off, doxorubicin (2mg/kg) once a week 
and roscovitine (4 days) followed by 1 day of doxorubicin, 3 days off, all given for 4 cycles.  
Mice began receiving treatment when tumors reached a volume of 100-150 mm3.  
Combination treated tumors did not increase in volume while on treatment, with tumors 
averaging at 125 mm3 on day 26.   Combination treated tumors were significantly smaller (p-
value <0.01) than vehicle treated tumors that averaged 330mm3 on day 26.  Moreover, 
combination treated tumors were significantly smaller (p-value <0.05) than both roscovitine 
and doxorubicin treated tumors at the end of treatment (Figure 9 A, B).  Following drug 
treatment, combination treated tumors remained significantly reduced compared to the other 
three treatment arms (Figure 9A).  Notably, no measurable difference was observed 
between vehicle and roscovitine treated mice; supporting clinical findings that roscovitine is 
inefficient as a single agent.     
 None of the combination treated mice suffered from increased toxicity or tumor 
burden during the 60-day experiment.  As such, combination therapy significantly increased 
overall survival (p-value < 0.05) compared to vehicle, roscovitine and doxorubicin treated 
mice (Figure 9C).  It is imperative to ensure that novel combination therapies do not cause 
increased toxicity.   Overall toxicity was assessed by weight loss during and following 
treatment.  Based on weight loss, combination therapy did not increase toxicity (Figure 9D).  
Roscovitine treatment also did not cause weight loss toxicity (Figure 9D).  However, 80% of 
doxorubicin treated mice had to be sacrificed due to >20% weight loss, again revealing the 
limitations of doxorubicin as monotherapy (Figure 9D, Table 15).   
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Western blot analysis of PARP-1 on tumors resected on day 26 found that 
combination therapy significantly increased apoptosis (p-value <0.05) compared to 
doxorubicin treated tumors.  Also, p21 expression was not detected in any of the tumors 
(Figure 9E).   Overall, this data suggests that roscovitine-doxorubicin combination therapy is 
both well tolerated and efficacious against TNBC, supporting future clinical studies.   
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Figure 9.  Combination treatment reduces tumor growth and increases overall 
survival without increasing toxicity.  Mice were treated with vehicle, roscovitine (50 
mg/kg 4 days on, 3 days off), doxorubicin (2mg/kg once a week), or roscovitine followed by 
doxorubicin for 4 cycles.  A, Tumor volume (L x W2 / 2) was measured twice a week.  B, 
Representative tumors shown of the four treatment arms were resected at the end of 
treatment on day 26.  Statistical analysis based on tumor volume. C, Kaplan-meier curve 
was generated to examine mouse overall survival. Survival analysis was performed using 
the Mantel-Cox test. D, Mouse weight was measured twice a week.  Percent change from 
weight at start of treatment is shown at times indicated.  E, Western blot analysis examining 
PARP-1 in protein lysates from tumors resected on day 26.  
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Table 15. Cause of euthanasia/death  
 
Euthanasia due to tumor 
burden 
 (%) 
Euthanasia due to weight 
loss/deteriorated health 
(%) 
Vehicle 100 0 
Roscovitine   100 0 
Doxorubicin 20 80 
Roscovitine  Doxorubicin 0 0 
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2.4 CONCLUSIONS 
 Roscovitine treatment causes a G2/M arrest exclusively in TNBC cells that can be 
exploited to augment the doxorubicin-induced apoptotic response.  The G2/M arrest 
detected only in TNBC cells suggests that the molecular characteristics that differentiate 
TNBC cells from non-TNBC cells can be exploited to target the cell cycle.  Roscovitine also 
induced a G2/M arrest in HMEC 76NE6 cells, which share the TNBC cell characteristic of 
p53 inactivity.  This similarity could be indicative of a marker for response, which will be 
thoroughly investigated in Chapter 3. 
Combination treatment caused a sustained cell death signal specifically in TNBC 
cells. However, neither single or combination treatment caused a significant amount of 
apoptosis in HMEC cells.  The prolonged combination-induced apoptotic response in TNBC 
cells inhibited cell recovery.  Although roscovitine is a pan-CDK inhibitor, transient 
knockdown of CDK1 and CDK2 revealed that inhibition of CDK1 is sufficient to induce 
synergism with doxorubicin in TNBC cells. Moreover, the addition of doxorubicin to CDK 
knockdown cells also caused an increased apoptotic signal only in TNBC cells.  These data 
validate the hypothesis that it is possible to induce synergistic cell death in TNBC cells while 
leaving non-malignant cells unharmed.      
  In vivo pre-clinical studies must be performed to translate a novel therapy to the 
clinic.  Although both roscovitine and doxorubicin have been clinically examined, well-
tolerated single agents can have increased toxicities when combined.  For example, 27% of 
patients had cardiac dysfunction when treated with trastuzumab and an anthracycline [221].  
However, our xenograft studies illustrate that combination treatment had increased efficacy 
over single agents without causing increased toxicity. The drugs were again administered 
sequentially.  Other cancer models have corroborated the finding that the sequence of drug 
administration affects combination efficacy and toxicity.  For example, a colorectal cancer 
pre-clinical model that examined the combination of the topoisomerase I inhibitor irinotecan 
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with 5-FU administered simultaneously and in both sequences found that when each drug 
was given at 50% MTD, irinotecan followed by 5-Fu caused the most growth inhibition 
without additional toxicity.  However, when the drugs were given at 75%, the same 
sequence was 100% lethal [354].  These findings, along with our own studies, demonstrate 
that combination sequence and dosage is crucial for maximizing efficacy while limiting 
adverse effects, and will need to be closely monitored in the clinic.          
The specificity of drug administration required for synergism also emphasizes that 
the effectiveness of combination treatment is pathway driven.  The concept of synthetic 
lethality was born from genetic studies performed in drosophila that found that loss of one 
gene was tolerated due to overcompensation in another pathway.  However, when genes 
from both pathways were inhibited, synthetic lethality occured [355].  This concept is now 
being applied to cancer therapy in order to maximize therapeutic benefit and limit toxicities 
[356].  PARP inhibitors, for instance, are synthetically lethal to cancer cells with BRCA 
mutations because these cells heavily rely on BER to compensate for impaired HR [170, 
262].  Studies performed in non-mammalian systems have also yielded potential synthetic 
lethal therapies. Drug screenings done in yeast, a readily genetically modified system, found 
that yeast with mutations in DNA HR proteins were especially sensitive to cisplatin [357].  
These findings illustrate the benefit of using DNA damage agents in cancer cells with altered 
or impaired DNA repair pathways to establish a synthetic lethality. 
The roscovitine-doxorubicin combination can be considered synthetic lethal in TNBC 
cells because it targets two major deregulated pathways in tumorgenesis, cell cycle 
regulation and DNA damage response.  Sporadic TNBC tumors are often characterized as 
having a “BRCAness” phenotype, or have BRCA1/BRCA2 dysfunction or downregulation, 
which is associated with deregulated HR and sensitivity to anthracycline-and platinum-
based chemotherapies [242, 358-361].  While the cell lines used in this study are BRCA 
wildtype, roscovitine has been shown to impair HR, one of the pathways that would be 
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required to repair doxorubicin-induced DNA damage [362].  Cancer cells often upregulate 
DNA repair pathways to survive assault from DNA-damaging agents used in therapy [356].  
Therefore, by potentially inhibiting DNA repair with roscovitine while targeting anthracycline-
sensitive TNBC cells with doxorubicin, we have generated a synthetic lethal combination.  
The proceeding chapter will further elucidate the possible mechanism of TNBC sensitivity to 
roscovitine-doxorubicin combination treatment.  
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CHAPTER 3:  ROSCOVITINE-DOXORUBICIN SYNTHETIC LETHALITY REQUIRES P53 
PATHWAY ABLATION 
3.1A EFFECT OF CHECKPOINT DEREGULATION ON THERAPEUTIC RESPONSE 
 Mutation or deregulation of checkpoint proteins Rb and p53 has been shown to affect 
prognosis and response of cancer cells to therapy.  Rb pathway deregulation can occur 
through multiple mechanisms, including Rb gene mutations, cyclin D1 
amplification/overexpression, CDK4 overexpression or point mutations, gene deletions or 
epigenetic silencing of CKIs p16 and p14 (Table 2).  Rb deregulation is often associated 
with poor prognosis [363].  Loss of Rb heterozygosity was measured in 72% and 62% of the 
more aggressive BLBC and Luminal B breast cancer subtypes, respectively [364].  
However, the effect of deregulation of the Rb pathway on prognosis and therapeutic 
response is subtype-specific. In patients with ER-positive tumors, the Rb-loss gene 
signature correlated with decreased relapse free survival [363].  Notably, ablation of the Rb 
pathway can reduce sensitivity to endocrine therapy and is associated with tamoxifen 
resistance [365].  However, for patients with ER-negative tumors, the Rb-loss signature was 
associated with improved relapse-free survival [363].  Disruption of the Rb pathway also 
correlated to increased sensitivity to cisplatin and ionizing radiation in cell culture and in 
xenograft models [365].  In accordance with these findings, an Rb-loss signature was 
associated with increased pCR in both ER-positive and ER-negative breast cancer patients 
who received neoadjuvant 5-FU/doxorubicin/cytoxan and taxane/doxorubicin chemotherapy 
regiments [366].  The paradox of Rb-loss being attributed to more aggressive tumors, but 
leading to increased sensitivity to DNA damaging agents, may be because cells that lack a 
G1 checkpoint are more sensitive to chemotherapy [367, 368].                       
 The effect of p53 mutations on prognosis and treatment response is less 
straightforward.  Similar to Rb, p53 is subject to a variety of gene mutations in cancer 
including, missense or point mutations, gene amplification of the p53 inhibitor MDM2, GOF 
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mutations and inhibition from viral oncogenic proteins (Table 2) [90].  The impact of 
compromised p53 function on treatment response may be dependent on the type of 
mutation present [369].  Examination of 60 cell lines, including breast, prostate, lung, colon, 
kidney, ovarian cancer, leukemia and melanoma cell lines, against 123 anti-cancer agents 
found that p53 mutant cell lines tended to be more resistant to the growth inhibitory effects 
of most compounds, including DNA cross-linking agents, antimetabolites and topoisomerase 
I and II inhibitors, compared to p53 wildtype cell lines.  However, response to antimitotic 
agents was independent of p53 status, indicating that the effect of p53 mutations on 
treatment may also be dependent upon the agent used [370].  IHC analysis of p53 
expression in tumors from NSCLC patients after receiving treatment found that aberrant 
overexpression of p53 correlated to cisplatin resistance and reduced pathological response 
[371].  However, disruption of p53 function via transfection of viral oncoprotein HPV-E6 or 
expression of a dominant negative p53 mutant increased sensitivity of ER-positive breast 
cancer cells MCF7 to cisplatin treatment in vitro.  Here, it was hypothesized that G1 
checkpoint deregulation and/or reduced NER contributed to increased cisplatin-sensitivity in 
MCF7 p53 mutant breast cells [372].  Clinical studies found that mutations in the zinc 
binding L2 and L3 domains of p53 (codons 163-195 and 236-251, respectively), which 
interact with DNA, were associated with decreased survival and de novo resistance to 
doxorubicin monotherapy in breast cancer patients [373, 374].  Moreover, meta-analysis of 
2,319 breast cancer patients found that when using a relative hazard ratio (RH), in which 
RH>1 indicates poor prognosis, node-negative and node-positive patients who had p53 
gene alterations had an RH of 1.7 and 2.6, respectively.  The RH >1 in both sets of patients 
associated p53 mutations with more aggressive breast tumors [375]. Also, microarray 
analysis of p53 wildtype and p53 mutant breast cancer tumors identified a 32-gene p53 
signature.  The study found that 89% of ER-negative tumors and 79% of grade III tumors 
were classified into the p53-mutant cluster.  Moreover the p53 gene-signature correlated 
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with decreased disease free survival both in ER-positive breast cancer patients who 
received adjuvant tamoxifen treatment and in ER-negative patients.  Similarly, the gene 
signature predicted that patients from the Sorlie, et al. study that received doxorubicin or 5-
FU and mitomycin and had tumors with p53-mutant like gene expression had a 35% 
probability of 5-year survival compared to a 90% probability for patients with p53-wildtype 
like expression [176, 376]. However, there was a significant correlation with premenopausal 
breast cancer patients who had p53 overexpression (IHC) and response to treatment with 
cyclophosphamide/methotrexate/5-FU [377].  Therefore, although there are some 
inconsistencies in the literature on the effect of p53 dysfunction, p53 mutations are generally 
correlated with more aggressive tumors that are refractory to treatment.             
3.1B CYCLIN DEPENDENT KINASES PARTICIPATE IN DNA DSB REPAIR 
 Several DSB DNA repair proteins are substrates for CDKs.  CDK phosphorylation 
can affect function and complex formation of DNA repair proteins.  Notably, CDK activity can 
serve as a molecular switch between faithful DNA repair and more error-prone pathways 
(Table 16).  
Table 16. CDKs participate in DNA DSB repair 
CDK Substrate (Site) Function Ref. 
CDK1 
53BP1 
(Unknown) 
Unknown, however, yeast studies indicate a 
role in checkpoint activation through Chk1  [378, 379] 
CtIP 
(T847) Required for DNA end resection [113] 
BRCA2 
(S3291) Inhibits binding to Rad51 [380] 
Unknown 
(CDK1 or 
CDK2) 
CtIP 
(S327) 
Required for CtIP/BRCA1/MRN complex 
formation.  Could serve as a switch between 
HR and MMEJ 
[114, 381, 
382] 
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As previously described, the MRN complex identifies DSBs for repair.  The ATM 
substrate p53 binding protein 1 (p53BP1) also accumulates at the site of damage to 
facilitate recruitment of downstream repair proteins, such as BRCA1, and is required for 
accurate intra-S phase and G2/M checkpoint activation [378, 383].  The CDK1-cyclin B 
complex has been shown to phosphorylate 53BP1 both in vitro and in vivo in proliferating 
mammalian cells.  Moreover, treatment with roscovitine inhibited CDK1 phosphorylation of 
53BP1 [379].  While the functional role of CDK1 phosphorylation of 53BP1 is currently 
unknown in mammalian cells, yeast protein Cdc2 (CDK1 homologue) phosphorylates the 
53BP1 orthologue Crb2 at T215 following DNA damage, leading to checkpoint activation 
through Chk1 regulation [384, 385].  Cdc2 phosphorylation stimulates binding of the DNA 
repair protein Cut5 (orthologue to human TopB1), which promotes Crb2 accumulation at the 
DNA damage site and is required for Chk1 activation [385].  Further investigation is needed 
to confirm the role of 53BP1 in activating Chk1 upon DNA damage in mammalian cells. 
 Following initial recognition of the damage site, to undergo HR, DNA end resection is 
required at the damage site to generate single strands (Figure 2).  Yeast studies 
demonstrated that CDK1 phosphorylates the endonuclease Sae2 at Ser267, which is 
required for DNA end resection [112, 386].  Moreover, mutating the Ser267 site on Sae2 to 
prevent CDK phosphorylation resulted in hypersensitivity to the topoisomerase I inhibitor 
camptothecin, indicating that CDK activity is necessary for repair of DSBs [386].  The human 
orthologue of Sae2 is CtIP, which is recruited to DNA DSBs only during S and G2 for end 
resection [387]. CDK1 also phosphorylates CtIP at Thr847.  Treatment of U2OS cells with 
roscovitine inhibited phosphorylation at the Thr847 site.  Furthermore, U2OS cells with a 
T847A mutation, which prevents CDK1 phosphorylation, were hypersensitive to 
camptothecin.  U2OS mutant cells that mimicked CtIP constitutive activation with a T847E 
mutation were resistant to camptothecin treatment.  Quantification of γ-H2AX revealed that 
camptothecin caused similar amounts of DNA damage in CtIP mutants; however, T847A 
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mutants had a significant reduction of RPA recruitment, which is downstream in the DNA 
end resection pathway (Figure 2) [113].  The observation that CDK1 activity was required for 
recruitment of downstream repair proteins, such as RPA, was corroborated in studies that 
found that roscovitine treatment reduced the ability of sarcoma cells to recruit RPA when 
exposed to ionizing radiation despite the formation of γ-H2AX foci [362]. Therefore, CDK 
activity is imperative for end resection and the recruitment of downstream repair proteins 
during HR. 
 CDK phosphorylation of CtIP is also important for DNA repair complex formation.  
CtIP has an additional CDK phosphorylation site at Ser327, which is required for its 
interaction with BRCA1 and MRN [381, 388].  The CtIP/MRN/BRCA1 complex occurs during 
S and G2, with roscovitine treatment abrogating the IR-induced interaction between BRCA1 
and MRN [381]. Moreover, CDK phosphorylation of CtIP at Ser327 may serve as a switch 
between more accurate pathways of DNA repair (e.g. HR) and a recently discovered 
process called microhomology-mediated end joining (MMEJ).  MMEJ occurs during G1 of 
the cell cycle phase and can repair DSBs in an error-prone manner that can contribute to 
genomic instability [114].  MMEJ repairs DNA DSBs differently from NHEJ in that it involves 
end resection followed by ligation of complimentary ends of DNA, resulting in nucleotide 
deletions [382].  An avian B-cell line DT40 model system demonstrated that while HR is 
dependent upon CDK phosphorylation at Ser327, MMEJ is not.  However, CtIP may still 
provide the endonuclease activity required for MMEJ. This suggests that inhibition of CDK 
activity can lead to a more error-prone method of DNA repair of DSBs, with CDK 
phosphorylation of CtIP serving as a switch between HR and MMEJ [114].   
 Paradoxically,  CDK phosphorylation of the HR protein BRCA2 can inhibit its activity 
[380].  BRAC2 facilitates loading of Rad51 onto the single strand filaments during HR  
(Figure 2) [117].  BRCA2 has a CDK phosphorylation site at Ser3291 at its C-terminus.  
CDK phosphorylation at Ser3291 prevents BRCA2 binding to Rad51 and is low during S-
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phase, but increases as cells enter mitosis during normal cell cycle progression.  Due to the 
increase in phosphorylation of BRCA2 specifically in nocodazole treated cells, which arrests 
cells in mitosis, the CDK1-cyclin B complex is most likely responsible for BRCA2 
phosphorylation.  However, both CDK1-cyclin A and CDK1-cyclin B complexes could 
phosphorylate BRCA2 in in vitro kinase assays.  Exposure to IR reduced CDK kinase 
activity and phosphorylation of BRCA2.  Therefore, CDK phosphorylation impairs the 
BRCA2-Rad51 interaction unless DNA DSBs are detected [380].   
 Overall, CDK activity has an important role in the recruitment and regulation of repair 
proteins required for DNA DSBs.  While necessary for checkpoint activation, complex 
formation and DNA end resection, CDK activity must eventually be reduced in order for HR 
to occur.  Importantly, CDK activity ensures a more accurate mode of DSB repair.  The 
absence of CDK activity can lead to a reliance on MMEJ for DSB repair, which can cause 
gene deletions and tumor-promoting chromosome rearrangements [114, 389].  Thus, 
inhibiting CDKs could potentially compromise DNA repair, sensitizing tumor cells to DNA-
damaging agents.   
3.1C HYPOTHESIS AND SPECIFIC AIMS 
 Although the effect of G1 checkpoint deregulation on endocrine therapy and 
chemotherapy has been examined, it is unknown what effect Rb and p53 pathway ablation 
will have on combination treatment response.  Moreover, CDK inhibition consistently 
compromises HR, possibly forcing cells to rely on more error-prone DDR pathways and 
increasing genomic instability.  Therefore, we hypothesized that G1 checkpoint ablation is 
required for roscovitine-doxorubicin-induced synergism in TNBC cells.  This hypothesis was 
addressed with the following specific aims: 
• Examine the effect of combination treatment on the cell cycle in HMEC and TNBC 
cells. 
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• Investigate the effect of combination treatment on G1 checkpoint pathways in HMEC 
and TNBC cells. 
• Determine how ablation of Rb and p53 pathways affects response to combination 
treatment. 
• Elucidate the mechanism that predisposes TNBC cells to roscovitine-doxorubicin 
combination sensitivity. 
• Examine the effect of combination treatment on DNA damage response and repair in 
HMEC and TNBC cells. 
 The data presented in this chapter shows that TNBC cells maintain a G2/M arrest in 
response to doxorubicin and sequential roscovitine-doxorubicin treatment, while HMEC 
cells are able to activate their G1 checkpoint in response to treatment.  Furthermore, 
ablation of the p53 pathway, and not the Rb, is crucial to roscovitine-doxorubicin induced 
synergism. Detection of DNA repair foci demonstrate that combination treatment increases 
DNA damage explicitly in TNBC cells, while simultaneously reducing the ability of these 
cells to recruit downstream HR repair proteins despite being arrested in the G2/M cell cycle 
phase.     
3.2 METHODS AND MATERIALS 
3.2B CELL CULTURE 
For medium ingredients and cell line origin of 76NE6, 76NF2V, MCF10A, MDA MB 
157, MDA MB 231 and MDA MB 468 please see chapter 2.2A. The colorectal cancer cells 
HCT116 p53 wildtype (p53+/+) and p53 knockout (p53-/-) were obtained from Dr. Junjie Chen 
and maintained in DMEM supplemented with 10% FCS. HEK-293T cells for lentiviral 
packaging were maintained in DMEM supplemented with 10% FCS.  
  3.2C DRUGS 
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 For origin and dilution of roscovitine and doxorubicin please see chapter 2.2B.  
Etoposide (Sigma-Aldrich) was diluted in DMSO to 10 mM and used at 5 µM.   
3.2D FLOW CYTOMETRY 
Cells were seeded in 10 cm dishes at 3.5 x 105 cells per plate to examine cell-cycle 
phases in response to single and combination drug treatment. After 24 hours, cells were 
treated with roscovitine for 24 hours, doxorubicin for 48 hours or roscovitine followed by 
doxorubicin at IC50 concentrations (Table 14).  Cells were harvested after treatment and 24 
hours-post treatment as indicated.  For methods of cell harvesting and sample analysis 
please see chapter 2.3C.  
3.2E HIGH-THROUGHPUT SURVIVAL ASSAY 
 For procedures on HTSA, including method of drug administration, harvesting with 
MTT and cell inhibition analysis, please see chapter 2.2D.  Number of cells seeded and IC 
concentrations of roscovitine and doxorubicin are found in Tables 17 and 18, respectively. 
 
Table 17. Cell number/well seeded for HTSA 
Cell Line Cells/well 
76NE6 150 
76NF2V 1000 
HCT116 (p53+/+ and p53-/-) 750 
    
Table 18. Drug concentrations used for combination treatment (RD) 
Cell Line 
R 
(µM) 
(IC10, 25, 50) 
D 
(nM) 
(IC10-IC50) 
76NE6 3, 6, 9 1-14 
76NF2V 15, 20, 22 1-14 
HCT116 (p53+/+ and p53-/-) 6, 12, 20 5-35 
 
3.2F WESTERN BLOT ANALYSIS  
 For methods on protein lysate extraction, western blot analysis or protein detection, 
please see chapter 2.2G.  Antibodies against PARP-1, CDK1, total Rb and phospho-Rb 
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(Ser807/811) (Cell Signaling Technology, Beverly, MA), CDK2 (Santa Cruz, Dallas, TX), p27 
(BD Biosciences, San Jose, CA), p53, p21, and actin (EMD Millipore, Billerica, MA) were 
used to probe for protein expression.  
3.2G GENERATION OF STABLE KNOCKDOWN 
  To generate Rb stable knockdown in 76NF2V cells, HEK-293T cells were 
transfected with lentiviral packaging vectors pMDG.2 and pCMV deltaR8.2 (produced by the 
Didier Trono laboratory (Lausanne, Switzerland) and made available through the Addgene 
repository) and lentiviral vector containing shRNA against Rb or scramble sequence 
(University of Texas MD Anderson Cancer Center ShRNA and ORFeome Core Facility) 
using LipoD293 transfection reagent (SignaGen, Rockville, MD) according to manufacturer’s 
protocols. Virus-containing medium was filtered through 0.45 µM filters and directly added to 
target cells in the presence of 8 µg/ml polybrene (Millipore).  76NF2V cells were selected in 
2 µg/ml puromycin (InvivoGen, San Diego, CA) and maintained at half selection 
concentration.  Knockdown of Rb was confirmed via Western blot analysis.  
3.2H TRANSFECTION 
 For the protocol used to transfect siRNA against CDK1, CDK2 or both CDKs in 
HMEC and TNBC cells, please see chapter 2.2H 
3.2I RT-qPCR 
 To measure transcription of p21, cells were subjected to roscovitine for 24 hours, 
doxorubicin for 48 hours or both drugs sequentially at IC50 concentrations, with untreated 
cells serving as a negative control (Table 14).  Twenty-four hours of etoposide at 5 µM 
treatment served as a positive control.  Following drug treatment, cells were harvested and 
RNA was extracted using the Qiagen RNeasy Mini Kit according to manufacturer’s protocols 
(Venlo, Netherlands).  Cell extracts were DNAase treated (Qiagen).  Following RNA 
extraction, cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit 
(AB Biosystems, Foster City, CA) according to manufacturer’s protocols.  Gene transcription 
  
101
of p21 was measured using SYBR Green Jumpstart Taq Ready Mix (Sigma-Aldrich) on a 
7500 Fast Real-Time PCR System equipped with 7500 software version 2.3 (AB 
Biosystems).  Forward primer used for p21 was (5’-3’): ACTCTCAGGGTCGAAAACGG and 
reverse primer was (5’-3’): CCTCGCGCTTCCAGGACTG (Sigma-Aldrich).  Relative mRNA 
was normalized to GAPDH.   
3.2J NEUTRAL COMET ASSAY 
  A neutral comet assay was performed according to Trevigen (Gaithersburg, MD) 
protocols to measure DNA double-strand breaks (DSBs) in HMEC and TNBC cells in 
response to single and combination drug treatment. Briefly, following treatment with single 
or combination drug treatment, cells were harvested from 10 cm dishes, combined with low-
melting agarose, and spread onto CometSlides (Trevigen).  After allowing the cells to 
adhere to the slides, cells were lysed with Trevigen lysis solution. The slides were then 
placed in an electrophoresis chamber with neutral electrophoresis buffer. A current of 21 V 
was used for 21 minutes. After drying, samples were stained with SYBR Green I and 
allowed to dry at room temperature in the dark. Images of nuclei were captured using an 
Eclipse 90i microscope equipped with the NIS-Elements Br 3.10 software program (Nikon, 
Tokyo, Japan). The tail moment was measured using the CometScore software program 
(TriTek, Sumerduck, VA). 
3.3K IMMUNOFLUORESCENCE TO DETECT DNA REPAIR FOCI 
 For γ-H2AX and Rad 51 immunofluorescence, HMEC, TNBC and HCT116 p53+/+ 
and p53-/- cells were seeded on 8-well chamber slides (Thermoscientific, Rochester, NY) 
and treated with roscovitine for 24 hours, doxorubicin for 48 hours or both drugs sequentially 
all at IC50 concentrations (Table 14).  Cells were fixed in 4% paraformaldehyde for 20 
minutes followed by permeabilization with a 0.3% triton solution (20mM Hepes, 50mM NaCl, 
3mM MgCl2, 300mM sucrose and TritonX-100) for 20 minutes.   Cells were blocked in PBS 
with 10% BSA and 2% horse serum for one hour.  Antibodies were diluted 1:500 and 1:1000 
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for anti-γ-H2AX (EMD Millipore) and anti-Rad51 (generously provided by Dr. Junjie Chen), 
respectively, and incubated at 4°C overnight. Secondary goat anti-mouse or goat anti-rabbit 
antibodies (Alexa Fluor 594 and 488, respectively, EMD Millipore) were diluted at 1:750 and 
incubated at room temperature at 1 hour. Nuclei were stained with DAPI (Life Technology, 
Grand Island, NY) at 1µg/ml for 5 minutes at room temperature. Cells were mounted with 
Dako fluorescent mounting medium (Carpentaria, CA). Images for quantification were 
captured using the Olympus FV1000 Laser Confocal Microscope at 60X magnification 
(Tokyo, Japan).  Images for corresponding figures were captured using Eclipse 90i 
microscope equipped with the NIS-Elements Br 3.10 software program at 100X 
magnification.  At least 100 cells were counted per sample per trial.  Cells with ≥5 foci of γ-
H2AX were considered positive.  Cells with ≥1 foci of Rad51 were considered positive.   
3.2L STATISTICAL ANALYSIS  
 The Student t-test with a 95% confidence interval was performed to determine p 
values. P values less than 0.05 were considered significant.  Mean ± SD.  
3.3 RESULTS 
3.3A SINGLE AND COMBINATION DRUG TREATMENT MAINTAIN A G2/M ARREST 
ONLY IN TNBC CELLS 
To determine the effect of single and combination treatment on the cell cycle, TNBC 
and HMEC cells were treated with roscovitine (24 hours), doxorubicin (48 hours), or 
sequential roscovitine-doxorubicin (cumulative 72 hours) at IC50 concentrations followed by 
cell-cycle-phase FACS analysis.  As seen in Figure 10, single and combination treatment 
had little effect on the cell-cycle-phase profile of MCF10A cells, with over 70% cells 
continuing to remain in G1.  However, doxorubicin treatment induced over 20% polyploidy in 
the TNBC cell line MDA MB 231, an effect that was maintained during combination 
treatment (Figure 10A). Notably, following a 24-hour release from doxorubicin and 
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combination treatment, 45% and 30% of MDA MB 231 cells had polyploid nuclei, 
respectively.  Doxorubicin reduced G1 phase cells in MDA MB 157 cells by 10% compared 
to control.  This G1 phase reduction was maintained in combination treatment, with nearly 
30% cells entering polyploidy (Figure 10B).  Fifty-percent of MDA MB 468 cells accumulated 
in G2/M in response to doxorubicin and combination based treatment (Figure 10B).  Unlike 
HMEC cells that accumulated in G1, accumulation of TNBC cells in G2/M and/or induction of 
polyploidy in response to combination treatment suggests that TNBC cells do not have an 
intact G1 cell cycle checkpoint.   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
  
Figure 10.  Single and combination drug treatment induces a G2/M arrest and 
polyploidy only in TNBC cells.
roscovitine, doxorubicin or roscovitine followed by doxorubicin and subjected to cell cycle 
analysis via flow cytometry.  G
trials.  B, HMEC and TNBC cells were treated with single and combination treatment 
followed by flow cytometry.  Three trials were performed per cell line.
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  A, MCF10A and MDA MB 231 cells were treated with 
raphs, generated using Kaluza, are representative of three 
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3.3B KNOCKDOWN OF CDK1 IS SUFFICIENT TO AUGMENT G2/M ARREST WITH 
DOXORUBICIN 
To determine if inhibition of CDK1, CDK2 or both is required for the G2/M arrest and 
induction of polyploidy in TNBC cells, we transiently transfected HMEC and TNBC cells with 
siRNA with and without the addition of doxorubicin (IC50 concentration) followed by cell cycle 
analysis.  Western blot analysis of CDK1 and CDK2 confirmed knockdown (Figure 11A).  
Cell cycle analysis revealed that MCF10A cells only had about a 10% increase in G2/M 
upon CDK knockdown, with the addition of doxorubicin either reverting cells to a G1 
accumulation (70-80%) or causing no change (Figure 11B).  In TNBC cells, knockdown of 
CDK1 or CDK1/CDK2 lead to a G2/M accumulation that was augmented with the addition of 
doxorubicin.  Indeed, 80% of MDA MB 468 cells accumulated in the G2/M cell cycle phase 
when knockdown of CDK1 was combined with doxorubicin treatment, demonstrating a 20% 
or 40% increase in G2/M cells compared to knockdown or doxorubicin treatment alone, 
respectively.  There was no additional gain in the G2/M phase when both CDKs were 
knocked down in the presence of doxorubicin compared to CDK1 knockdown plus 
doxorubicin in TNBC cells  (Figure 11B).  Therefore, while HMEC cells arrest in G1 in 
response to CDK inhibition and/or doxorubicin treatment, TNBC cells (with p53 mutations 
and Rb pathway inactivation) may lack the ability to arrest in G1, forcing them to accumulate 
in G2/M.       
 
   
 
Figure 11. Knockdown of CDK1 is sufficient to induce a G2/M arrest in the presence of 
doxorubicin. A, HMEC and TNBC cells were transiently transfected with siRN
CDK1, CDK2 or both.  Non-targeting siControl was used as a negative control.  Western blot 
analysis confirmed knockdown.  B, Following knockdown with and without doxorubicin 
treatment, HMEC and TNBC cells were subjected to cell cycle analysis via
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 flow cytometry.   
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3.3C SINGLE AND COMBINATION DRUG TREATMENT INDUCE G1 CHECKPOINT 
ARREST ONLY IN HMEC CELLS 
Activation of G1 checkpoint proteins was examined in both HMEC and TNBC cells 
through Western blot analysis and RT-qPCR.  MCF10A cells showed reduced expression of 
phospho-Rb in response to doxorubicin and combination treatment, suggesting Rb is 
actively inhibiting transcription factor E2F and inducing G1 checkpoint activation. 
Doxorubicin and combination treatment also increased p27 expression in MCF10A cells 
(Figure 12A).  Additionally, MCF10A cells had p53 pathway activation as measured by p21 
expression.   MCF10A cells had a modest increase in both p21 protein expression and 
transcription in response to treatment, with combination treatment inducing a 3-fold increase 
in p21 transcription (Figure 12A, B).  Etoposide treatment induced over a 15-fold increase in 
p21 transcription, exemplifying the ability of HMEC cells to induce p53 activity upon DNA 
damage.   
In contrast, drug treatment increased phospho-Rb expression in TNBC MDA MB 157 
cells, indicating Rb inhibition (Figure 12A).  Furthermore, MDA MB 157 cells showed no 
change in in p21 protein expression, with combination treatment inducing only a 1.8-fold 
change in p21 gene expression (Figure 12A, B).  Etoposide treatment caused a less than 5-
fold change in p21 expression, illustrating the diminished capacity of MDA MB 157 cells to 
induce p53 pathway activation upon DNA damage compared to HMEC cells (Figure 12B).  
Western blot data suggests that increased expression and activation of G1 checkpoint 
proteins upon single and combination drug treatment leads to the G1 accumulation 
measured in HMEC cells.    
 
 
 
 
 Figure 12. Single and combination treatment activates
HMEC cells. A, MCF10A and MDA MB 157 cells were subjected to 
(R), doxorubicin for 48 hours (D)
harvested as indicated followed by Western blot analysis to detect
checkpoint proteins.  All drugs were administered at IC
analysis of phospho-Rb, total Rb
normalized to β-actin. C, Cells were subjected to
by RNA extraction and qRT-PCR analysis to measure p21 transcription. Etoposide 
treatment was used as a positive control 
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 the G1 checkpoint only in 
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 and sequential combination treatment (R
 expression of G1 
50 concentrations.  B, D
, p21 and p27 using Image J per cell line.  All proteins were 
 single and combination treatment followed 
for p53 activation.  
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3.3D G1 CHECKPOINT ABLATION CORRELATES TO ROSCOVITINE-DOXOURBICIN 
SYNERGISTIC RESPONSE IN HMEC CELLS 
 To examine the effect of G1 checkpoint deregulation in HMEC cells, the immortalized 
isogenic cell lines 76NF2V and 76NE6 cells were subjected to synergistic combination drug 
treatment.  The viral oncoprotein HPV16-E6 binds and degrades p53 in 76NE6 cells (Table 
12) [390].  76NF2V cells were immortalized with a mutant HPV-16E6 gene (F2V), that is 
unable to degrade p53, but still immortalizes cells [391].  Sequential administration of 
roscovitine and doxorubicin caused an additive response in p53 wildtype 76NF2V cells 
(Figure 13A).  However, combination treatment induced synergism in the p53 inactive 
76NE6 cells (Figure 13A).  These findings suggest that G1 checkpoint deregulation, via p53 
degradation or other mechanisms, correlates to response to roscovitine-doxorubicin 
combination treatment. 
To determine how G1 checkpoint regulation affects cell cycle response of HMEC 
cells to single and combination treatment, 76NF2V and 76NE6 cells were subjected to flow 
cytometry.  Twice as many untreated control 76NE6 cells are in the G2/M phase compared 
to untreated 76NF2V cells, with 76NE6 cells demonstrating polyploid nuclei.  Although 
doxorubicin induced a G1 accumulation in both cell lines, the percent of 76NE6 cells in G1 
decreased by 10% 24-hours post doxorubicin treatment.  However, 76NF2V cells continued 
to have over 75% of cells accumulate G1 24-hours post doxorubicin treatment (Figure 13B).  
The faster recovery of 76NE6 cells from G1 phase arrest compared to 76NF2V cells 
suggests that 76NE6 cells are more prone to re-enter the cell cycle following DNA damage.  
Notably, both cells lines accumulated in almost equal amounts in the G2/M phase due to 
combination treatment.  However, 76NE6 cells had twice as many cells with polyploid nuclei 
both during and post release from combination treatment compared to 76NF2V cells (Figure 
13B).  Similar to TNBC cells, the detection of polyploid nuclei in untreated and combination 
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treated 76NE6 cells suggests that G1 checkpoint deregulation can lead to abnormal DNA 
content.   
To measure expression of G1 checkpoint proteins, 76NF2V and 76NE6 cells were 
subjected to single and combination treatment followed by Western blot analysis.  
Roscovitine and combination treatment reduced phospho-Rb expression in 76NF2V cells, 
with expression returning 24 hours post combination treatment (Figure 13C).  The decrease 
in phospho-Rb caused by single and combination treatment suggests that Rb is inhibiting 
E2F transcription factors and promoting G1 checkpoint activation.  While doxorubicin 
treatment increased p27 expression, both roscovitine and combination treatment increased 
p21 expression in 76NF2V cells (Figure 13C).  In contrast, roscovitine and combination 
treatment did not reduce phospho-Rb in 76NE6 cells; however, doxorubicin and 24-hours 
post release of combination treatment did cause a modest decrease in phospho-Rb 
expression. Neither single nor combination drug treatment induced p21 expression in 
76NE6 cells (Figure 13C).  It is expected that 76NE6 cells will be unable to induce p21 
expression since p53, the transcription factor for p21, is degraded in these cells.  Therefore, 
Western blot and cell cycle analysis revealed that 76NE6 cells have a reduced capacity to 
activate their G1-checkpoint.    
   
Figure 13.  Roscovitine-doxorubicin induced sy
checkpoint activation. A, 76NF2V and 76NE6 cells were subjected to HTSA where 
roscovitine and doxorubicin were administered sequentially.  Isobolograms and CI values 
generated with CalcuSyn.  B, HME
doxorubicin (D) for 48 hours 
Cells were also harvested 24 hours post release from treatment
combination drug treatment, Western blot analys
proteins in HMEC cells.   
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nergism correlates to reduced G1
C cells were treated with roscovitine (R) for 24 hours, 
and combination treatment (RD) followed by flow cytometry.
. C, Following single and 
is was used to detect G1 checkpoint 
-
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3.3E KNOCKDOWN OF RB IS INSUFFICIENT TO INDUCE SYNERGISM IN HMEC 
CELLS.     
Since doxorubicin and combination drug treatment reduced phospho-Rb expression 
in both MCF10A and 76NF2V cells, but remained elevated in MDA MB 157 cells, Rb was 
stably knocked down using lentiviral infection in 76NF2V cells to examine the effect of Rb 
inactivation on combination-induced synergy (Figure 12A and 13C).  Western blot analysis 
was used to confirm knockdown (Figure 14A).   When subjected to HTSA followed by 
CalcuSyn analysis, roscovitine-doxorubicin combination treatment induced additivity or 
antagonism in non-targeted shScramble or shRb cells, respectively (Figure 14C).  Moreover, 
cell cycle analysis of knockdown cells revealed that ablation of the Rb pathway did not 
cause 76NF2V cells to accumulate more in the G2/M phase compared to shScramble cells 
(Figure 14B).   Therefore, Rb inactivation is not sufficient to cause roscovitine-doxorubicin-
induced synergism in HMEC cells. 
 
 
 
 
 
 
 
 
 
  
Figure 14.  Knockdown of Rb is insufficient to cause HMEC cells to respond 
synergistically to combination treatment.  
76NF2V cells stably expressing
(shRB).  Western blot analysis was used to confirm knockdown.  B, shScrabmble and shRB 
cells were treated with single
cycle analysis.  C, 76NF2V shScramble and shRb cells we
roscovitine-doxorubicin combination treatment.  Isobolograms and CI values were generated 
using CalcuSyn.   
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A, Lentiviral infection was used to generat
 non-targeting shRNA (shScramble) or  shRNA against 
 (R or D) and combination treatment (RD) followed by cell 
re subjected to sequential 
e 
Rb 
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3.3F KNOCKOUT OF THE P53 PATHWAY CAUSES SENSITIVITY TO ROSCOVITINE-
DOXORUBICIN-INDUCED SYNERGISM IN TUMOR CELLS  
Thus far, only TNBC and HMEC cells with G1 checkpoint deregulation responded 
synergistically to roscovitine-doxorubicin treatment (Figure 5A, 13A).  However, knockdown 
of Rb was insufficient to induce synergism in HMEC cells (Figure 14C).  Therefore, the direct 
effect of p53 pathway abolishment in tumors cells was examined in the isogenic colon 
cancer cells HCT116 p53+/+ and HCT116 p53-/-.  Western blot analysis confirmed the 
presence or absence of p53 expression in p53 wildtype and knockout cells, respectively 
(Figure 15A).  When subjected to HTSA and CalcuSyn analysis, p53 wildtype cells 
responded antagonistically with a CI value of 1.23 to combination treatment.  However, 
knockout of p53 induced synergism in HCT116 cells (Figure 15B).  Consequently, 
abolishment of the p53 pathway is sufficient to sensitize tumor cells to the synthetic lethal 
roscovitine-doxorubicin combination.      
Western blot analysis was employed to examine expression of G1 checkpoint 
proteins.  Sequential roscovitine-doxorubicin treatment reduced phospho-Rb expression in 
p53 wildtype cells.  Moreover, both single and combination drug treatment caused increased 
expression of p27 and p21 in p53 wildtype cells (Figure 15C).  Although both roscovitine and 
combination treatment caused a reduction in phospho-Rb expression in p53 knockout cells, 
drug treatment did not increase p27 or p21 expression in these cells (Figure 15C).  The 
inability of HCT116 p53-/- cells to induce p21 expression indicates a compromised G1 
checkpoint in these knockout cells.             
 Cell cycle analysis was performed to examine the effect of combination treatment on 
p53 wildtype and knockout cells.  Although polyploidy was detected in both p53 wildtype and 
knockout untreated cells, p53 knockout untreated cells had twice as many polyploid nuclei, 
indicating that knockout of the p53 gene can lead to a propensity for irregular DNA content 
(Figure 15D).  Combination treatment and 24-hours post treatment increased G2/M 
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accumulation and polyploidy in both p53 wildtype and knockout cells.  However, 
combination-treated p53 knockout cells had twice the amount of Sub-G1 cells (20%) 
compared to p53 wildtype cells both during and following treatment (Figure 15D).  Sub-G1 is 
indicative of cell death, suggesting that lack of p53 expression correlates to increased cell 
death in response to roscovitine-doxorubicin treatment in tumor cells.  Detecting increased 
Sub-G1 in HCT116 p53-/- cells due to combination treatment is in accordance with the 
synergism that was measured using HTSA and CalcuSyn (Figure 15A, D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 15.  Abolishment of p53 pathway in tumor cells causes synergistic response to 
roscovitine-doxorubicin combination treatment.
expression and knockout of p53 in HCT116 p53
MCF10A cells served as a positive control for p53 expression. B, p53 wildtype and knockout 
cells were subjected to HTSA with sequential roscovitine
CalcuSyn analysis.  C, Western blot analysis was use
checkpoint proteins. D, p53 wildtype and knockout cells were subjected to flow cytometry 
following combination treatment and 24
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 A, Western blot analysis confirmed 
+/+
 and HCT116 p53-/- cells, respectively.  
-doxorubicin treatment followed by 
d to detect expression of G1 
-hours post release.     
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3.3G ROSCOVITINE-DOXORUBICIN TREATMENT INCREASED DNA DSBs 
SPECIFICALLY IN TNBC CELLS 
CDK1 activity is required for recruitment of HR proteins, which repairs DNA DSBs 
during late S, G2 and M cell cycle phases (Table 16) [112].   Also, pretreatment with 
roscovitine inhibits recruitment of HR protein RPA34 to damage sites [362].  Thus, we 
performed a neutral comet assay to quantify DNA DSBs in response to single and 
combination drug treatment.  The tail moment, or the amount of DNA in the distance 
traveled, measures the extent of DNA DSBs.   As expected, treatment with doxorubicin 
induced DNA DSBs, indicated by an increased tail moment, in both HMEC and TNBC cell 
lines (Figure 16). However, administering roscovitine prior to doxorubicin caused a 
significant (p value < 0.05) increase in the amount of DNA DSBs only in TNBC cells (Figure 
16).  Combination treatment did not cause an increase in DNA DSBs in MCF10A cells 
(Figure 16).  This indicates that treating TNBC cells with roscovitine prior to doxorubicin can 
enhance the DNA damage inflicted by doxorubicin. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 16. Administering roscovitine prior to doxorubicin increases DNA DSBs
explicitly in TNBC cells.  HMEC and TNBC cells were treated with 
doxorubicin (D) or combination drug treatment
assay.  Images were captured at 10x.  Tail moment was measured using Comet Score.
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3.3H COMBINATION TREATMENT INCREASES DNA DSBs WHILE REDUCING 
RECRUITMENT OF DOWNSTREAM HR PROTEINS 
 Due to the increase in DNA DSBs we measured in TNBC cells, γ-H2AX foci, a 
marker of DNA DSBs, was examined in response to single and combination treatment.  
Doxorubicin treatment induced γ-H2AX foci in about 60% of MCF10A cells and both TNBC 
cell lines (Figure 17A, B, C).  However, treatment with roscovitine prior to doxorubicin 
significantly increased (p-value < 0.05) the percentage of γ-H2AX positive cells by 20% 
explicitly in TNBC cells (Figure 17B,C).  Combination treatment did not cause an increase in 
DNA damage in MCF10A cells (Figure 17A, C).  Indeed, combination treated MDA MB 157 
cells had significantly 20% more (p-value < 0.05) γ-H2AX positive cells than combination 
treated MCF10A cells (Figure 17C).  The increase in γ-H2AX foci only in TNBC cells 
confirms that combination treatment causes more DNA DSBs than doxorubicin treatment 
alone.   
 As previously shown, combination treatment causes accumulation of TNBC cells in 
the G2/M cell cycle phase, where cells rely on HR for DSB repair (Figure 10) [105].  The HR 
protein Rad51 binds to the excised single strands to facilitate strand invasion (Figure 2).    
Quantification of γ-H2AX positive cells with Rad51 foci was used to examine the recruitment 
of downstream HR proteins. Untreated control HMEC and TNBC cells had limited DNA 
damage, but had over 60% or over 80% cells with Rad51 positivity when γ-H2AX was 
present, respectively (Figure 17A, B, D).  Roscovitine treatment reduced the recruitment of 
Rad51 in both MCF10A and MDA MB 157 cells.  Moreover, combination treatment 
significantly (p-value < 0.05) reduced the formation of Rad51 foci by 20% compared to 
doxorubicin treatment in TNBC cells, even though over 80% of these cells had γ-H2AX 
positivity (Figure 17B, D).  Combination and doxorubicin only treated MCF10A cells were 
able to recruit Rad51 foci at a similar percentage of 35% (Figure 17A, D).  However, over 
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70% of these cells are in G1, and thus do not rely on HR for DSB repair (Figure 10A, B).  
These findings are consistent with previous studies demonstrating that roscovitine 
decreased RPA34 foci in response to irradiation despite formation of γ-H2AX foci [362].  
Therefore, treatment with roscovitine prior to doxorubicin impaired TNBC cell DNA damage 
response to DNA DSBs, regardless of increased DNA damage and cell cycle phase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 17. Roscovitine-doxorubicin treatment increases DNA DSBs while reducing 
recruitment of downstream HR proteins in TNBC cells.  
231 cells were treated with single and combination drug treatment followed by 
immunofluorescence to detect 
quantified in HMEC and TNBC cells
of γ-H2AX-positive cells with Rad51 positivity.  Cells with 
One hundred cells per sample were counted per trial (n 
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γ-H2AX and Rad51 foci. C, Percent of cells with 
.  Cells with ≥5 foci were considered positive. D, Percent 
≥1 foci were considered positive.  
≥ 3).      
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3.3I ABSENCE OF P53 ALLOWS COMBINATION TREAMENT TO INCREASE DNA 
DSBs 
 HCT116 p53+/+ and HCT116 p53-/- were used to determine the effect of p53 pathway 
abolishment on DNA damage and repair.  Presence or absence of p53 had little effect on 
doxorubicin-induced DNA damage, with 41% and 46% of p53 wildtype and p53 knockout 
cells having γ-H2AX positivity, respectively (Figure 18A, B, C).  However, combination 
treatment significantly increased (p-value < 0.01) γ-H2AX positive cells to 60% only in p53 
knockout cells compared to doxorubicin treated cells.  Combination treatment did not 
augment γ-H2AX positivity in p53 wildtype cells.  Moreover, combination treated p53 
knockout cells had significantly 20% more (p-value < 0.01) γ-H2AX positive cells compared 
to combination treated p53 wildtype cells (Figure 18C).  As such, absence of p53 causes 
tumor cells to have increased DNA damage in response to combination treatment.   
 The effect of deletion of p53 on DNA DSB repair through the HR pathway was 
measured through the recruitment of Rad51 foci in γ-H2AX positive cells. Upon doxorubicin 
treatment, p53 wildtype and p53 knockout cells recruited Rad51 to γ-H2AX sites in 63% and 
59% of cells, respectively (Figure 18A, B, D).  Combination treatment had no effect on 
Rad51 recruitment in p53 wildtype cells.   However, p53 knockout cells had a significant 
decrease (p-value < 0.05) in the percent of γ-H2AX positive cells with Rad51 foci compared 
to doxorubicin treated cells (Figure 18A, B, D).  Despite having more G2/M cells, p53 
knockout cells had almost 20% less recruitment of Rad51 foci than p53 wildtype cells during 
combination treatment (Figure 15D, Figure 18A, B, D).  Therefore, deletion of p53 reduces 
the ability of tumor cells to recruit downstream HR proteins during roscovitine-doxorubicin 
combination treatment.         
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Figure 18. Abolishment of p53 pathway causes combination treatment to increase 
DNA DSBs. A, B HCT116 p53+/+ and HCT116 p53-/- cells were subjected to single and 
combination drug treatment followed by immunofluorescence to detect γ-H2AX and Rad51 
foci.  C, Percent of γ-H2AX positive cells were quantified. Cells with ≥5 foci were considered 
positive.  D, Percent of γ-H2AX positive cells with Rad51 foci quantified.  Cells with ≥1 foci 
were considered positive.  At least one hundred cells per sample were counted per trial    
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3.4 CONCLUSIONS 
 Roscovitine-doxorubicin combination treatment is synthetic lethal explicitly in tumor 
and HMEC cells with an abrogated p53 pathway.  The role of p53 inactivity in sensitizing 
cells to combination treatment was addressed using isogenic HMEC and tumor cells with 
and without p53 activity.  Here, loss of p53 at the protein or genomic level, and concordant 
lack of p21 expression, lead combination treatment to be synthetically lethal.  Cells with p53 
activity were consistently less sensitive to combination treatment.  Moreover, loss of Rb did 
not sensitize HMEC cells to combination treatment.  Therefore, G1 checkpoint deregulation 
via p53 inactivity is required for roscovitine-doxorubicin-induced synergism in TNBC cells.   
Loss or mutated p53 is associated with increased accumulation in the G2/M cell 
cycle phase and polyploid nuclei in untreated, single and combination treated cells.  HMEC 
and tumors cells with an intact p53 pathway are more prone to arrest or accumulate in the 
G1 cell cycle phase in response to treatment.  Whereas knockdown of CDK1 is sufficient to 
cause accumulation of cells in G2/M arrest in the presence of doxorubicin in TNBC cells, 
p53 wildtype HMEC cells continued to accumulate in the G1 phase during these conditions.  
Moreover, ablation of the Rb pathway did not increase G2/M phase accumulation in HMEC 
cells.  These findings demonstrate that p53 pathway abrogation allows TNBC cells to 
bypass the G1 checkpoint, causing increased G2/M accumulation and potentially irregular 
DNA content in response to combination therapy.   
The role of p53 is not limited to the G1 checkpoint, as p21 also inhibits CDK activity 
during G2 and M phases (Figure 1).   DNA damage can cause p53 to arrest cells in G1 or 
G2 [84].  Irradiation of HCT116 p53-/- cells demonstrated that p53 is required for G2 arrest 
maintenance, with knockout cells entering mitosis and failing cytokinesis [392].  Therefore, 
the observation of polyploid nuclei in untreated and treated p53 mutant TNBC cells may also 
be due to a compromised G2 checkpoint that allows cells to progress through mitosis 
regardless of damaged DNA.    
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Combination treatment caused increased DNA DSBs in TNBC cells while reducing 
the recruitment of downstream HR proteins.  Arresting TNBC cells in the G2/M cell cycle 
phase via CDK inhibition primes them for DNA damage assault.  Cells rely on HR to repair 
DNA DSBs during late S, G2 and M phases of the cell cycle.  Inhibition of CDK1 impairs 
DNA end resection and recruitment of HR proteins, potentially forcing cells to rely on more 
error-prone methods (i.e. MMEJ) for repair or leaving breaks unrepaired.  Thus, by inducing 
a G2/M accumulation via CDK inhibition followed by doxorubicin treatment, TNBC cells are 
being subjected to DNA damage while having a compromised HR pathway.  Moreover, p53 
pathway abolishment enabled combination treatment to increase DNA DSBs while inhibiting 
recruitment of HR proteins in tumor cells.  The conclusion that TNBC and other tumor cells 
that are accumulated in the G2/M phase have increased sensitivity to doxorubicin treatment 
is consistent with previous studies that found doxorubicin induced more cytotoxicity in 
mouse-derived leukemia p53-mutant cells when they were synchronized to S and G2/M 
[393].  In the present study, non-transformed cells with an intact p53 pathway are protected 
from the most damaging effects of doxorubicin because they arrest in G1 phase.  p53 
wildtype tumor cells were also protected from additional DNA damage.  Therefore, upon 
combination treatment, TNBC cells undergo increased DNA damage with compromised 
DNA DSB repair pathways; HMEC cells remain relatively unharmed.    
The concept of chemoprotecting normal tissues from cytotoxic drugs by inducing a 
reversible cell cycle arrest is called cyclotherapy [394].  This concept is especially promising 
for targeting p53 mutant tumors.  Current studies have utilized p53 activators antinomycin D 
and nutlin-3, a MDM2 inhibitor, to activate p53 and arrest normal cells, shielding them from 
S and M phase toxins [395].  For example, treatment with nutlin-3 protected p53 competent 
tumor cells U2OS and HCT116 p53+/+ and non-transformed human keratinocytes from 
gemcitabine treatment.  However, pre-treatment with nutlin-3 did not arrest HCT116 p53-/-, 
allowing gemcitabine to remain cytotoxic in these cells [396].   
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Both single and combination treatment induced G1 arrest that correlated to p53 
activity, as measured by p21 expression, in p53-competent HMEC and tumor cells.  
Activation of p53 protected these cells from doxorubicin-associated cyto-toxicities.  The 
shielding of non-transformed cells via p53 activation supports the finding that doxorubicin 
treatment was more toxic in vivo than combination treatment (Figure 9C,D and Table 15).   
Also, administering roscovitine first is also advantageous because it further sensitized TNBC 
cells to doxorubicin treatment.  The requirement of abrogated p53 activity to cause 
combination-induced synergism enables specific targeting of p53-mutant TNBC cells while 
simultaneously limiting the damage inflicted on non-transformed cells.   
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CHAPTER 4 DISCUSSION AND FUTURE DIRECTIONS  
4.1 MAJOR FINDINGS 
TNBC is an aggressive disease associated with decreased overall survival in which 
tumors are molecularly and clinically distinct from non-TNBC tumors. Since patients with 
TNBC tumors cannot benefit from clinically available targeted therapies, there is an urgent 
need to develop novel treatment strategies that target the specific biology of TNBC tumors.  
Due to a majority of TNBC tumors carrying mutations in the cell cycle machinery, including 
p53, Rb and cyclin E, it was hypothesized that TNBC cells are sensitive to cell cycle 
targeted combination therapy, leaving non-transformed cells unharmed.  The data 
presented in this dissertation addressed the questions posed in the first chapter. 
1.  Would the deregulation of the cell cycle sensitize TNBC cells to cell cycle 
inhibitors; would non-TNBC and non-transformed cells react differently? 
 Treatment with roscovitine induced a significant G2/M arrest in TNBC cells (all p53-
mutant) and in the HMEC cell line 76NE6 cells, which does not express p53.  Roscovitine 
treatment did not induce a major G2/M arrest in HMEC and ER-positive cells with intact (or 
heterozygous) p53 pathways.  Therefore, sensitivity to cell cycle inhibitors is sub-type and 
p53-mutant specific.   
2. Can a synthetic lethal combination of cell-cycle inhibition and chemotherapeutics 
specifically target TNBC cells, without inflicting harm to non-transformed cells? 
 Sequential administration of roscovitine and doxorubicin treatment was synthetic 
lethal specifically in TNBC cells, but was antagonistic in HMEC cells.  Notably, simultaneous 
drug administration or treating with doxorubicin prior to roscovitine was antagonistic in TNBC 
cells.  Combination treatment prolonged and increased apoptosis only in TNBC cells 
compared to single drug treatments. 
3. Will combination cell cycle targeted therapy be an effective method in a pre-clinical 
model? 
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 Combination treatment was both efficacious and well tolerated in mice with human 
TNBC xenografts.  Since combination treatment inhibited tumor growth without increasing 
toxicity, no combination treated mice were euthanized, resulting in a significant increase in 
overall survival.  Despite being well tolerated, roscovitine had very limited efficacy, causing 
all mice to be euthanized due to excessive tumor burden.  Mice treated with doxorubicin 
suffered from excessive tumor burden and deteriorated health, illustrating its inadequacy as 
a single agent.     
4. What affect would combination therapy have on the cell cycle of TNBC cells 
compared to non-transformed cells? 
 Both single and combination treatment maintained a G2/M arrest and/or induced 
polyploid nuclei specifically in TNBC cells.  In contrast, HMEC cells accumulated in the G1 
phase in response to treatment.  Moreover, knockdown of CDK1 was sufficient to augment 
the percent of G2/M accumulation in the presence of doxorubicin only in TNBC cells.   
5. Is there a molecular target/pathway that can be used as a marker to predict 
combination treatment response? 
 TNBC cells with p53 mutations had a diminished capacity to induce p21 transcription 
compared to p53 wildtype HMEC cells.  Knockdown of Rb was insufficient to cause a 
synergistic response in HMEC cells.  However, combination treatment was synthetic lethal in 
p53-compromised HEMC and tumors cells, whereas the paired isogenic p53 wildtype cells 
were additive or antagonistic to treatment.  Moreover, the cell cycle profile of HMEC and 
tumor cells lacking p53 activity closely mimicked the cell cycle profile of TNBC cells; the 
isogenic p53 wildtype cells had less G2/M accumulation.  Thus, p53 inactivation serves as a 
putative predictor of synergistic response to roscovitine-doxorubicin combination treatment.    
6. Can combination treatment augment the DNA damage inflicted by 
chemotherapeutics explicitly in TNBC cells? 
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 Administration of roscovitine prior to doxorubicin caused increased DNA DSBs while 
reducing the recruitment of the downstream HR protein Rad 51 in TNBC cells.  Combination 
treatment did not subject HMEC cells to increased DNA damage.  Moreover, combination 
treatment increased DNA damage and reduced recruitment of HR proteins in p53-null tumor 
cells compared to isogenic p53-wildtype cells.  Therefore, ablation of the p53 pathway in 
TNBC cells can further sensitize cells to combination treatment-associated DNA damage.   
4.2 LIMITATIONS 
 The present study focused on increasing the innate sensitivity of TNBC cells to 
anthracycline-based therapy.  However, TNBC tumors are also sensitive to platinum-based 
chemotherapies, such as cisplatin.  Since platinum-based therapies also induce DNA 
damage by binding to DNA purine bases, it is reasonable to hypothesize that roscovitine 
treatment could synergize with cisplatin.  Additionally, because anthracyclines are 
associated with cardiotoxicity, it would be beneficial to determine how well tolerated 
roscovitine and platinum-based chemotherapy combination treatment is.   
4.3 FUTURE DIRECTIONS 
 The roscovitine-doxorubicin combination is a novel treatment strategy that can 
specifically target p53-mutated TNBC tumors.  However, TNBC is a heterogeneous disease 
and identifying the population of patients that will benefit the most from combination 
treatment, while preventing unnecessary treatment of non-responder patients, is necessary 
for effectively implementing this therapy.  The TNBC cell lines used in this study, including 
MDA MB 157, MDA MB 231 and MDA MB 468 have a range of p53 mutations.  MDA MB 
157 cells have a 26 base pair deletion in codon 261, MDA MB 231 cells have a missense 
mutation in codon 280 and MDA MB 468 cells have a missense mutation in 273, all of which 
occur in the DNA binding domain of p53 [348].  However, p53 is deregulated through 
multiple mechanisms, including missense mutations, deletions, GOF mutations, MDM2 
overexpression and deletions in p14 (a negative regulator of MDM2).  The effect of p53 
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status on treatment response has been inconsistent.  As previously described, p53 
mutations in the zinc binding domain conferred resistance to doxorubicin treatment [373].   
Moreover, Bourdon et al. found that the p53 gene has an alternative internal promoter that 
can transcribe 9 splice variants with differing functions.  For example, variant p53β can 
heighten p53 target gene expression, whereas variant ∆133p53 acts as a dominant-
negative and inhibits p53 full-length activity.  These isoforms were differentially expressed 
between normal versus tumor tissue [397].  These splice variants potentially contribute to 
the discrepancies between p53 status and treatment response [348, 397].  The effects of 
these splice variants and other p53 mutations have not been directly investigated in the 
present study. Since HCT116 p53-/- cells were synergistic to combination treatment, it can 
be hypothesized that MDM2 signaling for p53 degradation would induce synergism in tumor 
cells.  However, it is undetermined whether MDM2 overexpression or p14 gene deletions 
are sufficient to sensitize tumor cells to combination treatment.  Therefore, further 
investigation is required to examine the effect of differing p53 mutations and pathway 
deregulations on combination treatment response.  As a result, it is likely that patient tumors 
will have to be sequenced to distinguish responders from non-responders.     
 Roscovitine-doxorubicin treatment was well tolerated in an in vivo model system.  
However, a phase I study examining the MTD and efficacy of dinaciclib in combination with 
the anthracycline epirubicin found that this treatment was very toxic, ending the trial before 
efficacy could be determined.  Dose-limiting toxicities included neutropenia, syncope and 
vomiting (NCT01624441).  To increase the efficacy of combination treatment while reducing 
toxicity, the drugs could be paired with a nanocarrier delivery system.  Coupling roscovitine 
or doxorubicin with nanotechnology drug deliverance system will limit dispersal of the drug 
to only at the site of action, protecting other organs and tissues from cytotoxicity [398].  For 
example, anti-HER2 immunoliposomes containing doxorubicin were targeted to HER2 
overexpressing tumors, increasing the therapeutic benefit of doxorubicin while reducing 
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toxicity in a xenograft mouse model [399].  Roscovitine could be directly delivered to the 
tumor site if it was bound to a ligand-mediated active binding nanoparticle.  EGFR, which is 
overexpressed in a majority of TNBC tumors, is a cell surface receptor that provides a 
putative target to deliver roscovitine to the tumor site.  Indeed, EGFR-targeted polymer 
nanocarriers delivered paclitaxel and ionidamine to multi-drug resistant EGFR-
overexpressing tumor cells, increasing drug cytotoxicity [400].  Developing EGFR-targeted 
nanocarriers to deliver to roscovitine directly to the tumor site could increase the therapeutic 
benefit of CDK inhibition while reducing toxicities. Moreover, liposomal-doxorubicin, which 
accumulates at tumor sites due to leaky vasculature, is clinically available to treat breast 
cancer [401].  Thus, it would be clinically beneficial to consider incorporating roscovitine-
doxorubicin combination treatment with nanoparticle delivery system.   
 Investigating the application of this combination treatment in other types of cancers 
was beyond the scope of the present study.  However, p53 is mutated in over 50% of 
cancers.  Previous studies in our laboratory found that roscovitine-doxorubicin combination 
treatment induce synergism in sarcoma cells [343].  Additionally, this study found that 
combination treatment was synergistic in the colorectal cancer cell line HCT116 p53-/-.  
Furthermore, pretreatment with roscovitine could enhance the cytotoxicity in the broad range 
of malignancies that doxorubicin is currently used to treat, including bladder, head and neck, 
liver, lung, ovarian cancer and sarcomas [254].  As such, the therapeutic benefit of this 
novel combination treatment strategy may extend beyond TNBC.  Future studies should 
assess the efficacy of roscovitine-doxorubicin combination treatment in other cancers with 
p53 pathway deregulation.   
4.4 SIGNIFICANCE  
   TNBC patients have no therapeutic options beyond chemotherapy and surgery.  Due 
to the aggressive nature of TNBC and decreased overall survival of these patients, there is 
a pressing need to develop innovative treatment strategies that target the molecular and 
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biological characteristics attributed to TNBC cells.  Here, sequential administration of 
roscovitine prior to doxorubicin is synthetic lethal explicitly in TNBC cells, with non-
transformed cells remaining unharmed.  Demonstrating promise in a pre-clinical in vivo 
model, this combination strategy can greatly impact the treatment and care of TNBC 
patients.  Since the success of this combination treatment requires p53 pathway abrogation, 
mutated p53 status provides a putative predictor of response.  Overall, roscovitine-
doxorubicin combination could potentially become a powerful tool for clinicians to treat 
TNBC.         
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